{"title": "PDF", "author": "PDF", "url": "http://bibliotecavirtual.dgb.umich.mx:8083/jspui/bitstream/DGB_UMICH/3796/1/IIQB-D-2020-0697.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "  \n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Universidad Michoacana de San Nicol\u00e1s de Hidalgo  \n \nPrograma Institucional de Doctorado en Ciencias \nBiol\u00f3gicas  \n \nFacultad de Medicina Veterinaria y Zootecnia  \nCentro Multidisciplinario de Estudios en Biotecnolog\u00eda  \n \nInstituto de Inves tigaciones Qu\u00edmico -Biol\u00f3gicas  \n \n \nCaracterizaci\u00f3n qu\u00edmica , toxicidad  y efecto \nantipsori\u00e1sico anti -IL17  del extracto acuoso, \netan\u00f3lico  y de aceites pirol\u00edticos de plantas usadas \nen la etnomedicina Pur\u00e9pecha  \n \n \nTesis  \n \nPara obtener el grado de:  \nDoctor en Ciencia s Biol\u00f3gicas  \nOpci\u00f3n : Biotecnolog\u00eda Molecular Agropecuaria  \n \nPresenta:  \nM.C. Roberto Esquivel Garc\u00eda  \n \nDirectora : \nDra. Martha Estrella Garc\u00eda P\u00e9rez  \n \nCodirectora : \nDra. Alejandra Ochoa Zarzosa  \n \nSinodales:  \nDra. Rosa Elva Norma Del R\u00edo Torres  \nDr. Joel Edmundo L\u00f3pe z Meza  \nDr. Manuel Garc\u00eda P\u00e9rez  \n \n \nMorelia, Michoac\u00e1n. Agosto de 2020  \n \n  \n \n \n \n  \n \n \n \n \n \n \n \nEl presente trabajo se realiz\u00f3 en el Instituto de \nInvestigaciones Qu\u00edmico -Biol\u00f3gicas y el Centro \nMultidisciplinario de Estudios en Biotecnolog\u00eda de la \nFacultad de Medicina Ve terinaria y Zootecnia de la \nUniversidad Michoacana de San Nicol\u00e1s de Hidalgo, bajo \nla direcci\u00f3n de la Dra s. Martha Estrella Garc\u00eda P\u00e9rez y \nAlejandra Ochoa Zarzosa. Adem\u00e1s,  se realiz\u00f3 una estancia \nde investigaci\u00f3n en la Universidad de l Estado de  \nWashington,  campus Pullman.  \n \n \n \n \n \n \n \n \n  \nI DEDICATORIA  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nA mi familia, porque hay estrellas q ue gu\u00edan mis pasos, iluminando el  camino y hacen que \nesta vida me parezca maravillosa y perfecta  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \nII AGRADECIMIENTO S \n \nA mi esposa Elena, graci as por escucharme, por tus consejos y paciencia, por darme lo mejor de ti, sin \ndobleces ni ego\u00edsmos, con alegr\u00eda y dulzura; manifest\u00e1ndolo en nuestras hijas Vanessa e Itzi Ximena, quienes \nnos impulsan a mantener la determinaci\u00f3n de alcanzar nuestros sue\u00f1os . Mi orgullo por ustedes aumenta sin \ncesar, \u00a1las amo!  \n \nA mi padre Roberto\u2020, por guiarme sobre el camino de la educa ci\u00f3n y el trabajo. A Martha mi madre; por tu \namor, apoyo y ejemplo que me permiten sentir que puedo lograr lo que me proponga. A Claudia, Mar tha, \nAna, Beatriz y Mercedes por ser excelentes hermanas y ayudarme con mis obligaciones para facilitar el \ncumplimi ento de muchas metas, \u00a1los quiero mucho!  \n \nA mis suegros Lucila y Humberto, por el apoyo incondicional y la confianza que han depositado en m\u00ed , as\u00ed \ncomo a Martha, Alejandra y Guadalupe, sin su ayuda la dificultad de alcanzar esta meta hubiera sido \ngigantesc a. \n \nA la Dra. Martha E. Garc\u00eda, gracias por dirigirme en este proyecto de investigaci\u00f3n, usted deposit\u00f3 su \nconfianza en m\u00ed para integrarme a su equipo de investigaci\u00f3n y siempre me ha motivado para afrontar con \ndeterminaci\u00f3n  los retos que se presentan en l a vida del investigador, agradezco sus criticas llenas de verdad, \nsus consejos y la gran paciencia que me ha tenido durante todos estos a\u00f1os.  A la Dra. Alejandra Ochoa, gracias \npor dirigirme en este proyecto de investigaci\u00f3n, el cual sin su apoyo hubiera s ido dif\u00edcil realizar, agradezco \npor su atenci\u00f3n y sus comentarios acertados que contribuyeron a mejorar la calidad de la investigaci\u00f3n y a mi  \nformaci\u00f3n profesional.  \n \nAgradezco a la Dra. Rosa E. del R\u00edo,  al Dr. Joel E. L\u00f3pez y al Dr. Manuel Garc\u00eda por forma r parte de mi \ncomit\u00e9 tutorial, por dedicar su tiempo para evaluar y corregir mi proyecto de investigaci\u00f3n y por sus \ncontribuciones que fueron  esenciales para realizar el presente trabajo. Dr. Manuel gracias por permitirme \nrealizar una estancia de investiga ci\u00f3n en la WSU , por su apoyo incondicional en todo lo que me fue requerid o \ny por la gran experiencia de trabajar con su grupo.  \n \nA los poblado res Pur\u00e9pecha que compartieron sus conocimientos de medicina tradicional. Al Dr. Emmanuel \nP\u00e9rez del INECOL, por sus consejos y por realizar la identificaci\u00f3n de las especies para la realizaci\u00f3n del \nestudio etnofarmacol\u00f3gico. A los doctores Rosalio Mercado y H\u00e9ctor Mart\u00ednez por permitirme trabajar en sus \nrespectivos laboratorios de la Facultad de QFB . A la Dra. Er\u00e9nd ira Valencia y a la Mtra. Eunice Tranquilino \npor su ayuda en el trabajo de laboratorio y de campo . Al Dr. Omar Guzm\u00e1n por su apoyo en mi etapa d e \nevaluaci\u00f3n predoctoral.  A Anamaria Paiva, Dra. Ayca Seker, Dorota Wilk, Evan Terrel, Jonathan Lomber, \nDr. Jos\u00e9 Mart\u00ednez, Kalidas Mainali, Dr. Michael Apasiku, Sohrab Hag highi, Yaime Jefferson, Dr. Yinlgei \nHan y dem\u00e1s compa\u00f1eros de la WSU por todo el apoy o que me brindaron durante mi estancia de \ninvestigaci\u00f3n. A la Dra. Eva M. Salinas de la UAA y al Dr. Bruno Rivas  del IMSS por facilitarme la  l\u00ednea de \ncultivo celular . \n \nA todos mis amigos y familiares que estuvieron conmigo compartiendo tantas experiencias y triunfos. \nEspecialmente a quienes me ayudaron a afrontar grandes retos sin dudas ni condiciones: Andrea Falc \u00f3n, \nBeatriz Bautista, Blanca  Tetitla , Esteban  Ram\u00edrez , Efigenia Carrillo, Esther  Tadeo , Gabriela  Flores , \nGuadalupe  Salgado , Ildefonso S\u00e1nchez, Judith Prieto , Linda  Hurtado , Marco  Barajas , Margarita  Avi\u00f1a , Mar\u00eda \nHern\u00e1ndez,  Marisol  B\u00e1ez , M\u00f3nica  S\u00e1nchez , Nancy  Alejandre , Paola  Jim\u00e9nez , Rosa  Garc\u00eda , Salvador  Padilla , \nSusana  Bautista , Teresa Arceo e Yvette  Resendiz . No olvidar\u00e9 sus ense\u00f1anzas ni la agrad able convivencia.  \n \n\u00a1Gracias! \nIII CONTENIDO  \nP\u00e1gina  \nDEDICATORIA  ................................ ................................ ................................ ..........................  I \nAGRADECIMIENTOS  ................................ ................................ ................................ ..............  II \nLISTA DE FIGURAS  ................................ ................................ ................................ ..............  VI \nLISTA DE TABLAS  ................................ ................................ ................................ ..............  VIII  \nLISTA DE ABREVIATURAS  ................................ ................................ ................................ . IX \nRESUM EN ................................ ................................ ................................ ................................ .. 1 \nABSTRACT  ................................ ................................ ................................ ................................  3 \nI. INTRODUCCI\u00d3N  ................................ ................................ ................................ ...............  5 \nI.1. Psoriasis  ................................ ................................ ................................ ........................  5 \nI.1.1.  Interleucina -17 y la patog\u00e9nesis de la psoriasis  ................................ .................  7 \nI.1.2.  El desarrollo de f\u00e1rmacos para la psoriasis  ................................ ......................  10 \nI.2. La etnofarmacolog\u00eda y el desarrollo farmac\u00e9utico en la psoriasis  ..............................  13 \nI.3. Uso de extractos acuosos y etan\u00f3licos de plantas como candidatos terap\u00e9uticos para el \ntratamiento de  la psoriasis  ................................ ................................ ................................ ..... 16 \nI.4. Estructura qu\u00edmica de los compuestos fen\u00f3licos extra\u00edbles  ................................ ........  18 \nI.5. Caracterizaci\u00f3n qu\u00edmica de la lignina  ................................ ................................ .........  21 \nI.6. La pir\u00f3lisis: un medio para obtener aceites pirol\u00edticos ricos en compuestos fen\u00f3licos\n 23 \nI.7. Uso de productos pirol\u00edticos para el tra tamiento de la psoriasis  ................................ . 26 \nII. JUSTIFICACI\u00d3N  ................................ ................................ ................................ ..............  28 \nIII. HIP\u00d3TESIS  ................................ ................................ ................................ ....................  30 \nIV. OBJETIVOS  ................................ ................................ ................................ ...................  31 \nIV.1.  Objetivo general  ................................ ................................ ................................ ..........  31 \nIV.2.  Obje tivos particulares  ................................ ................................ ................................ . 31 \nV. ESTRATEGIA EXPERIMENTAL  ................................ ................................ ...................  32 \nVI. RESULTADOS  ................................ ................................ ................................ ..............  33 \nCAP\u00cdTULO 1. Flora etnomedicinal utilizada para el tratamiento de afecciones dermatol\u00f3gicas  \nen la Meseta Pur\u00e9pecha, Michoac\u00e1n, M\u00e9xico  ................................ ................................ ...........  34 \nVI.1.  PREFACIO  ................................ ................................ ................................ .................  35 \nVI.2.  ART\u00cdCULO  ................................ ................................ ................................ ................  36 \nVI.2.1.  Abstract  ................................ ................................ ................................ ............  36 \nVI.2.2.  Resumen  ................................ ................................ ................................ ...........  36 \nVI.2.3.  Introduction  ................................ ................................ ................................ ...... 37 \nVI.2.4.  Materials and methods  ................................ ................................ .....................  38 \nVI.2.5.  Results  ................................ ................................ ................................ ..............  41  \nIV VI.2.6.  Discussion  ................................ ................................ ................................ ........  43 \nVI.2.7.  Conclusions  ................................ ................................ ................................ ...... 48 \nVI.2.8.  Author contributions  ................................ ................................ ........................  49 \nVI.2.9. Financing  ................................ ................................ ................................ .........  49 \nVI.2.10.  Acknowledgment  ................................ ................................ .............................  49 \nVI.2.11.  Literature cited  ................................ ................................ ................................ . 49 \nVI.2.12.  Appendix 1. Plants used by inhabitants from Pur\u00e9pecha Plateau for the \ntreatment of dermatological conditions: use value, fidelity level, modes of preparation and \nethnomedicinal studies.  ................................ ................................ ................................ ..... 58 \nCAP\u00cdTULO 2. Extracto etan\u00f3lico, fracciones y bio -aceites de partes a\u00e9rea s de Urtica subincisa : \nun an\u00e1lisis comparativo de su composici\u00f3n qu\u00edmica, toxicidad y actividad anti -IL17 en \nqueratinocitos HaCaT  ................................ ................................ ................................ ................  74 \nVI.3.  PREFACIO  ................................ ................................ ................................ .................  75 \nVI.4.  ART\u00cdCULO  ................................ ................................ ................................ ................  76 \nVI.4.1.  Abstract  ................................ ................................ ................................ ............  77 \nVI.4.2.  Introduction  ................................ ................................ ................................ ...... 78 \nVI.4.3.  Mate rial and methods  ................................ ................................ .......................  80 \nVI.4.4.  Results and Discussion  ................................ ................................ ....................  85 \nVI.4.5.  Conclusions  ................................ ................................ ................................ .... 102 \nVI.4.6.  Auth or contributions  ................................ ................................ ......................  103 \nVI.4.7.  Conflict of interest  ................................ ................................ .........................  104 \nVI.4.8.  Acknowledgements  ................................ ................................ ........................  104 \nVI.4.9.  References  ................................ ................................ ................................ ...... 104 \nCAP\u00cdTULO 3. Lo s aceites pirol\u00edticos de la corteza de Amphipterygium adstringens  inhiben la \nproducci\u00f3n de IL -8 en queratinocitos  HaCaT estimulados con IL -17. ................................ ... 108 \nVI.5.  PREFACIO  ................................ ................................ ................................ ...............  109 \nVI.6.  ART\u00cdCULO  ................................ ................................ ................................ ..............  110 \nVI.6.1.  Abstract  ................................ ................................ ................................ ..........  110 \nVI.6.2.  Introduction  ................................ ................................ ................................ .... 110 \nVI.6.3.  Material and methods  ................................ ................................ .....................  111 \nVI.6.4.  Results and Discussion  ................................ ................................ ..................  114 \nVI.6.5.  Conclusions  ................................ ................................ ................................ .... 118 \nVI.6.6.  Credit authorship contribution statement  ................................ .......................  118 \nVI.6.7.  Declaration of Competing Interest  ................................ ................................ . 118 \nVI.6.8.  Acknowledg ements  ................................ ................................ ........................  118 \nVI.6.9.  Referen ces ................................ ................................ ................................ ...... 118 \nCAP\u00cdTULO 4. Caracterizaci\u00f3n qu\u00edmica, toxicolog\u00eda y actividad antiinflamatoria del extracto \nacuoso de la corteza de Amphipterygium adstringens  y sus fracciones e n queratinocitos HaCaT.\n ................................ ................................ ................................ ................................ .................  120 \nVI.7.  PREFACIO  ................................ ................................ ................................ ...............  121 \nVI.8.  ART\u00cdCULO  ................................ ................................ ................................ ..............  122 \nVI.8.1.  Abstract  ................................ ................................ ................................ ..........  123 \nVI.8.2.  Introduc tion ................................ ................................ ................................ .... 124  \nV VI.8.3.  Material and methods  ................................ ................................ .....................  126 \nVI.8.4.  Results and Discussi on ................................ ................................ ..................  129 \nVI.8.5.  Conflict of interest statement  ................................ ................................ .........  138 \nVI.8.6.  Authors\u2019 contributions  ................................ ................................ ...................  138 \nVI.8.7.  References  ................................ ................................ ................................ ...... 139 \nVII.  DISCUSI\u00d3N  GENERAL  ................................ ................................ .............................  142 \nVIII.  CONCLUSI\u00d3N GENERAL  ................................ ................................ .....................  150 \nIX. PERSPECTIVAS  ................................ ................................ ................................ .........  151 \nX. BIBLIOGRAF\u00cdA  ................................ ................................ ................................ .............  152 \nXI. ANEXOS  ................................ ................................ ................................ ......................  159 \nXI.1.  ANEXO 1 - La psoriasis: de la investigaci\u00f3n b\u00e1sica y cl\u00ednica al desarrollo de nuevos \ntratamientos  ................................ ................................ ................................ .........................  159 \nXI.1.1.  PREFACIO  ................................ ................................ ................................ .... 159 \nXI.1.2. ART\u00cdCULO  ................................ ................................ ................................ ... 160 \nXI.1.3.  Resumen  ................................ ................................ ................................ .........  160 \nXI.1.4.  Abstract  ................................ ................................ ................................ ..........  160 \nXI.1.5.  Introdu cci\u00f3n ................................ ................................ ................................ ... 161 \nXI.1.6.  Conceptos etiopatog\u00e9nicos actuales de la psoriasis  ................................ ....... 161 \nXI.1.7.  De la investigaci\u00f3n b\u00e1sica y cl\u00ednica al desarrollo de  tratamientos antipsori\u00e1sicos\n 163 \nXI.1.8.  Nuevos f\u00e1rmacos antipsori\u00e1sicos en desarrollo  ................................ .............  164 \nXI.1.9.  Perspectivas futuras en el desarro llo de nuevos medicamentos antipsori\u00e1sicos\n 164 \nXI.1.10.  Bibliograf\u00eda  ................................ ................................ ................................ .... 165 \n \n \n \n   \nVI LISTA DE FIGURAS  \nP\u00e1gina  \nFig. 1.  Circuitos inflamatorios en la psoriasis.  ................................ ................................ ............  6 \nFig. 2. V\u00eda de se\u00f1alizaci\u00f3n de IL -17. ................................ ................................ ...........................  8 \nFig. 3. Esquema cl\u00e1sico de desarrollo farmac\u00e9utico . ................................ ................................  11 \nFig. 4. Proceso de evaluaci\u00f3n cient\u00edfica en etnofarmacolog\u00eda.  ................................ .................  15 \nFig. 5. Estructuras qu\u00edmicas de polifenoles encontrados frecuent emente en las plantas.  .........  20 \nFig. 6. Mon\u00f3 meros precursores de la lignina.  ................................ ................................ ...........  22 \nFig. 7. Pir\u00f3lisis de una part\u00edcula de biomasa.  ................................ ................................ ............  24 \nFig. 8. Estrategia metodol\u00f3gica empleada en el presente trabajo.  ................................ .............  32 \nFig. 9. Resumen gr\u00e1fico.  ................................ ................................ ................................ ............  35 \nFig. 10. Major steps depicted in this paper.  ................................ ................................ ...............  81 \nFig. 11. Pyrograms of the dried aerial parts and residual biomass of U. subincisa ...................  86 \nFig. 12. TGA (A) and DTG (B) curves of the crude extract, its fractions, and pyrolytic products \nfrom U. subincisa.  ................................ ................................ ................................ .....................  90 \nFig. 13. FTIR spectra of  the crude extract, its fractions, and b io-oils from U. subincisa.  ........  92 \nFig. 14. UV -Fluorescence spectra of the  crude extract, its fractions, and bio -oils from U. \nsubincisa.  ................................ ................................ ................................ ................................ ... 93 \nFig. 15. GC-MS chromatograms of the crude extract, its fractions, and bio -oils from Urtica \nsubincisa . ................................ ................................ ................................ ................................ ... 95 \nFig. 16. Effect of the crude extract, phases A -C, and bio -oils on the IL -8 production in \nkeratinocytes HaCaT stimulated with IL -17. ................................ ................................ ..........  100 \nFig. 17. Graphical abstract.  ................................ ................................ ................................ ...... 121 \nFig. 18. Py -GC/MS analysis chromatogram of dry bark po wder from A. adstringens.  ..........  130 \nFig. 19. TGA (A) and DTG (B) curves for the dry bark, crude aqueous extract and its fractions \nfrom A. adstringens . ................................ ................................ ................................ ................  132 \nFig. 20. FTIR spectra of the dry bark, aqueous crude extract and fractions from A. adstringens .\n ................................ ................................ ................................ ................................ .................  133 \nFig. 21. Chromatograms obtained by GC -MS in aqueous bark extract from A. adstrin gens and \nits solvent fractions.  ................................ ................................ ................................ .................  134 \nFig. 22. UV -fluorescence spectra of the crude extract and its fractions from A. adstringens bark.\n ................................ ................................ ................................ ................................ .................  136 \nFig. 23. Effect of crude extract and phases A -C from A. adstringens  bark on the IL -17-induced \nproduction of IL -8 on HaCaT keratinocytes. ................................ ................................ ...........  137 \nFig. 24. Esquema representativo de los resultados obtenidos en este trabajo.  ........................  149 \n \nFiguras en el Cap\u00edtulo 1  \nP\u00e1gina  \nFig. 1. Study area \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 39 \nFig. 2. Characteristics of the participants in the ethnopharmacological study on the Pur\u00e9pecha \nPlateau \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 40 \nFig. 3. Family distribution of medicinal plants used on the Pur\u00e9pecha Plateau \u2026\u2026\u2026\u2026\u2026\u2026... 42 \nFig. 4. Number of plant species used for treating dermatological conditions on the Pur\u00e9pecha \nPlateau \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 \u2026\u2026\u2026\u2026 44  \nVII Fig. 5. Plant parts and preparation modes used by inhabitants of Pur\u00e9pecha Plateau for treating \ndermatological disorders \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 44 \nFig. 6. Plants with higher use values (UV) for treating dermatological ailments on the Pur\u00e9pecha \nPlateau \u2026\u2026\u2026 \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 45 \n \nFiguras en el Cap\u00edtulo 3 \nP\u00e1gina  \nFig. 1. Schematic representation of mayor tasks described in this paper \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... 111 \nFig. 2. System used for pyrolytic collection of oil -1 and oil -2\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. 112 \nFig. 3. TGA (A) and DT G (B) curves for the residual biomass and pyrolytic products from A. \nadstringens bark\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... 112 \nFig. 4. FTIR spectra of residual biomass and pyrolytic fractions from A. adstringens  bark\u2026..113 \nFig. 5. Py-GC-MS analys is chromatogram of residual biomass from A. adstringens \u2026\u2026\u2026... 113 \nFig. 6. GC-MS analysis chromatograms of pyrolytic oils from A. adstringens \u2026\u2026\u2026\u2026\u2026\u2026. 115 \nFig. 7. UV -fluorescence spectra of the oil samples from A. adstringens \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... 116 \nFig. 8. HPLC -DAD prof iles of liquid p yrolysis samples from A. adstringens \u2026\u2026\u2026\u2026\u2026\u2026. .117 \nFig. 9. Effect of pyrolytic oils on the IL -17-induced production of IL -8 on HaCaT \nkeratinocytes \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.... 117 \n \nFiguras en el Anexo 1  \nP\u00e1gina  \nFig. 1. Patog\u00e9nesis de la psoriasis e implica ci\u00f3n de los nuevos f\u00e1rmacos en desarrollo \u2026\u2026.. 162 \n \n \n \n \n \n \n \n \n \n \n  \nVIII LISTA DE TABLAS  \nP\u00e1gina  \nTabla. 1. Estudios que utilizan extractos acuosos y etan\u00f3licos de plantas empleados por la \nmedicina tradicional para el  tratamiento de la psoriasis.  ................................ ...........................  17 \nTabla. 2. Porcentaje de los diferentes monolignoles presentes en la lignina de diversas plantas.\n ................................ ................................ ................................ ................................ ...................  23 \nTabla 3. Tipos de pir\u00f3lisis y productos principales.  ................................ ................................ .. 25 \nTable 4. Compounds identified by Py -GC/MS in U. subincisa  aerial parts and residual biomass .\n ................................ ................................ ................................ ................................ ...................  86 \nTable 5. Yields of the crude extract, its frac tions, and pyrolytic products from aerial parts from \nU. subincisa.  ................................ ................................ ................................ ..............................  88 \nTable 6. Proximate and elemental analysis of the crude extract , its fractions, and pyrolytic \nproducts from U. subincisa.  ................................ ................................ ................................ ....... 89 \nTable 7. Compounds identified by GC -MS in the crude extract, phases A -C and bio -oils \nobtained from aerial parts of U. subincisa . ................................ ................................ ................  95 \nTable 8. T otal phenols and initial toxicity values (IC 90) of different fractions of U. subincisa .\n ................................ ................................ ................................ ................................ ...................  98 \nTable 9. Py -GC/MS characterization  of dry bark from A. adstringens . ................................ .. 130 \nTable 10. Proximate and elemental analysis of  A. adstringens bark,  crude extract and fractions.\n ................................ ................................ ................................ ................................ .................  132 \nTable 11. Compounds identified by GC -MS in the crude aqueous extract from A. adstringens  \nbark and its fractions. ................................ ................................ ................................ ...............  135 \n \nTablas en el Cap\u00edtulo 1  \nP\u00e1gina  \nTabla 1. Consensus factor values for different dermatological affection categories on the \nPur\u00e9pecha Plateau\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 ..\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. ..43 \n \nTablas e n el Cap\u00edtulo 3 \nP\u00e1gina  \nTabla 1. Pyrolytic products yield of residual biomass from A. adstringens \u2026\u2026 \u2026\u2026 \u2026\u2026\u2026112  \nTabla 2. Proximate and elemental analyses of A. adstringens  samples\u2026 \u2026\u2026\u2026\u2026 \u2026\u2026 \u2026...112  \nTabla 3. Py-GC-MS characterization of the main compounds found in t he residual biomass from \nA. adstringens \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 \u2026\u2026. \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..114  \nTabla 4. GC -MS characterization of the main compounds found in the pyrolytic oils from A. \nadstringe ns\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026... 116 \nTabla 5. HPLC -DAD quali -quantitative analysis of phenolic compounds in A. adstringens  \noils\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 117 \n \nTablas en el Anexo 1  \nP\u00e1gina  \nTabla 1. Nuevos medicamentos en desarrollo para el tratami ento de la psoriasis\u2026\u2026 \u2026\u2026 ...165 \n   \nIX LISTA DE ABREVIATURAS  \n \nAhR   Receptor de hidrocarburos de arilo  \nCCL   Ligando de quimiocina CC  \nCXCL   Quimiocinas  \nFTIR   Espectroscop\u00eda infrarroja por transformada de Fourier  \nGC-MS Cromatograf\u00eda de gases acoplada a espectrometr \u00eda de masas  \nHaCaT   L\u00ednea celular de queratinocitos humanos espont\u00e1neamente transformados  \nIL  Interleucina  \nIL-17R  Receptor de interleucina 17  \nINF  Interfer\u00f3n  \nMAPK   Cinasas de prote\u00ednas activadas por mit\u00f3genos  \nNF-\u03baB  Factor nuclear potenciador de las cadena s ligeras kappa de la c\u00e9lula B activ ada \nPGE2   Prostaglandina E2 (dinoprostona)  \nPY-GC-MS Pir\u00f3lisis - cromatograf\u00eda de gases acoplada a espectrometr\u00eda de masas  \nS100A7  Psoriasina  \nSTAT   Activadores de las se\u00f1ales de transcripci\u00f3n  \nTGF   Factor de crecimiento tra nsformante  \nTh  Linfocito T  \nTNF   Factor de necrosis tumoral  \nUV  Radiaci\u00f3n ultravioleta  \n \n   \n1 RESUMEN  \n \nLa psoriasis es una enfermedad dermatol\u00f3gica incurable caracterizada por la presencia de placas \nrojizas bien delimitadas que afecta aproximadamente a 3 millon es de mexi canos.  Aunque no es \nconsiderada una enfermedad mortal sus repercusiones sobre la calidad de vida de los pacientes \nse han comparado con las del c\u00e1ncer y la hipertensi\u00f3n.  En la actualidad  no se conocen  con \nexactitud  sus bases etiopatog\u00e9nicas, si bien se cons idera a la interleucina ( IL) 17 como un \nmediador clave en su desarrollo y perpetuaci\u00f3n . De hecho, los medicamentos biotecnol\u00f3gicos  \n(secukinumab, ixekizumab , brodalumab ) dirigidos a inactivar esta citocina  o su receptor, han \nmostrado  una elevada  eficacia , aunque sus altos  costos, la imposibilidad de ser administrados \npor v\u00eda t\u00f3pica  y su toxicidad han propiciado la b\u00fasqueda incesante por parte de las compa\u00f1\u00edas \nfarmac\u00e9uticas de nuevas terapias. El presente trabajo se enmarca en una visi\u00f3n de desarrol lo \nfarmac\u00e9utico, donde se sigui\u00f3 un enfoque etnofarmacol\u00f3gico para la b\u00fasqueda de nuevos \ncandidatos terap\u00e9uticos de ori gen natural con posible actividad antipsori\u00e1sica. La Meseta \nPur\u00e9pecha se seleccion\u00f3 como \u00e1rea de estudio para la realizaci\u00f3n del estudio etnofarmacol\u00f3gico \nde partida , lo que permiti\u00f3 la identificaci\u00f3n  de dos especies candidatas ( Urtica subincisa  y \nAmphipte rygium adstringens ) con alto valor de uso por esta poblaci\u00f3n . Noventa y siete especies \nde plantas pertenecientes a 47 familias fueron doc umentadas  por vez primera  para el tratamiento \nde 19 afecciones dermatol\u00f3gicas en la Meseta Pur\u00e9pecha , siendo la familia  Asteraceae la \nprincipal entre las plantas colectadas (20.61%) . La comparaci\u00f3n de los resultados con la \nliteratura etnomedicinal revel\u00f3 q ue 8.25% de las plantas utilizadas en la Meseta Pur\u00e9pecha se \nregistraron por primera vez para tratamiento de afecciones  dermatol\u00f3gicas.  El extracto etan\u00f3lico \nde U. subincisa , acuoso de A. adstringens , sus fracciones  (A-Hexano; B -Acetato de etilo; C -\nAgua)  as\u00ed como  los aceites pirol\u00edticos 1 y 2 derivados de la biomasa extra\u00edda fueron \nqu\u00edmicamente caracterizados  (an\u00e1lisis proximal, elemental, FTIR, Fluorescencia -UV, Py -GC-\nMS, GC-MS) adem\u00e1s de que se determin\u00f3 su toxicidad y capacidad para inhibir la producci\u00f3n  \nde IL -8 en queratinocitos HaCaT estimulados con IL -17. Los resultados del an\u00e1lisis qu\u00edmico \npermitieron constatar que tanto la composici\u00f3n qu\u00edmica de los extractos como de los aceites \npirol\u00edticos  de ambas especies  fue variable . En el caso de U. subincisa , el extr acto etan\u00f3lico  y las \nfases A y B mostraron ser ricas en \u00e9steres, mientras que en la fase C y el aceite pirol\u00edtico -2 \nprevalecieron los compuestos nitrogenados. En contraste, el aceite pirol\u00edtico -1 de esta especie   \n2 mostr\u00f3 una preponderancia de fenoles.  El ext racto acuoso de A. adstringens , as\u00ed como sus \nfracciones A y B, presentaron un predominio  de fenoles y \u00e1cidos, mientras que la fase C mostr\u00f3 \nuna gran abundancia de \u00e1cidos. En los aceites pirol\u00edticos  1 y 2 de A. ad stringens  los fen oles \nrepresentaron e l grupo  dominante  de mol\u00e9culas  identificadas . Tanto para U. subincisa , como  \npara A. adstringens  la muestra con mayor toxicidad estuvo representada por el aceite pirol\u00edtico -\n2, mientras que los extractos obtenidos por extracci\u00f3n convencional presentaron una menor \ntoxicidad sobre los queratinocitos HaCaT . Respecto a la capacidad de inhibir la acci\u00f3n \nproinflamatoria de la IL -17, pudo constatarse diferencias en ambas especies. En el caso de U. \nsubincisa , los extra ctos mostraron un efecto generalmente proinflamat orio, mientras que el \naceite pirol\u00edtico -2 a una concentraci\u00f3n de 7.5 \u03bcg/m L provoc\u00f3 una disminuc i\u00f3n significativa de \nla producci\u00f3n de IL-8, en forma comparable a la dexametasona. En cambio, para A. adstringens  \nel extracto crudo  y la fase C, mostraron una acci\u00f3n anti -IL-17 significativamente mayor que la \nde la dexametasona  y los aceites pirol\u00edticos  (p<0.05 ). Aunque los resultados de este trabajo \npermitieron demostrar por vez primera el potencial  antinflamatorio de los aceites pirol\u00edticos de \nA. adstringens  y U. subincisa , se consider\u00f3  al extracto acuoso de A. adstringens  como el \ncandidato  m\u00e1s prometedor, dado su alto rendimiento de extracci\u00f3n, baja toxicidad y elevada \nacci\u00f3n anti -IL17 .  \n \nPalabras clave : bio-aceites, extractos,  fenoles, IL-17, psoriasis, toxicidad  \n \n \n \n \n \n \n \n   \n3 ABSTRACT  \n \nPsoriasis is an incurable dermatological disease  characterized by well -defined reddish plaques \naffecting  around  3 million Mexicans. Although it is not considered a fatal disease, its \nrepercussions on the patients\u2019 quality of life are comparable to those of  cancer and hypertension. \nAt present, its etiopa thogenic bases have  not been elucidated , although interleukin (IL) 17 is \nconsidered as a key mediator in its development and perpetuation. In fact, biological  drugs  \n(secukinumab, ixekizumab , brodalumab ) aimed to inactivat e this cytokine or its receptor, ha ve \nshown high efficacy, although their high costs, the impossibility of being administered topically \nand their toxicity have led to an incessant search by pharmaceutical companies for new \ntherapies.  The present work follows  a vision of pharmaceutical devel opment, where an \nethnopharmacological study  was performed  to identify  new therapeutic candidates of natural \norigin with possible antipsoriatic activity. The Pur\u00e9pecha Plateau was selected a s the study area  \nfor the ethnomedical research, which allowed the i dentification of two candidate species ( Urtica \nsubincisa  and Amphipterygium adstringens ) according to the  high use value  reported by this \npopulation . Ninety -seven plant species belonging to  47 families were documented for  the first \ntime for treating 19 der matological conditions at the Pur\u00e9pecha Plateau, Asteraceae was the \nmain family of the collected  plants  (20.61%) . The ethanolic extract from  U. subincisa , the \naqueous extract from A. adstringens , their solvent  fractions (A -Hexane; B -Ethyl acetate; C -\nWater)  as well as the pyrolytic oils 1 and 2 derived from the extracted biomass were chemically \ncharacterized (proximal  and elemental  analysis , FTIR, Fluorescenc e-UV, Py -GC-MS, GC -MS) \nin addition to determining their toxicity and ability to inhibit IL -8 producti on in HaCaT \nkeratinocytes stimulated with IL -17. The results of the chemical analysis confirmed that the \nchemical composition of the extracts and the pyrol ytic oils of both species was variable. In the \ncase of U. subincisa,  the ethanolic extract and phases  A and B showed to be rich in esters, \nwhereas in phase C and oil -2, nitrogenous compounds prevailed. In contrast,  oil-1from this \nspecies showed a preponder ance of phenols. The aqueous extract of A. adstringens , as well as \nits fractions A and B, presented a  preponderance of phenols and acids, while phase C showed \nhigh abundance of acids. In oils 1 and 2  from A. adstringens , phenols represented the dominant \ngroup. For both , U. subincisa  and A. adstringens , the sample with the highest toxicity was \nrepresented by pyrolytic oil -2, while the extracts obtained by conventional extraction were   \n4 generally less toxic.  Regarding the ability to inhibit the pro -inflammatory  action of IL -17, \ndifferences were found in both species. As to  U. subincisa , the extract ives showed a \nproinflammatory effect, while pyrolytic oil -2 at 7.5 \u03bcg/mL caused a significant decrease in the \nproduction of IL -8, comparable to that of dexamethasone. On the other hand, for A. adstringens  \nthe crude extract and phase C, showed a significantly higher anti-IL-17 action than that of \ndexamethasone and pyrolytic oils (p <0.05).  Although the results of this work demonstrate d for \nthe first time  the anti -inflammatory potential  of the pyrolytic oils from  A. adstringens  and U. \nsubincisa , the aqueous extract from  A. adstringens  was considered the most promising \ncandidate , given its high extraction yield , low toxicity and significative  anti-IL17 activity. \n \nKey words : bio-oils, extracts, phenols, IL -17, psoriasis, toxicity  \n5 I. INTRODUCCI\u00d3N  \n \nI.1. Psoriasis  \nLas enfermedades der matol\u00f3gicas constituyen un motivo principal de consulta en la atenci\u00f3n \nprimaria  de salud, destac\u00e1ndose entre ellas l a psoriasis que es una enfermedad incurable de la \npiel caracterizada por la presencia de placas rojizas bien delimitadas y escamas secas de color \nblanco -plateado  (Boehncke & Sch\u00f6n, 2015) . La prevalencia mundial de esta patolog\u00eda var \u00eda de \n0.51 a 11.43% en adultos  (Michalek et  al., 2017) ; y en M\u00e9xico, pese a que hay pocos estudios \nepidemiol\u00f3gicos sobre las enfermed ades cut\u00e1neas, se ha estimado u na prevalencia de 2.9% ; lo \nque equivaldr\u00eda a que alrededor de 3 millones de mexicanos estar\u00edan afectados (International \nPsoriasis Council, 2009) . Se estima que del 5 al 30% de los pacientes desarrollan artritis \npsori\u00e1sica, un a enfermedad inflamatoria dolor osa que afecta mayoritariamente las \narticulaciones. La psoriasis tiene un impacto negativo en la calidad de vida de los pacientes, \nfundamentalmente de aquellos con psoriasis moderada o severa (25 -35%), al punto que las \nreperc usiones sobre sus funciones f\u00eds icas y psicol\u00f3gicas se han comparado con las del c\u00e1ncer, \nla hipertensi\u00f3n, las enfermedades cardiovasculares, la diabetes o la depresi\u00f3n (Rapp et  al., \n1999) . \nLa etiolog\u00eda  de la psoriasis no est\u00e1 completamente elucidada , pero l a mayor\u00eda de los conceptos \naceptados indican que su patog\u00e9nesis est\u00e1 impulsada por una interacci\u00f3n compleja entre los \nqueratinocitos y las c\u00e9lulas inmunes  en donde las citocinas y quimiocinas juegan un papel \ncrucial (Fig. 1) (Lowes et  al., 2014) . Una de las hip\u00f3 tesis aceptadas hasta ahora propone que la \nproliferaci\u00f3n acelerada de los queratinocitos psori\u00e1sicos comparativamente a los normales (7 -\n10 d\u00edas vs. 28 -50 d\u00edas) y la diferenciaci\u00f3n incompleta de estas c\u00e9lulas , est\u00e1n relacionadas con \nun aumento de la infiltr aci\u00f3n de linfocitos T  (Th1, Th17, Th22)  y con la liberaci\u00f3n de \ncompuest os inmunomoduladores y quimioatrayentes en la dermis y la epidermis que generan \ncircuitos inflamatorios complejos responsables de perpetuar la enfermedad  (Fig. 1) (Cai et al., \n2012; Lowes et  al., 2007) . \nLas terapias actuales, dirigidas fundamentalmente hacia el manejo de los s\u00edntomas, incluyen \nproductos t\u00f3picos, fototerapia y tratamientos sist\u00e9micos. Estos se encaminan  a: a) inhibir la \nhiperproliferaci\u00f3n de los q ueratinocitos ( ciclosporina A, retinoides ); b) normalizar el proceso   \n6 de diferenciaci\u00f3n aberrante de los queratinocitos ( an\u00e1logos de la vitamina D, retinoides ); c) \ndisminuir el reclutamiento y la activaci\u00f3n de inmunocitos ( ciclosp orina A, medicamentos \nbiote cnol\u00f3gicos ) y d) neutralizar citoc inas proinflamatorias ( medicamentos biotecnol\u00f3gicos ) \n(Garc\u00eda -P\u00e9rez et  al., 2012) . Desafortunadamente, ninguno de estos medicamentos  es curativo , \npor lo que  la industria farmac\u00e9utica contin\u00faa con la b\u00fasqueda incesante de nu evos candidatos \nterap\u00e9uticos para el manejo de la enfermedad  (v\u00e9ase Anexo 1 ). \n \n \nFig. 1. Circuitos inflamatorios en la psoriasis.  \nLa psoriasis implica la interacci\u00f3n compleja entre neutr\u00f3filos, c\u00e9lulas d endr\u00edticas (D C), queratinocitos y linfocitos \nTh1 y Th17 quienes producen mediadores  inflamatorios  (IL-17A, IL -17F, IL -22, TNF -\u03b1 e IFN -\u0263) que estimulan la \ngeneraci\u00f3n de quimiocinas (CXCL y CCL) , citocinas (TNF, IL -26,IL -29), prote\u00ednas proinflamatorias (S100 ) que \ncontribuyen a la activaci\u00f3n de factores de transcripci\u00f3n (NF -\u03baB, STATs)  en los queratinocitos  (KC) , con la \nconsecuente producci\u00f3n de una mayor cantidad de citocinas y quimiocinas que finalmente contribuyen al \nreclutamiento de m\u00e1s inmunocitos en la pi el. \n \n  \n7 I.1.1.  Interleucina -17 y la patog\u00e9nesis de la psoriasis  \nNumerosas evidencias sugieren que la activaci\u00f3n de la respuesta inmunitaria mediada por \nlinfocitos Th1/Th17 participa en el desencadenamiento y perpetuaci\u00f3n de la psoriasis . En la piel \npsori\u00e1sica, los n iveles de interleucina (IL) -17 son hasta 6 veces superiores que en la piel normal \ny estos correlacionan con el grado de severidad de la enfermedad (Johansen et  al., 2009) . De \nhecho, la  eficacia cl\u00ednica  con medicamentos biotecnol\u00f3gicos que bloquean la IL -17 o su \nreceptor, no dejan dudas sobre el impacto de la IL-17 sobre esta  patolog\u00eda.  \nEn el contexto de la piel, la IL -17 es producida, entre otros, por linfocitos Th17, c\u00e9lulas linfoides \ninnatas,  neutr\u00f3filos, y mastocitos . La familia IL -17 est\u00e1 integrada por  6 miembros (IL -17A-F), \nsiendo la IL -17A la isoforma m\u00e1s estudiada . La IL -6 y el TGF \u03b2 promueven la diferenciaci\u00f3n \ninicial de las c\u00e9lulas Th0 a Th17, mientras que la IL-23, producida por las c\u00e9lulas dendr\u00edticas  \nd\u00e9rmicas y los macr\u00f3fagos, estabiliza y expande las c\u00e9lulas Th17. La IL -23, es un heterod\u00edmero \nconstituido por  las subunidades p19  y p40, esta \u00faltima  compartida con la  IL-12. Al unirse a su \nreceptor, la IL -23 activa factores de transcripci\u00f3n co mo ROR \u03b3t y STAT3 presentes en las  c\u00e9lulas \nTh17 , desencaden ando  la liberaci\u00f3n de la IL-17A-F (Sakkas & Bogdanos, 2017) . La familia de \nreceptore s de IL -17 posee  cinco miembros: IL -17RA, IL -17RB, IL -17RC, IL -17RD e IL-17RE.  \nLa IL-17A se une n al heterod\u00edmero I L-17RA/IL -17RC, favoreciendo la activaci\u00f3n de la prote\u00edna \nadaptadora (ACT1), quien activa al  factor nuclear \u03baB (NF -\u03baB). Una vez que el NF-\u03baB est\u00e1 \ncompletamente activado, participa en la regulaci\u00f3n de varios genes diana en las c\u00e9lulas \nepid\u00e9rmicas y d\u00e9rmicas , modul ando la expresi\u00f3n de citocinas inflamatorias  (TNF, IL-1, IL -6), \nquimiocinas  (IL-8), receptores inmunes y mol\u00e9culas de adhesi\u00f3n en la superficie celular  (ICAM -\n1) (Fig. 2). Adem\u00e1s , la IL -17 tambi\u00e9n activa otras v\u00edas como las relacionadas con  las MAPKs \nquinasas  como la quinasa N -terminal c -jun (JNK) , la quinasa regulada por se\u00f1al extracelular \n(ERK) , as\u00ed como la ruta JAK/STAT ( quinasa Janus /el transductor de se\u00f1al y el activador de la \ntranscripci\u00f3n ) y la de la  fosfoinositol 3 quinasa (PI3K) induciendo la formaci\u00f3n de p\u00e9ptidos \nantimicrobianos (\u03b2 -defensina) , citocinas y metaloproteinasas de la matriz  extracelular  (Adami \net al., 2014) .    \n8  \nFig. 2. V\u00eda de se\u00f1alizaci\u00f3n de IL -17. \nLa se\u00f1alizaci\u00f3n de IL -17 comienza con la uni\u00f3n de la s citocina s IL-17 a sus receptores IL -17RA e IL -17RC. Tras \nla uni\u00f3n del ligando, Act1 activa m\u00faltiples v\u00edas de se\u00f1alizaci\u00f3n i ndependientes que median a trav\u00e9s de diferentes \nprote\u00ednas TRAF. La activaci\u00f3n de TRAF6 da como resultado la activaci\u00f3n de las v\u00edas NF -\u03baB, C/EB P\u03b2, C/EBP \u03b4 y \nMAPK. El complejo IL -17R-Act1 tambi\u00e9n se asocia con MEKK3 y MEK5 a trav\u00e9s de TRAF4, lo que resulta en \nla activaci\u00f3n de ERK5. Si bien la se\u00f1alizaci\u00f3n de IL -17 mediada por TRAF6 y TRAF4 da como resultado la \ntranscripci\u00f3n de genes inflama torios, la se\u00f1alizaci\u00f3n de IL -17 a trav\u00e9s del complejo ACT1 -TRAF2 -TRAF5 da \ncomo resultado el control de la estabilidad del ARNm de los genes diana de IL -17 (Hsp: prote\u00edna de choque t\u00e9rmico, \nTRAF: factor asociado al receptor de TNF, TAK1: quinasa 1 activada  por TGF -\u03b2, IKK: inhibidor de la quinasa \nkappa B, ERK: quinasa relacionada con la se\u00f1al extracelular, JNK: quinasa Janus, HuR: ant\u00edgeno humano R, SF2: \nfactor de empalme 2 . Modificado de Amatya et al., 2017) . \n \nLos queratinocitos, son c\u00e9lulas epid\u00e9rmicas que desempe\u00f1 an un papel crucial  en el desarrollo \nde la psoriasis mediado por la IL -17. Un estudio reciente en un modelo animal de psoriasis \ninducida por imiquimod demostr\u00f3  que la eliminaci\u00f3n de los receptores IL -17RA en c\u00e9lulas T o \nmieloides  no tuvo un impacto signifi cativo en el desarrollo de la psoriasis, en cambio la carencia  \n  \n9 de este receptor en los queratinocitos result\u00f3 en una disminuci\u00f3n del engrosamiento epid\u00e9rmico \ny la inflamaci\u00f3n en los animales estudiado s (Moos et  al., 2019) . La IL-17 no solo es fuertemente \nproinflamatoria,  sino que tambi\u00e9n estimula la hiperproliferaci\u00f3n y la diferenciaci\u00f3n aberrante \nde los queratinocitos dentro de la epidermis  (Ekman et  al., 2019) . Los efectos de la IL -17 sobre \nlos queratinocitos no se presentan en forma  aislada, sino que  act\u00faa en sinergismo con otras \ncitocinas  relevantes en la psoriasis  como el factor de necrosis tumoral (TNF -\u03b1), induciendo la \nexpresi\u00f3n de numerosos genes proinflam atorios  caracter\u00edsticos de la enfermedad (psoriasina \nS100A7, \u03b2-defensina DEFB4, IL -8, CCL 20, IL -23 (p19) y CXCL1) . Aunque se ha sugerido que \nesta acci\u00f3n puede deberse a la activaci\u00f3n conjunta de NF-\u03baB, tambi\u00e9n es necesaria la \nparticipaci\u00f3n  de otros mecanis mos post -transcripcionales que no han sido  dilucidados  \n(Chiricozzi et  al., 2011) . \nUna quimiocina fuertemente inducida por la IL -17 en los queratinocitos  es la IL -8, tambi\u00e9n \nconocida como CXCL -8 que ac t\u00faa atrayendo  a los leucocitos, fundamentalmente a los \nneutr\u00f3filos, hacia la piel psori\u00e1sica, mediante quimiotaxis  (Duan et  al., 2001) . La acumulaci\u00f3n \nde los neutr\u00f3filos en la piel, se considera un evento temprano de gran relevancia en la formaci\u00f3n \nde las placas pso ri\u00e1sicas , ya que estas c\u00e9lulas activadas pueden influir no solo en el crecimiento \ny la diferenciaci\u00f3n de los queratinocitos e pid\u00e9rmicos, sino tambi\u00e9n en el estado de activaci\u00f3n \nde los linfocitos  T (Terui et  al., 2000) . La producci\u00f3n de IL -8 es ma yor en el suero y la piel de \npacientes con psoriasis  (Bai et  al., 2017) , y sus niveles se correlacionan con la severidad de la \nenfermed ad (Arican et  al., 2005) . Recientemente se ha sugerido que la variaci\u00f3n de los niveles \nde IL -8 en pacientes con psoriasis  podr\u00eda ser utilizado como un marcador de respuesta \nterap\u00e9utica  (Bai et  al., 2017) . Los marcadores de respuesta terap\u00e9utica son de gran  utilidad \ndurante el desarrollo temprano de medicamentos, ya que facilitan  la toma de decisiones respecto \na estudios ulte riores con el candidato  terap\u00e9utico  de inter\u00e9s.  \nEl descubrimiento de productos biotecnol\u00f3gicos dirigidos a inactivar a la interleucina  IL-17 o a \nsu receptor ( secukinumab, ixekizumab y brodalumab),  han demostrado una eficacia \nantipsori\u00e1sica superior a la d e inhibidores del TNF -\uf061 (Griffiths et  al., 2010) ; aunque los eventos \nadversos, los altos costos , la imposibilidad de administraci\u00f3n t\u00f3p ica y la falta de respuesta en \nalgunos pacientes pueden limitar su uso  (Bissonnette et  al., 2014; Lv et  al., 2018) .    \n10 Para alcanzar el \u00e9xito terap\u00e9utico la adherencia al tratamiento es esencial, desafortunadamente \nen el caso de la psoriasis hay una gran ins atisfacci\u00f3n que conduce a los pacientes al uso de \nmedicina complementaria o alternativa donde los extractos de plantas y los productos pirol\u00edticos \ncomo el alquitr\u00e1n de hulla son ampliamente utilizados (Moscaliuc et  al., 2013; Svendsen et  al., \n2017; Talbott & Duffy, 2015) . Sin embargo, muchos de estos extractos y productos pirol\u00edticos \nno est\u00e1n caracterizados qu\u00edmicamente  o bi en no cuentan con pruebas toxicol\u00f3gicas o \nfarmacodin\u00e1micas pudiendo  contribuir a la  aparici\u00f3n de eventos adversos y a la exacerbac i\u00f3n \nde la enfermedad  (Fleischer et  al., 1996) . Por lo tanto, la b\u00fasqueda de agentes terap\u00e9uticos anti -\nIL-17 m\u00e1s asequibles, ef ectivos y seguros sigue  en curso  (v\u00e9ase Anexo 1 ). \nI.1.2.  El desarrollo de f\u00e1rmacos para  la psoriasis  \nEl desa rrollo farmac\u00e9utico puede definirse como un conjunto ordenado de fases  que conducen \nal desarrollo de un medicamento  (King et  al., 2010) . El esquema cl\u00e1sico de desarrollo de \nf\u00e1rmacos est\u00e1 conformado convencionalmente  por el traslado de conocimientos desde la \ninvestigaci\u00f3n b\u00e1sica hacia la investigaci\u00f3n cl\u00ednica en un sentido unidireccional , involucra ndo \nvarias fases: 1) Fase de des cubrimiento; 2) Fase de investigaci\u00f3n precl\u00ednica; 3) Fase de \ninvestigaci\u00f3n cl\u00ednica; 4) Fase de registro y apro baci\u00f3n, y la 5) Fase de desarrollo qu\u00edmico -\nfarmac\u00e9utico (Fig. 3). Estas fases cuentan a su vez con las  etapas  siguientes : a) establecimiento \nde hip\u00f3tesis etiopatog\u00e9nica s de la enfermedad; b) identificaci\u00f3n de dianas farmacol\u00f3gicas; c) \ndescubrimiento y selecci\u00f3n de candidatos terap\u00e9uticos; d) optimizaci\u00f3n qu\u00edmica de los \ncompuestos seleccionados; e) pruebas precl\u00ednicas en anim ales de experimentaci\u00f3n; f) \nevaluaci\u00f3n de la se guridad en seres humanos y el establecimiento de las propiedades \nfarmacocin\u00e9ticas (fase I); g) las pruebas de eficacia (prueba de concepto; fase II) y finalmente \nf) los ensayos cl\u00ednicos multic\u00e9ntricos a mayor escala para evaluar la seguridad y eficacia (fa se \nIII) (Turner, 2010) . La vigilancia posterior a la comercializaci\u00f3n del medicamento , tambi\u00e9n \nconocida como farmacovigilancia,  contin \u00faa vigente ante cualquier eventualidad que se presente  \ncon el uso no contro lado de los f\u00e1rmacos  (Turner, 2010) .   \n11  \nFig. 3. Esquema cl\u00e1sico de desarrollo farmac\u00e9utico . \nEl esquema cl\u00e1sico de desarrollo farmac\u00e9utico se inicia por la fase de descubrimiento y termina con la fase cl\u00ednica \nque brindan la evidencia p ara el registro de aprobaci\u00f3n ante las agencias reguladoras. Pocos f\u00e1rmacos son \naprobados anualmente y estos contin\u00faan bajo vigilancia durante su comercializaci\u00f3n.  \n \nEn los \u00faltimos a\u00f1os ha nacido el t\u00e9rmino \u201cmedicina traslacional\u201d, que se refiere a un nuevo  \nparadigma basado en la necesidad de in tegrar los conocimientos cient\u00edficos que se generan \ndurante la investigaci\u00f3n b\u00e1sica al desarrollo de tratamientos con impacto cl\u00ednico (bench -to-\nbedside). En su acepci\u00f3n  m\u00e1s amplia el concepto de medicina traslacional puede entenderse \ncomo un proceso bidire ccional, donde  adem\u00e1s del traslado de conocimientos desde la ciencia \nb\u00e1sica a la cl\u00ednica, los nuevos hallazgos derivados de la investigaci\u00f3n cl\u00ednica sirven de base para \nla generaci\u00f3n de hip\u00f3tesis cient\u00edficas utilizada s en ciencia fundamental (bedside -to-bench) \n(Guttman -Yassky & Krueger, 2007) . La psoriasis constituye un excelente ejemplo de la \nimportancia de la medicina traslacional  para el desarrollo de nuevos tratamientos. De hecho, los \nprimeros tratamientos antipsor i\u00e1sicos, como la fototerapia o la ciclo sporina, se desarrollaron a \n  \n12 partir de una aproximaci\u00f3n emp\u00edrica que parti\u00f3 de la evidencia cl\u00ednica y se traslad\u00f3 r\u00e1pidamente \na nuevos conceptos en ciencia b\u00e1sica (bedside -to-bench).  \nLa relevancia de los enfoques de me dicina traslacional se evidencia en des cubrimientos que han \nsacudido los paradigmas etiopatog\u00e9nicos  de la enfermedad . Un ejemplo de ello es la reconocida \nimportancia de la IL -17 y el desarrollo ulterior de medicamentos biotecnol\u00f3gicos. \nInvestigaciones  de c iencia b\u00e1sica combinados con comprobaciones cl\u00ednicas (be nch-to-\nbedside/bedside -to-bench)  permitieron el establecimie nto de l nuevo paradigma en la \nfisiopatolog\u00eda de la enfermedad relacionado con el eje IL -23/ IL -17. La consecuencia l\u00f3gica de \nestas investiga ciones fue el desarrollo de dos anticuerpos contra la subunidad p40: el \nustekinumab y briakinumab, as\u00ed  como de inhib idores de la IL -17 o de su receptor (secukinumab, \nixekizumab, brodalumab) (v\u00e9ase Anexo 1 ). \nEn la actualidad, l a psoriasis es una de las enfermedades que presenta mayor desarrollo \nfarmac\u00e9utico a escala global  (Cervantes -Dur\u00e1n e t al., 2020; Esquivel -Garc\u00eda et  al., 2018 a). Sin \nembargo, son numerosos los  retos a enfrentar para  llevar  con \u00e9xito este proceso, dentro de los \nque se destaca : 1) la identificaci\u00f3n de biomarcadores predictivos de toxicidad, farmacocin\u00e9tica \ny eficacia farma col\u00f3gica; b) el desarrollo de modelos in vitro  e in vivo  m\u00e1s representativos de \nla enfermedad , as\u00ed como  c) la integraci\u00f3n de aspectos farmac ogen\u00f3micos al proceso del \ndescubrimiento de f\u00e1rmacos  (Esquivel -Garc\u00eda  et al., 2018 a). \nUna vez que los f\u00e1rmacos son desarrollados, estos se integran en  esquemas cl\u00ednicos que deben \najustarse a  las caracter\u00edsticas y necesidades de los pacientes. Ello implica que durante el \ndesarrollo  farmac\u00e9utico se tenga en cuenta la poblaci\u00f3n a la que va a s er administrado el \nproducto de inter\u00e9s. La individualizaci\u00f3n de las terapias para la psoriasis encuentra algunos \ndesaf\u00edos, ya que cada paciente tiene su propia forma de p soriasis, e incluso dentro del mismo \npaciente, las caracter\u00edsticas de la psoriasis pue den variar considerablemente  (van de Kerkhof, \n2008) . De hecho, se han descrito  diferencias inter-paciente  en t\u00e9rminos del inicio de la \nenfermedad, la cronicidad, su ubica ci\u00f3n anat\u00f3mica, los factores desencadenantes y las \ncomorbilidades existentes. Adem\u00e1s, los polimorfismos en los genes que codifican prote\u00ednas \nimportantes para la farmacocin\u00e9tica y farmacodin\u00e1mica de los medicamentos antipsori\u00e1sicos  \npodr\u00edan explicar  la varia bilidad  encontrada en la respuesta a los tratamientos  (Lebwohl, 2016; \nWoolf & Smith, 2 010). Aunque el uso de biotecnol\u00f3gicos  anti-IL-17 ha sido bien aceptado por   \n13 pacientes con psoriasis severa, su administraci\u00f3n parenteral, elevados costos y presencia de \nreacciones de inmunogenicidad constituyen limitaciones para  individuos con psoriasis le ve y \nmoderada  (aproximadamente el 80% de los pacientes ) (Armstrong et  al., 2013) , quienes \nprefieren el uso de medicamentos t\u00f3picos  (Kim et  al., 2017) . El desarrollo de me dicamentos \nanti-IL17  administrados en la piel  mejor adaptados a las necesidades de  personas con psoriasis \nleve y moderada  ser\u00eda una estrategia , que, de lograrse  permitir\u00eda  elevar la adherencia  a las \nterapias  y el \u00e9xito de los tratamientos  con el consecuent e incremento de  la calidad de vida de \nestos  individuos .  \nI.2.  La etnofarmacolog\u00eda y el desarrollo farmac\u00e9utico en la psoriasis  \nVarias son las estrategias que se utilizan  durante la fase de descubrimiento de nuevos \nmedicamentos  para la psoriasis , destac\u00e1ndose e l uso de mol\u00e9culas o mezclas de mol\u00e9culas \nobtenidas por s\u00edntes is qu\u00edmica,  a partir de procesos biotecnol\u00f3gicos o bien utilizando fuentes \nnaturales. Los productos naturales presentan numerosas ventajas  para el desarrollo de nuevos \nmedicamentos  antipsori\u00e1sic os ya que poseen una amplia gama de farmac\u00f3foros con alta \ncomp lejidad este reoqu\u00edmica  (Harvey et  al., 2015) , lo que favorece la uni\u00f3n  sobre dianas \ncomplejas que implican interacciones prote\u00edna -prote\u00edna como las que se presentan en  los \ncircuitos inflamatorio s mediados por citocinas.  Otra ventaja del uso de productos na turales  para \nla psoriasis se relaciona con el hecho de provenir directamente de la naturaleza , ya que se ha \nsugerido que numerosos compuestos exitosos como f\u00e1rmacos tienen la propiedad de \u201csemej anza \nde metabolitos\u201d (\u201c metabolite -likeness \u201d), que significa qu e tales compuestos no solo son \nbiol\u00f3gicamente activos , sino que tambi\u00e9n pueden ser sustratos para uno o m\u00e1s sistemas \ntransportadores , facilitando  la cesi\u00f3n de los compuestos activos  a su sitio d e acci\u00f3n intracelular  \n(Hert et  al., 2009) . \nLa elecci\u00f3n de la fuente natural sobre la cual se estructurar\u00e1 el desarrollo farmac\u00e9utico es de \ncrucial importancia para la obtenci\u00f3n de candidatos terap\u00e9uticos relevantes. Este proceso puede \nseguir varias estrate gias: a) estrategia al azar; b) estrategia quimiotaxon\u00f3mica; c) estrategia \netnofarmacol\u00f3gica ; d) estrategia ecol\u00f3gica  (Abreu Guirado & Cu\u00e9llar Cu\u00e9llar, 2008) . La \nestrategia etnofarmacol\u00f3gica ha sido una de las m\u00e1s eficaces en el descubrimiento de nuevos \nmedicamentos, siendo la etnofarmacolog\u00eda cons iderada como \u201cla exploraci\u00f3n cient\u00edfica \ninterdisciplinaria de productos biol\u00f3gicamente activos utilizados u observados por el hombre\u201d    \n14 (Bruhn & Helmstedt, 1981) . En este enfoque cobran extraordinaria importancia l as tradiciones  \nque se consideran como  entida des din\u00e1micas de conocimiento experimental en continua \nevoluci\u00f3n  a medida que las comunidades y los individuos descubren  nuevas t\u00e9cnicas que \ntransforman el uso de las plantas  (Patwardhan, 2005) .  \nLa etnofarmacolog \u00eda como un campo de investigaci\u00f3n bien defi nido tiene una historia de \ndesarrollo que se inicia en el siglo XX (Heinrich & Gibbons, 2001) . Sin embargo, mediante su \ninteracci\u00f3n con otras \u00e1reas del conocimiento como la antropolog\u00eda, la bot\u00e1nica y la farmacolo g\u00eda \nse ha transformado en una herramienta e sencial para la b\u00fasqueda de nuevos candidatos \nterap\u00e9uticos a trav\u00e9s del uso, entre otros, de plantas medicinales relevantes para la medicina \ntradicional de distintas regiones del mundo (Heinrich et  al., 2009) . \nSiguiendo el enfoque etnofarmacol\u00f3gico las especies elegidas para el desarrollo farmac \u00e9utico  \nson aquellas que han demostrado una eficacia terap\u00e9utica como consecuencia de su utilizaci\u00f3n \ntradicional por la poblaci\u00f3n (Abreu Guirado & Cu\u00e9llar Cu\u00e9llar, 2008) . A p artir de estos est udios \nse inicia un proceso de validaci\u00f3n cient\u00edfica ( Fig. 4), en donde las mol\u00e9culas de origen natural \nque se consideran candidatos para el desarrollo de nuevos f\u00e1rmacos son sometidas a rigurosas \npruebas para contar con la evidencia de seguridad y eficacia  requerida para su uso en una \npatolog\u00eda determinada  (Fabrican t & Farnsworth, 2001; Gertsch, 2009) . En la psoriasis este \nproceso cobra extraordinaria importancia al tratarse de una enfermedad caract erizada por la \npresencia de circuitos inflamatorios complejos donde las mol\u00e9culas naturales podr\u00edan ofrecer \nalternativas  terap\u00e9uticas dada su complejidad estructural y acci\u00f3n multidiana  (Patwardhan, \n2005) .   \n15  \nFig. 4. Proceso de evalua ci\u00f3n cient\u00edfica en etnofarmacolog\u00eda.  \nFases de validaci\u00f3n en el proceso de evaluaci\u00f3n etnofarmacol\u00f3gica. Los medicamentos  tradicionales a base de \nplantas pueden evaluarse directamente en ensayos cl\u00ednicos, utilizarse como base para la bioprospecci\u00f3n o somete rse \na estudios in vitro  relacionados con la indicaci\u00f3n etnofarmacol\u00f3gica. Las hip\u00f3tesis farmacol\u00f3gicas pueden ser \nrefuta das en base a estudios in vitro  y en animales. Sin embargo, solo los estudios cl\u00ednicos aleatorizados, doble \nciego y controlados con plac ebo permiten la confirmaci\u00f3n o refutaci\u00f3n de  la evidencia anecd\u00f3tica (conocimiento \ntradicional . Modificado de Gertsch, 2 009). \n \nLa medicina tradicional mexicana es reconocida a nivel mundial por su gran riqueza cultural , \nalta diversidad flor\u00edstica, y por su  contribuci\u00f3n en  el desarrollo de medicamentos de gran \nimpacto en la terap\u00e9utica (Heinrich et  al., 2014) . Los estudios etnofarmacol\u00f3gicos realizados en \nel territorio mexicano no solo muestran que la pr\u00e1ctica de la medicina tradicional  contin \u00faa \nvigente (Alonso-Castro et  al., 2017; Heinrich et  al., 2014) , sino que tambi\u00e9n permiten \nresguardar el conocimiento etnomedicinal que desafortunadamente  se pierde en el paso de \ngeneraci\u00f3n a generaci\u00f3n (Calvo et  al., 2011) . \nUna de las regiones de inter\u00e9s etnofarmacol\u00f3gic o en M\u00e9xico es l a meseta Pur\u00e9pecha , la cual es  \nun rico reservorio de biodiversidad  (Bello -Gonz\u00e1lez et  al., 2015; Medina, 2003) . La \nparticipaci\u00f3n de la medicina tradicional como parte de los servicios de salud en esta regi\u00f3n es \nmuy importante, principalment e en aquellos lu gares donde el sistema de salud p\u00fablica a\u00fan es \ndeficiente (BDMTM, 2009; Gallardo Ruiz, 2002) . A pesar de l vasto conocimiento tradicional \n  \n16 de la flora medicinal de los terapeutas Pur\u00e9pecha s desde tiempos precortesianos , no hay estudios \netnofa rmacol\u00f3gicos dis ponibles que reporten el uso de plantas para el tratamiento de afecciones \ndermatol\u00f3gicas por esta poblaci\u00f3n. Por lo tanto, se considera que la documentaci\u00f3n de este \nconocimiento podr\u00eda contribuir a la identificaci\u00f3n de especies de inter\u00e9s p ara el desarroll o de \nnuevos candidatos terap\u00e9uticos o preparaciones herba rias antipsori\u00e1sic as. \nUno de los objetivos de la etnofarmacolog\u00eda  durante el proceso de validaci\u00f3n cient\u00edfica es \nrealizar el  an\u00e1lisis fitoqu\u00edmico de las especies de inter\u00e9s (Gertsch, 2009) . Dicho an\u00e1lisis debe \nser congruente con la forma de preparaci\u00f3n reportada en la medicina tradicional  (Gupta et  al., \n2010) . Dada la baja toxicidad de los solventes empleados en las culturas tr adicionales, es \nfrecuente el uso de preparaciones acuosas , alcoh\u00f3licas e  hidroalcoh\u00f3licas de las plantas  para \ntratar padecimientos de la piel . Estos solventes polares permiten extraer d iversos grupos de \nmetabolitos  como polifenoles, az\u00facares, terpenos y co mpuestos nitrogenados, implicados en los \nsistemas de defens a de las plantas . Muchos de estos metabolitos se han empleado como \ncandidat os terap\u00e9uticos  para el tratamiento de la psoriasis  (Edeas, 2008) . \nUna vez que se completa el an\u00e1lisis fitoqu\u00edmico, los ex tractos deben evaluarse desde el punto \nde vista farmacol\u00f3gi co y toxicol\u00f3gico  usando  modelos precl\u00ednicos in vitro  o in vivo  relevantes \npara la patolog\u00eda de inter\u00e9s . Esta evaluaci\u00f3n es de extraordinaria importancia ya que permite \ncorroborar el uso tradiciona l, y pone en evidencia los riesgos del consumo para la pobl aci\u00f3n . En \ncaso de obtenerse una buena relaci\u00f3n beneficio/riesgo  durante el desarrollo precl\u00ednico , las \npreparaciones analizadas deben ser probadas como parte de estudios cl\u00ednicos controlados en \nseres humanos . Finalmente, u n elemento esencial que distingue a l desarrollo de medicamentos \nsiguiendo el enfoque etnofarmacol\u00f3gico debe ser una comprensi\u00f3n s\u00f3lida de la base \nsociocultural del grupo \u00e9tnico y una integraci\u00f3n de la informaci\u00f3n recopilada a lo lar go de los \nestudios cient\u00edficos con el contexto  socio cultura l de partida  (Heinrich et  al., 2009) .  \nI.3. Uso de extractos acuosos  y etan\u00f3licos  de plantas como candidatos \nterap\u00e9uticos para el tratamiento de la psoriasis  \nEl uso de extractos acuosos  y etan\u00f3licos  para el tratamiento de la psoriasis en diversos sistemas \nm\u00e9dic os tradicionales en todo el mundo est\u00e1 bien documentado en la literatura cient\u00edfica. La \nTabla. 1 muestra los extractos y las especies que han encontrado mayor aplicaci\u00f3n para esta \nenfermedad basado en su uso en la medicina tradicional .   \n17  \nTabla. 1. Estudios que utilizan extractos acuosos y etan\u00f3licos de plantas empleados por la medicina \ntradicional para el tratamiento de la psoriasis.  \nEspecie  Parte de la \nplanta  Tipo de \nextracto  Resultados  Referen cia \nCassia \nauriculata  L. Flores  Etan\u00f3lico  Reducci\u00f3n del grosor epid\u00e9rmico y \ndisminuci\u00f3n de la severidad de las placas \n(eritema, enrojecimiento y descamaci\u00f3n) \nen la piel psori\u00e1sica de un modelo animal.  (Vijayalakshmi \net al., 2019)  \nGentiana lutea  \nL. Ra\u00edz Etan\u00f3lico  Modulaci\u00f3n de la s\u00edntesis de ceramidas en \ncultivos de queratinocitos.  (Gendrisch \net al., 2020)  \nTinospora  \ncordifolia  \n(Willd.) Miers \nex Hook. f. & \nThomson ; \nCurcuma longa  \nL. Tallos  \nRa\u00edz Acuoso  \nEtan\u00f3lico  Mejora la apariencia de la piel en un \nmodelo a nimal de psoriasis inducida con \nImiquimod, disminuye los niveles de \nARNm de IL-17, IL -23, IL -1 y TNF en la \npiel y la sangre de los animales tratados.  (Arora et  al., \n2016)  \nDillenia indica  \nL. Frutos  Etan\u00f3lico  Reducci\u00f3n de la ortoqueratosis y \nparaqueratosis en un modelo animal de \npsoriasis.  (Kviecinski \net al., 2016)  \nMahonia \naquifolium  \n(Pursh) Nutt.  Cortezas  \nFrutos  Acuoso  \nEtan\u00f3lico  Inhibidor de la proliferaci\u00f3n de los \nqueratinocitos. En estudios cl\u00ednicos se \ndemostr\u00f3 una mejor\u00eda de las lesiones \npsori\u00e1sicas con  un perfil favorable de \neventos adversos.  (Gulliver & \nDonsky, 2005; \nM\u00fcller et  al., \n1995)  \nAloe vera  (L.) \nBurm. f.  Hojas  Etan\u00f3lico  En un modelo de cola de rat\u00f3n, el extracto \nestimul\u00f3 la diferenciaci\u00f3n de la \nepidermis. La actividad antipsori\u00e1sica fue \ndel 81. 95% comparativamente al 87.94% \ndel grupo que recibi\u00f3 el Tazaroteno como \ncontrol positivo.  (Dhanabal \net al., 2012)  \nMelissa \nofficinalis  L. Partes \na\u00e9reas  Acuoso  Alta capacidad antioxidante. \nReestablecimiento de la hidrataci\u00f3n de la \npiel y la funci\u00f3n de barre ra epid\u00e9rmica en \nun modelo murino de psoriasis inducida.  (Dimitris et  al., \n2020)  \nPicea mariana  \n(Mill.) Britton, \nSterns  & \nPoggenb.  Cortezas  Acuoso  Disminuci\u00f3n de la producci\u00f3n de IL -8, \nIL-6, fractalkina, \u00f3xido n\u00edtrico y PGE2 en \nqueratinocitos normales y ps ori\u00e1sicos \nestimulados con TNF -\u03b1 v\u00eda la inhibici\u00f3n \nde la activaci\u00f3n de NF-\u03baB. (Garc\u00eda -P\u00e9rez \net al., 2014)  \nArtemisia \ncapil laris \nThunb . Partes \na\u00e9reas  Etan\u00f3lico  Disminuci\u00f3n de la severidad de la \npsoriasis en un modelo animal de \npsoriasis inducida con Imiquimo d. \nDisminuci\u00f3n del engrosamiento \nepid\u00e9rmico y de la expresi\u00f3n de Ki67. \nEfectos antiproliferativos en \nqueratinocitos HaCaT.  (Lee et  al., \n2018)  \n \nLa elecci\u00f3n de estos solventes , adem\u00e1s de ser aceptables desde el punto de vista toxicol\u00f3gico,  y \npor lo tanto de  gran uso en la medicina tradicional, permiten  extraer numerosos metabolitos   \n18 secundarios, siendo los  fenoles, dad a su polaridad, uno de los grup os de compuestos bioactivos \nmayoritariamente presentes  en este tipo de extractos .  \nEl uso de compuestos fen\u00f3lico s, extra\u00eddos de manera convencional con solventes polares a partir \nde plantas medicinales (Edeas, 2008; Stevanovic et  al., 2009) , ha quedado pla smado en la \nmedicina tradicional de distintas regiones del mundo, y actualmente diferentes formulaciones \nque los  contienen son utilizadas en las medicinas convencional, complementaria y alternativa \npara el tratamiento de placas psori\u00e1sicas (Svendsen et  al., 2017; Talbott & Duffy, 2015) . Aunque \nestos estudios demuestran el potencial farmacol\u00f3gico de estos extractos, las plantas m\u00e1s \nutilizadas son en su mayor\u00eda provenientes de  sistemas m\u00e9dicos tradicionales de otros pa\u00edses, \nmientras que falta documentaci\u00f3n so bre las propiedades antipsori\u00e1sicas de plantas nativas de \nM\u00e9xico.  \nSe ha demostrado que los polifenoles del t\u00e9 ve rde pueden inducir la expresi\u00f3n de la caspasa 14, \nuna proteasa cuya expresi\u00f3n aparece disminuida en la piel psori\u00e1sica y que participa en la \ndiferenciaci\u00f3n terminal de los queratinocitos y la formaci\u00f3n del stratum corneum  (Hsu et  al., \n2007) . Adem\u00e1s, polife noles como la curcumina, presente en la planta C. longa , pueden \ndisminuir la expresi\u00f3n de citocinas proinflamatorias como la IL -6 e IL -8 en los queratinocitos \n(Miquel et  al., 2002) .  \nLos polifenoles de P. mariana  han demostrado ser potentes antinflamatorio s, bloqueando la \nacci\u00f3n del TNF -\u03b1 en queratinocitos psori\u00e1sicos, con una actividad incluso superior a la \ndexametasona, un f\u00e1rmaco utilizado para  el tratamiento de esta enfermedad (Garc\u00eda -P\u00e9rez et  al., \n2014) . Aunque estos estudios indican el potencial antinflamatorio  de estas mol\u00e9culas pa ra el \ntratamiento de la psoriasis, su efecto farmacol\u00f3gico en otras dianas terap\u00e9uticas como la IL -17, \nde import ancia capital para la patog\u00e9nesis de esta enfermedad, no ha sido elucidado.  \nI.4. Estructura qu\u00edmica  de los compuestos fen\u00f3licos extra\u00edbles  \nLos polife noles son un extenso grupo de compuestos que se utilizan como agentes \nantipsori\u00e1sicos a partir de diversas modalidades terap\u00e9uticas  y que son considerados como \nextra\u00edbles en las plantas ya que pueden ser obtenidos por extracci\u00f3n convencional con solventes \npolares . Se trata de una gran variedad de metabolitos secundarios que se caracterizan por \ncontener  uno o m\u00e1s grupos fen\u00f3licos y reciben el nombre de polifenoles, compuestos fen\u00f3licos \no bien de fenilpropanoides.    \n19 Desde el punto de vista de la estructura qu\u00ed mica, son un grupo diverso que comprende desde \nmol\u00e9culas sencillas como los fenoles simples y \u00e1cid os fen\u00f3licos hasta pol\u00edmeros complejos \ncomo los taninos y la lignin a, aunque esta \u00faltima no puede ser extra\u00edda con solventes por \nm\u00e9todos de extracci\u00f3n convenc ional  y no pertenece al grupo de los extra\u00edbles . En el grupo \ntambi\u00e9n se encuentran los flavonoides , estilbenos y lignanos, muchos de los cuales est\u00e1n \nimplicados en las interacciones planta -herb\u00edvoro  (Schultz et  al., 1992) . En combinaci\u00f3n con \nfototerapia, e l psoraleno  es uno de los fenoles m\u00e1s representativos para el tratamiento de la \npsoriasis (Lapolla  et al., 2011) . \nLa ruta del \u00e1cido shik\u00edmico  es responsable de la bios\u00edntesis de la mayor\u00eda de los fenoles de \nplantas. A partir de eritrosa -4-P y de \u00e1cido fosf oenolpir\u00favico se inicia una secuencia de \nreacciones que conduce a la s\u00edntesis de l \u00e1cido shik\u00edmico  y, derivados de \u00e9ste, como los \namino\u00e1cidos arom\u00e1ticos (fenilalanina, tript\u00f3fano y tirosina). La mayor\u00eda de los compuestos \nfen\u00f3licos derivan de la fenilalanina . Esta ruta est\u00e1 presente en plantas, hongos y bacterias, pero \nno en animales  (Garc\u00eda & Carril, 20 11).  \nLos fenoles simples, los aldeh\u00eddos y los \u00e1cidos fen\u00f3licos presentan  estructuras  qu\u00edmicas  simples , \ny poseen un peso molecular bajo respecto a los taninos . Los fenoles simples est\u00e1n representados \npor una estructura C 6 formada por un anillo benc\u00e9nico y sus derivados. Dentro de este subgrupo \nse encuentra el pirocatecol, resorcinol y el orcinol  (Fig. 5). Las estructuras  C6-C1 constitui da por \nun anillo benc\u00e9nico al cual se une un \u00e1tomo de carbono, son caracter\u00edsticas de m\u00faltiples \naldeh\u00eddos fen\u00f3licos presentes en el reino de las plantas como la vainillina, el  salicilaldeh\u00eddo e \nhidroxibenzaldeh\u00eddo , pero tambi\u00e9n de \u00e1cidos fen\u00f3licos qu e se h an considerado bioactivos como \nlos \u00e1cidos g\u00e1lico y salic\u00edlico  (Fig. 5) (Stevanovic et  al., 2009) . \nEntre los compuestos fen\u00f3licos con estructuras C 6-C2 se encuentr an compuestos relacionados \ncon e l \u00e1cido fenilac\u00e9tico y las acetofenon as, dentro de los que se encuentran los  derivados de la \np-hidroxiacetofenona que han sido identificados en plantas como Populus balsam\u00edfera  L. \n(Stevanovic & Perrin, 2009) . Los \u00e1cidos hidroxicin\u00e1micos, por su parte tienen una estructura \nC6-C3 y han sido rec onocidos por sus propiedades antioxidantes y ant iinflamatorias, dentro de \nlos que se encuentran los \u00e1cidos clorog\u00e9nico, cafeico y fer\u00falico  (Fig. 5) (Stevanovic et  al., 2009) .   \n20  \nFig. 5. Estructuras qu\u00edmicas de  polifenoles encontrados frecuentemente en las plantas.  \n \nLos estilbenos  son otro subgrupo de compuestos fen\u00f3licos que contienen muchas mol\u00e9culas  \nbioactiv as, siendo el resveratrol  (Fig. 5) uno de los m\u00e1s reconocid as (Shen et  al., 20 09). Se \nsintetizan mediante la adici\u00f3n de 1 a 3 mol\u00e9culas de malonil -CoA a los \u00e1cidos cin\u00e1micos . La \nestructura m\u00e1s simple de los estilbenos est\u00e1 representada por el 1,2-difeniletano. Adem\u00e1s, \nexisten tambi\u00e9n  derivados hidroxilados. Juntamente con  los biben cilos, que tambi\u00e9n tienen un \nesqueleto C6 -C2-C6, forman la familia de los estilbenoides  (Stevanovic & Perrin, 2009) .  \nLos lignanos y los neolignanos son d\u00edmeros naturales de fenilpropano  que tambi\u00e9n son \nreconocidos por sus propiedades biol\u00f3gicas. C uando las  unidades de fenilpropano est\u00e1n unidas \npor enlaces C -C en las posiciones 8 y 8 ', el compuesto se considera un lignano. Si los d\u00edmeros \nde fenilpropano est\u00e1n unidos por otro tipo de enlaces,  es un neolignano. Por lo tanto, hay \nneolignanos que contienen enlac es C-C 8-O-4', 3-O-4' (oxineolignanos), 3 -3', 8-3', 1-3', etc . \n(Moss, 2000) . El (-)-matairesinol (Fig. 5) es un intermediario central en la bios\u00edntesis de muchos \nlignanos, dentro de los que se encuentra la podofilotoxina, un agente antiviral  con propiedades \nanticancer\u00edgenas  obtenido de los rizoma s y ra\u00edces de plantas perennes del g\u00e9nero Podophyllum  \nL. (X. Zhang et  al., 2018) . La podofilotoxina es el ingrediente activo de Condylox\u00ae o \nCondyline\u00ae, utilizado cl\u00ednicamente para el tratamie nto de las verrugas genitales.  \n  \n21 Los flavonoides  son uno de los gru pos de polifenoles m\u00e1s distribuidos en el reino de las plantas \ny est\u00e1n representados por compuestos que tienen esqueletos C6 -C3-C6, es decir, una parte \nbasada en el fenilpropano. Su estructur a molecular se caracteriza por un esqueleto de carbono \ndel tipo d ifenil 1,3 -propano que comprende 15 \u00e1tomos de carbono distribuidos en dos anillos de \nbenceno , denominados A y B , unidos entre s\u00ed por la estructura de cromano con tres carbonos. \nExisten varios s ubgrupos de flavonoides seg\u00fan el grado de insaturaci\u00f3n y oxidaci\u00f3 n del \nheterociclo : flavonas, flavanonas, flavanos e isoflavonas  (Stevanovic & Perrin, 2009) . Los \nflavonoides generalmente existen en la naturaleza en forma hidroxilada,  aunque  la pre sencia de \ncarbohidratos o grupos metilo en hidroxilos fen\u00f3licos e s muy frecuente.  Dentro de este grupo \nse encuentran compuestos como el galato de epigalocatequina y la miricetina (Fig. 5) con \npropiedades antipsori\u00e1sicas  (Lee & Lee,  2016; Zhang et  al., 2016) .  \nLos taninos son compuestos polifen\u00f3licos, solubles en agua, cuyas masas molares est\u00e1n entre \n500 y 3000 Da. Adem\u00e1s de ex hibir las reacciones caracter\u00edsticas de los fenoles, pueden \nprecipitar alcaloides, gelatina y otras prote\u00edna s. Existen dos tipos de taninos, en funci\u00f3n de su \nestructura y propiedades: taninos hidrolizables y taninos condensados.  Los taninos hidrolizables \nse caracterizan por una parte central que consiste en un poliol (con mayor frecuencia glucosa), \ncuyas funcion es hidroxilo est\u00e1n esterificadas con \u00e1cido g\u00e1lico  o el\u00e1gico  (Stevanovic et  al., \n2009) . Las proantocianidinas o taninos condensados son olig\u00f3meros o pol\u00edmeros de flavan -3-\nols y flavan -3,4-dioles.  Las proantocianidinas se pueden clasificar en dos categor\u00edas seg\u00fan su \ngrado de polimerizaci\u00f3n de unidades monom\u00e9ricas: olig\u00f3meros (desde d\u00edmeros  a pent\u00e1meros) \ny pol\u00edmeros (a partir de hex\u00e1meros)  (Stevanovic & Perrin, 2009) . Los taninos act\u00faan como \nrepelentes alimenticios y tambi\u00e9n son reconocidos por sus propiedades beneficiosas sobre la \nsalud humana .  \nAunque la lignina es tambi\u00e9n considerada un c ompuesto fen\u00f3lico, no puede ser obtenida por \nm\u00e9todos de extracc i\u00f3n convencional y sus caracter\u00edsticas qu\u00edmicas var\u00edan respecto a los \ncompuestos fen\u00f3licos de bajo peso molecular.  \nI.5.  Caracterizaci\u00f3n qu\u00edmica de la lignina  \nLa lignina es un pol\u00edmero heterog\u00e9neo de alto peso molecular y constituido por unidades de \nfenilpropa no que comparte la misma v\u00eda biosint\u00e9tica que los polifenoles extra\u00eddos por m\u00e9todos \nconvencionales (Stevanovic et  al., 2009) . Durante la evoluci\u00f3n, la lignificaci\u00f3n de las paredes   \n22 vegetales est uvo relacionada al paso de las plantas del medio acu\u00e1tico al terrestre, de hecho, \nespecies acu\u00e1ticas como las  algas no contienen lignina como constituyente qu\u00edmico  (Stevanovic, \n2005) . El desarrollo del sistema de lignificaci\u00f3n estuvo influenciado por la ne cesidad de un \nsistema excretor mejorado en las plantas superiores. La lignina constituye uno de los \ncomponentes vegetales de la pared celular de las c\u00e9lulas vegetales, en estrecha asociaci\u00f3n con \nla celulosa y la hemicelulosa. Los tejidos lignificados prese ntan una resistencia superior contra \nlos ataques biol\u00f3gicos, sobre todo de microorganismos , lo que asegura la longevidad de las \nplantas lignosas.  \nLa lignina no es exclusiva de los \u00e1rboles, sino que tambi\u00e9n se presentan en las plantas herb\u00e1ceas. \nLos mon\u00f3me ros (monolignoles)  precursores de la lignina son derivados del alcohol cin\u00e1mico : \na) el alcohol conifer\u00edlico; b) el alcohol sinap\u00edlico  y, c) alcohol p -cumar\u00edlico, cuyas estructuras \nse muestran en la Fig. 6. Estos  se forman en el citoplasma a trav\u00e9s de la ruta del \u00e1cido shik\u00edmico \nque produce fenilalanina como intermedi ario clave. Los monolignoles se generan mediante \nreacciones de desaminaci\u00f3n, hidro xilaci\u00f3n, reducci\u00f3n y metilaci\u00f3n catalizadas por diversas \nenzimas . Estos monolignoles reaccionan en la pared celular, a trav\u00e9s de reacciones de oxidaci\u00f3n \ncatalizadas por peroxidasas (intermedios radicalarios) para formar finalmente pol\u00edmeros de \nlignina.  \n \nFig. 6. Mon\u00f3meros precursores de la lignin a. \n \nLos monolignoles son dirigidos (temporal y espacialmente) a diferentes tipos de regiones de la \npared celular, en las que polimerizan formando biopol\u00edmeros con propiedades biof\u00edsicas \ncarac ter\u00edsticas, los cuales en conjunto refuerzan la pared celular. La s ligninas son consideradas \n  \n23 mezclas rac\u00e9micas, como se evidencia por an\u00e1lisis de diversos fragmentos dim\u00e9ricos tales como, \n(\u00b1)-pinoresinoles y (\u00b1) -siringoresinoles  (Ch\u00e1vez -Sifontes & Domine, 2013) .  \nEn dependen cia del tipo de especie , los porcentajes de dis tribuci\u00f3n de los monolignoles var\u00edan \n(v\u00e9ase Tabla. 2). Por ejemplo, el monolignol m\u00e1s abundante de las maderas de especies \ncon\u00edferas  es el alcohol conifer\u00edlico, que puede llegar a superar el 95% del total de monolig noles \npresentes, en cambio, en las maderas provenientes de especies latifoliadas  coexisten los \nalcoholes conifer\u00edlico y sinap\u00edlico  (Hon & Shiraishi, 2000) . En el caso de plantas herb\u00e1ceas, \npuede haber proporciones similares de los tres monolignoles princip ales. Adem\u00e1s, e l contenido \nde lignina tambi\u00e9n var\u00eda entre \u00e1rboles y las plantas herb\u00e1ceas, siendo m enor en estas \u00faltimas \n(Novaes et  al., 2010) .  \n \nTabla. 2. Porcentaje de los diferentes monolignoles presentes en la lignina de diversas  plantas.  \nTipo de planta  Monolignol (%)  \nAlcohol p -\ncoumar\u00edlico  Alcohol \nconifer\u00edlico  Alcohol sinap\u00edlico  \nGimnospermas  Con\u00edferas  <5 >95 0 \nAngiospermas  Latifoliadas  0-8 25-50 45-75 \nHerb\u00e1ceas  5-35 35-80 20-55 \n(Modificado de Gellerstedt & Henriksson, 2008) . \n \nLa lignina , debido a su alto peso molecular, no puede penetrar las membrana s biol\u00f3gica s y \nconsecuentemente no puede modular la activaci\u00f3n/desactivaci\u00f3n de v\u00edas de se\u00f1alizaci\u00f3n \nimplicadas en la patog\u00e9nesis de enfermedades. Sin embargo, esta puede  ser deg radada \nt\u00e9rmicamente por pir\u00f3lisis para producir fenoles de bajo peso molecular (mono y oligo -fenoles) , \ntambi\u00e9n conocidos como fenoles pirol\u00edticos  (Liaw et  al., 2013) . Estos fenoles pirol\u00edticos  puede n \nser separados  f\u00e1cilmente por precipitaci\u00f3n en agua  (Scho lze & Meier, 2001) . La producci\u00f3n de \npolifenoles por v\u00eda t\u00e9rmica es un medio de  obtenci\u00f3n de  estas mol\u00e9culas a muy bajo precio.  \nI.6. La pir\u00f3lisis: un medio para obtener  aceites pirol\u00edticos ricos en  \ncompuestos fen\u00f3licos  \nLa pir\u00f3lisis consiste en la  descomposici\u00f3 n t\u00e9rmica  de un s\u00f3lido que ocurre  en ausencia de \nox\u00edgeno  o agentes oxidantes, resultando en la producci\u00f3n de gases, l\u00edquidos ( aceites pirol\u00edticos  \no alquitr\u00e1n) y un carbonizado . Durante el proceso, la temperatura se incrementa localmente, por   \n24 lo que primera mente ocurre la evaporaci\u00f3n de la humedad (etapa de seca do), mientras que \nposteriormente  ocurre la liberaci\u00f3n de vol\u00e1tiles (primera etapa de la pir\u00f3lisis). Estos compuestos \nvol\u00e1tiles se producen a partir de la ruptura t\u00e9rmica de los enlaces qu\u00edmicos de la celulosa, la \nhemicelulosa y la lignina, as\u00ed como los ext ractivos, cada uno de los cuales tiene sus propias \ncaracter\u00edsticas cin\u00e9ticas  (Oasmaa et  al., 2016) . La Fig. 7 muestra las reacciones de \ndescomposici\u00f3n que tienen lugar en una part\u00edcula de biomasa sometida a pir\u00f3lisis.  \n \nFig. 7. Pir\u00f3lisis de una part\u00edcula de biomasa.  \nEn el esquem a se pueden observar los principales mecanismos de calentamiento, descomposici\u00f3n y los productos \ndel proceso de pirolisis  de biom asa (Modificado de Montoya Arbel\u00e1ez et  al., 2013) . \n \nConsiderando la temperatura y la velocidad de calentamiento, la pir\u00f3lisis p uede subdividirse en: \nlenta o convencional, r\u00e1pida , carbonizaci\u00f3n y torrefacci\u00f3n. La Tabla 3 muestra las \ncaracter\u00edsticas de cada uno de los tipos antes mencionados . \n  \n25  \nTabla 3. Tipos de pir\u00f3lisis y productos principales.  \nTipo de pir\u00f3lisis  Condiciones  L\u00edquido  (aceites \npirol\u00edticos ) S\u00f3lido  Gas \nLenta/intermedia  Temperatura d el reactor: 400 -500oC \nTasas de calentamiento: 1 -1000 oC/s \nTiempos de residencia: 1 -10 s 50% 25% 25% \nR\u00e1pida  Temperatura del reactor: 500 oC \nTasas de calentamiento: >1000 oC/s \nTiempos de residencia: ~ 1s 75% 12% 13% \nTorrefacci\u00f3n  Temperatura del reactor: 29 0 oC \nTasas de calentamiento: 1oC/s \nTiempos de residencia: ~ 30 min  0-5% 77% 23% \nCarbonizaci\u00f3n  Temperatura del reactor: 400 -500oC \nTasas de calentamiento: 1 oC/s \nTiempos de residencia: horas, d\u00edas  30% 35% 35% \n(Tomado de Montoya Arbel\u00e1ez et  al., 2013) . \n \nLos aceites pirol\u00edticos  son mezclas multicomponentes que contienen diferentes tipos de \nmol\u00e9culas primarias derivadas de las reacciones de despolimerizaci\u00f3n y fragmentaci\u00f3n de la \ncelulosa, la hemicelulosa y la lignina. Una de las aplicaciones industriales m\u00e1s importantes de \nestos aceites es el desarrollo de biocombu stibles. El contenido de ox\u00edgeno de los aceites \npirol\u00edticos  suele ser del 35 -40% (Czernik & Bridgwater, 2004) . La presencia de ox\u00edgeno en los \naceites pirol\u00edticos  es la raz\u00f3n principal de las diferenc ias en las propiedades y el comportamiento \nobservados ent re los combustibles f\u00f3siles  y los bio-aceites . El alto contenido de ox\u00edgeno da \ncomo resultado un bajo poder calor\u00edfico , por lo que esta caracter\u00edstica podr\u00eda considerarse una \ndesventaja  para el uso d e aceites pirol\u00edticos como biocombustibles . El ox\u00edgeno es t\u00e1 presente en  \nm\u00e1s de 300 compuestos identificado s en los aceites pirol\u00edticos  (Czernik & Bridgwater, 2004) , \nsiendo l os compuestos fen\u00f3licos de los  compuestos oxigenados m\u00e1s importantes (2 -20% w/w), \nlos que se generan principalmente de la despolimerizaci\u00f3n de lignina  y que est\u00e1n representados \npor mono fenoles ( ~5-10 %) y olig\u00f3meros ( ~6-15%)  (Oasmaa et  al., 2016) .  \nSi bien  para el desarrollo de combustible s la presencia de estas mol\u00e9culas en los aceites  \npirol\u00edticos  puede ser un problema y, por lo tanto, se han utilizado m\u00faltiples estrategias de \ndesoxigenaci\u00f3n, podr\u00eda ser ventajoso para el desarrollo de nuevos f\u00e1rmacos. La pir\u00f3lisis  es una \nforma muy econ\u00f3mica de obtener fenoles a partir de lignina con alt os rendimien tos. Un aspecto   \n26 interesante es que puede llevarse a cabo despu\u00e9s de la extracci\u00f3n convencional, lo que permite \nel uso integral de la matriz vegetal extra\u00edda , frecuentemente considerada como un desecho.  \nI.7. Uso de productos pirol\u00edticos para el trata miento de la  psoriasis  \nLa utilizaci\u00f3n de aceites pirol\u00edticos en el desarrollo de medicamentos como fuentes valiosas de \nmol\u00e9culas bioactivas ha sido soslayada por la comunidad cient\u00edfica . Sin embargo, el uso de otros \nproductos pirol\u00edticos como el alquitr\u00e1n para tratar afecciones dermatol\u00f3gicas se remonta a m\u00e1s \nde 2000 a\u00f1os, mientras que el alquitr\u00e1n de hulla , generado a partir de la pir\u00f3lisis lenta del carb\u00f3n,  \nse ha utilizado precisamente para la psoriasis durante m\u00e1s de 100 a\u00f1os  (Zeichner, 2010) .  \nEl r\u00e9gime n de Goecker man, actualmente utilizado para la psoriasis , que consiste en la \nexposici\u00f3n a la radiaci\u00f3n ultravioleta B combinada con la aplicaci\u00f3n de alquitr\u00e1n de hulla, es un \nejemplo de la importancia que los productos pirol\u00edticos pueden tener como terapia s \nantipsori\u00e1 sicas eficaces. Introducido por primera vez en  la terap\u00e9utica en  1925, el r\u00e9gimen de \nGoeckerman sigue siendo una de las opciones de tratamiento m\u00e1s antiguas y confiables para \npacientes con psoriasis moderada a severa  (Zhu et  al., 2016) . La vent aja de usar alquitr\u00e1n y \nfototerapia juntos es que el alquitr\u00e1n es un fotosensibilizador y cuando se combina con la luz \nUVB act\u00faa sin\u00e9rgicamente para producir mejores resultados que cuando se usan cualquiera de \nlos tratamientos solos. En comparaci\u00f3n con otr as modalidad es de tratamiento, como los agentes \nbiotecnol\u00f3gicos , los medicamentos  sist\u00e9micos y los tratamientos  t\u00f3picos, la terapia Goeckerman \nsigue siendo extremadamente efectiva con relativamente pocos efectos secundarios. Esto la \nconvierte en  una excele nte alternat iva para pacientes que pueden haber fracasado previamente \ncon otras  terapias,  incluyendo  ancianos, pacientes embarazadas, ni\u00f1os e individuos con  \ninmunodepr esi\u00f3n  (Zhu et  al., 2016) . \nSe ha reportado que  el 100% de los pacientes que reciben el r\u00e9g imen de  Goec kerman durante \nun per\u00edodo de 12 semanas logran  una mejora del 75% o m\u00e1s en sus lesiones de psori \u00e1sicas  (Lee \n& Koo, 2005) . Otra ventaja de este tratamiento  es el largo per\u00edodo de remisi\u00f3n despu\u00e9s de la \nfinalizaci\u00f3n de la terapia, que puede durar  entre 8 meses y m\u00e1s de un a\u00f1o , en dependencia del \ntipo de paciente  (Koo & Lebwohl, 1999) . Los estudios tambi\u00e9n han demostrado que la terapia \nde Goeckerman puede aume ntar significativamente la satisfacci\u00f3n de  los paciente s hacia su \ntratamiento, mejorando s u calidad de vida  (Chern et  al., 2011) . Adem\u00e1s, puede usarse para tratar \notras enfermedades de la piel, como eccema, prurigo nodular y prurito.    \n27 El alquitr\u00e1n de hulla consta de miles de componentes qu\u00edmicos , muchos de los cuales no est\u00e1n \nidentificados. De e stos ingredientes, se ha concedido mayor importancia  farmacol\u00f3gica  a los  \nhidrocarburos de arilo polic\u00edclicos. Se cree que estos hidrocarburos , particularmente  el carb azol, \nson responsable s de la eficacia  del alquitr\u00e1n como agente antipsori\u00e1sic o (Sekhon et  al., 2018) . \nAunque su mecanismo de acci\u00f3n no est\u00e1 completamente dilucidado, se presume que el alquitr\u00e1n \nde hulla  activa el receptor de hidrocarburos de arilo (AhR), l o que resulta en la inducci\u00f3n de la \ndiferenciaci\u00f3n epid\u00e9rmica. La eliminaci\u00f3n de AhR en ra tones revirti\u00f3 completamente este \nefecto, destacando la importancia de este receptor en la homeostasis cut\u00e1nea  (Bogaard et  al., \n2013) . Un estudio ulterior demostr\u00f3 qu e los ligandos activadores de AhR como el alquitr\u00e1n \nreducen  la inflamaci\u00f3n en la piel psori\u00e1sica , mientras que los antagonistas de AhR aumenta n la \ninflamaci\u00f3n  (Di Meglio et  al., 2014) . \nSin embargo, mucho queda a\u00fan por conocer acerca de la se\u00f1alizaci\u00f3n medi ada por este receptor  \ny se desconoce si otros productos pirol\u00edticos  como los aceites pirol \u00edticos  derivados de nuevas \nfuentes naturales, podr\u00edan tener un potencial antiinflamatorio  sobre dianas relevantes para la \npsoriasis, como la IL -17. \nLa presente investigaci\u00f3n sigui\u00f3 una estrategia de desarrollo farmac\u00e9utico, usando el enfoque \netnofarmacol\u00f3g ico con el f\u00edn de identificar especies mexicanas prometedoras para tratar la \npsoriasis, a partir de la etnomedicina Pur\u00e9pecha. Los aceites pirol\u00edticos y extractos acuoso y \netan\u00f3lico de especies relevantes fueron qu\u00edmicamente caracterizados y analizados res pecto a su \ntoxicidad y capacidad de inhibir la producci\u00f3n de IL -8 en queratinocitos HaCaT estimulados \ncon IL -17. La  investigaci \u00f3n presentada aporta elementos que sirven para validar la informaci\u00f3n \netnom\u00e9dica reportada por la medicina tradicional Pur\u00e9pecha y proponer futuras aplicaciones \npara el desarrollo de nuevos tratamientos para la psoriasis.   \n28 II. JUSTIFICACI\u00d3N  \n \nLa psoriasis es un a enfermedad dermatol\u00f3gica inflamatoria incurable que afecta a 120 millones \nde personas a nivel mundial y a m\u00e1s de  3 millones de mexicanos . La psoriasis tiene un impacto \nnegativo en la calidad de vida de los pacientes, tanto que su s repercusi ones en las funciones \nf\u00edsicas y psicol\u00f3gicas  se ha n comparado con la s que genera el  c\u00e1ncer, la diabetes o la depresi\u00f3n.  \nLos tratamientos antips ori\u00e1sicos actuales se orientan a tratar la sintomatolog\u00eda,  pero su uso a \nlargo plazo se ve limitado por su falta de eficacia, c osto y toxicidad . Por consiguiente, existe \nuna b\u00fasqueda incesante por parte de la industria farmac\u00e9utica de nuevos candidatos ter ap\u00e9uticos. \nDurante este proceso, la identificaci\u00f3n de dianas farmacol\u00f3gicas prometedoras resulta crucial. \nEn los \u00faltimos a\u00f1os, se ha considerado que la inhibici\u00f3n de la IL -17 o su receptor representa \nuna opci\u00f3n para tratar la psoriasis, y en consecuencia han sido dise\u00f1ados medicamentos \nbiotecnol\u00f3gicos novedosos, con alta eficacia. Sin embargo, los eventos adversos, los altos costo s \ny la falta de respuesta en algunos pacientes limitan  su uso. Por lo tanto, la b\u00fasqueda de agentes \nterap\u00e9uticos anti -IL17 m\u00e1s as equibles, efectivos y seguros est\u00e1 en curso. El desarrollo de nuevos \nproductos naturales t\u00f3picos que muestr en efectos anti -IL-17 ofrece varias ventajas en \ncomparaci\u00f3n con los productos bio tecnol\u00f3gicos  con respecto a su administraci\u00f3n, ya que estos \n\u00faltimos , a diferencia de las mol\u00e9culas naturales, no pueden cruzar el estrato c\u00f3rneo, lo que \nimpide su uso en formulaciones t\u00f3picas, pr eferidas por los pacientes que tienen psoriasis leve y \nmoderada  (~80 %) . En consecuencia, deben identificarse nuevos productos na turales siguiendo \nesquemas de desarrollo farmac\u00e9utico con vistas a garantizar la  caracterizaci\u00f3n qu\u00edmica rigurosa, \neficacia y seguridad de los candidatos en estudio.  \nUna de las estrategias m\u00e1s usad as para este fin, utiliza el enfoque etnofarmacol\u00f3gico par a la \nidentificaci\u00f3n de especies de inter\u00e9s. Siguiendo esta estrategia, las especies elegidas son aquellas \nque han demostrado eficacia terap\u00e9utica como consecuencia de su utilizaci\u00f3n tradicional por la \npoblaci\u00f3n. M \u00e9xico es un pa\u00eds con una impresionante riqueza cultural y alta diversidad flor\u00edstica. \nDiversas regiones del territorio nacional, como la Meseta Pur\u00e9pecha, son reconocidas por su  \nconocimiento ancestral de pr\u00e1cticas de la  Medicina Tradicional,  lo que representa una \noportunidad \u00fanica  para la identific aci\u00f3n  de plantas medicinales como  candidatas terap\u00e9uticas \npara la psoriasis.  A pesar de la importancia de la medicina tradicional Pur\u00e9pecha,  ning\u00fan  estudio   \n29 etnofarmacol\u00f3gico  ha sido  reportado  sobre el uso de plantas para tratar  afecciones \ndermatol\u00f3gicas po r esta poblaci\u00f3n. Por lo tanto, se requiere documentar e ste conocimiento \netnomedicinal y preservarlo para las futuras generaciones . En los sistemas tradicionales, son \nfrecuentes el uso de extractos acuosos y etan\u00f3licos para tratar patolog\u00edas  dermatol\u00f3gicas  dada \nla baja toxicidad y asequibilidad de los solventes involucrados. Estos solventes permiten extraer \nuna pl\u00e9yade de metabolitos secundarios, dependiendo de la planta de que se trate, destac\u00e1ndose  \nlos compuestos fen\u00f3licos. Aunque las propiedades biol\u00f3gic as antipsori\u00e1sicas de los extractos \netan\u00f3licos y acuosos de m\u00faltiples plantas usadas en la medicina tradicional a nivel mundial son \nreconocidas, las plantas nativas de M\u00e9xico de importancia etnomedi cinal para tratar afecciones \ndermatol\u00f3gicas contin\u00faan sin ser suficientemente exploradas . \nLos compuestos fen\u00f3licos  pueden  ser obtenid as usando m\u00e9todos de extracci\u00f3n convencional  \ncon solventes polares  o ser generad os como parte de bioaceites  a partir de la pir\u00f3lisis de la \nlignina . El uso  de aceites pirol\u00edticos com o fuente valiosa de mol\u00e9culas bioactivas para el \ndesarrollo de nuevos tratamientos para la psoriasis  ha sido soslayado por la comunidad \ncient\u00edfica, a pesar de que el alquitr\u00e1n de hulla , obtenido  a partir de la pir\u00f3lisis lenta del carb\u00f3n,  \nse ha utilizado pr ecisamente para esta enfermedad  durante m\u00e1s de 100 a\u00f1os.  Hoy d\u00eda, las \npropiedades antiinflamatorias s obre dianas relevantes para la psoriasis, como la IL -17, de los \naceites  pirol\u00edticos y de extractos  provenientes de plantas mexicanas , son casi desconocidas , \naunque es probable que sean comparables , pero a\u00fan se necesita n m\u00e1s investigaci ones \nmultidisciplinar ias para demostrarlo . \n \n \n \n \n \n \n   \n30 III. HIP\u00d3TESIS  \n \nLos extractos etan\u00f3lico, acuoso  y los aceites pirol\u00edticos  de una planta herb\u00e1cea y un \u00e1rbol , \nnativos de M\u00e9xico,  de alto valor de uso por la  etnomedicina Pur\u00e9pecha , poseen , sobre los  \nqueratinocitos humanos, un potencial antinflamatori o anti-IL17,  una diana farmacol\u00f3gica \nimplicada en la patog\u00e9nesis de la psoriasis.  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n   \n31 IV. OBJETIVOS  \n \nIV.1.  Objetivo general  \n \nDeterm inar el potencial antinflamatorio  anti-IL17 en queratinocitos humanos de l extracto \netan\u00f3lico, acuoso y de aceites pirol\u00edticos  de una planta herb\u00e1cea y un \u00e1rbol con alto valor de uso \npor la etnomedicina Pur\u00e9pecha para el tratamiento de enfermedades dermatol \u00f3gicas.  \n \nIV.2.  Objetivos particulares  \n \nIV.2.1.  Identificar plantas utilizadas por la etnomedicina Pur\u00e9pecha para el tratamiento de \nafecciones dermatol\u00f3gicas y seleccionar una especie herb\u00e1cea y un \u00e1rbol  de alto \nvalor de uso  nativos de M\u00e9xico  como candidatos antipsori\u00e1s icos. \n \nIV.2.2.  Realizar la  caracterizaci\u00f3 n qu\u00edmica de l extracto  acuoso, etan\u00f3lico , sus fracciones, \nas\u00ed como  de los aceites pirol\u00edticos de las especies seleccionad as. \n \nIV.2.3.  Determinar la toxicidad y el potencial antiinflamatorio anti -IL17 de las muestras \nobtenidas en qu eratinocitos HaCaT y seleccionar el candidato terap\u00e9utico m\u00e1s \nprometedor.  \n \n \n \n \n \n \n \n   \n32 V. ESTRATEGIA EXPERIMENTAL  \n \nLa estrategia experimental llevada a cabo en  el presente trabajo de investigaci\u00f3n se representa \nen la Fig. 8. \n \n \nFig. 8. Estrategia metodol\u00f3gica empleada en el presente trabajo .\nObtenci\u00f3n de extractos naturales  \nEstudio etnofarmacol\u00f3gico de plantas \nutilizadas para afecciones dermatol\u00f3gicas \nen la Meseta Pur\u00e9pecha  \nObtenci\u00f3n de aceites pirol\u00edticos  \nCaracterizaci\u00f3n qu\u00edmica primaria de polifenoles \ntotales, an\u00e1lisis proximal y eleme ntal. \nEstudio toxicol\u00f3gico en \nqueratinocitos humanos (HaCaT)  \nCaracterizaci\u00f3n qu\u00edmica \nexhaustiva: GC -MS, UV -\nfluorescencia, FTIR  \nCribado farmacol\u00f3gico: Acci\u00f3n inhibitoria sobre la \nproducci\u00f3n de IL -8 en queratinocitos HaCaT \nestimulados con IL -17 \nSelecci\u00f3n  del candidato m\u00e1s \nprometedor    \n33 VI. RESULTADOS  \n \nLos resu ltados generados con la realizaci\u00f3n del presente trabajo se presentan en los cap\u00edtulos  \nsiguientes : \n \n\u2022 Cap\u00edtulo 1 . Flora etnomedicinal utilizada para el tratamie nto de afecciones \ndermatol\u00f3gicas en la Meseta Pur\u00e9pecha, Michoac\u00e1n, M\u00e9xico . (Art\u00edculo publicado)  \n \n\u2022 Cap\u00edtulo 2 . Extracto etan\u00f3lico, fracciones y bio -aceites de las partes a\u00e9reas de Urtica \nsubincisa : un an\u00e1lisis comparativo de su composici\u00f3n qu\u00edmica, toxicida d y actividad \nanti-IL17 en los queratinocitos HaCaT . \n \n\u2022 Cap\u00edtulo 3 . Aceites pirol\u00edticos de la corteza de  Amphipterygium adstringens  inhiben la \nproducci\u00f3n de IL -8 en queratinocitos HaCaT estimulados por IL -17. (Art\u00edculo \npublicado)  \n \n\u2022 Cap\u00edtulo 4. Caracterizaci\u00f3n  qu\u00edmica, toxicolog\u00eda y actividad antiinflamatoria del \nextracto ac uoso de la corteza de Amphipterygium adstringens  y sus fracciones en \nqueratinocitos HaCaT.  \n \nAdem\u00e1s, se presenta una revisi\u00f3n de la literatura que complementa el trabajo desarrollado:  \n \n\u2022 Anexo 1 - La psoriasis: de la investigaci\u00f3n b\u00e1sica y cl\u00ednica al desarrollo de nuevos \ntratamientos . (Art\u00edculo publicado)  \n34  \n \n \n \n \n \n \n \n \n \nCAP\u00cdTULO 1. Flora etnomedicinal utilizada para el tratamiento \nde afecciones dermatol\u00f3gicas en la Meseta Pur\u00e9pecha, Michoac\u00e1n, \nM\u00e9xico  \n \n \n \n \n \n \n \n \n \n \n \n \n \n   \n35 VI.1.  PREFACIO  \n \nEste cap\u00edtulo es el tema de un art\u00edculo titulado: \u201cEthnomedicinal plants used for the treatment \nof dermatological affections on the Pur\u00e9pecha Plateau, Michoac\u00e1n, Mexico\u201d . El cual fue \npublicado en Acta Botanica Mexicana , 125: 95 -132. Su identifica dor de objeto digital es: \nhttps://doi.org/10.21829/abm125.2018.1339  \n \nEl cap\u00edtulo se dirige a dar respuesta al objetivo particular #  1, relacionado con la  identificaci\u00f3n \nde plantas utilizadas  en la etnomedicina Pur\u00e9pecha  para el tratamiento de afecciones \ndermatol\u00f3gicas y permiti\u00f3 la selecci\u00f3n de  una especie herb\u00e1cea  (Urtica subincisa ) y un \u00e1rbol  \n(Amphipterygium adstringens ) nativos de M\u00e9xico de alto valor de uso como candidatos \nantip sori\u00e1sicos , los que se utilizaron en el resto de las investigaciones .  \n \n \nFig. 9. Resumen gr\u00e1fico.  \n \n \n \n \n \n \n \n  \n36  \nVI.2.  ART\u00cdCULO  \n \n \n \n \n \n \nVI.2.1.  Abstract  \n \n \n \n \n \nVI.2.2.  Resumen  \n \n \n \n \n \n \n \n \n \n \n  \n37  \nVI.2.3.  Introduction  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \n38  \n \n \nVI.2.4.  Materials and methods  \nVI.2.4.1.  Study area  \nVI.2.4.2.   \nVI.2.4.3.  Studi ed population characteristics  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \n39  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nStudy area.  \n \nVI.2.4.4.  Ethnomedical survey and plant collection  \n \n \n \n \n  \n40  \n \n \n \n \n \nVI.2.4.5.  Statistical analysis and literature review  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nCharacteristics of the participants in the ethnopharmac ological study on  the Pur\u00e9pecha Plateau . \n \n  \n41  \n \n \n \n \n \n \nVI.2.5.  Results  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \n42  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nFamily distribution of medicinal plants used on the Pur\u00e9pecha Plateau.  \n \n \n \n \n \n \n  \n43  \nConsensus factor values for different dermatological affection categories o n the  Pur\u00e9pecha Plateau . \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nVI.2.6.  Discussion  \n \n \n  \n44  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nNumber of plant species used for treating dermatological conditions o n the Pur\u00e9pecha Plateau . \n \n \n \n \n \n \n \n \n \n \nPlant parts and preparation modes used by inhabitants of Pur\u00e9pecha Plateau for treat ing dermatological disorders.  \n \n \n  \n45  \n \n \n \n \n \n \n \n \n \n \n \n \n \nPlants with higher use values (UV) for treating dermatological ailments on the Pur\u00e9pecha Plateau.  \n \n \n \n \n \n \n \n \n \n \n \n  \n46 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n   \n47 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n   \n48  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nVI.2.7.  Conclusions  \n \n \n  \n49  \n \nVI.2.8.  Author cont ributions  \n \nVI.2.9.  Financing  \n \nVI.2.10.  Acknowledgment  \n \nVI.2.11.  Literature cited  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \n50  \n  \n51  \n  \n52  \n  \n53  \n  \n54  \n  \n55  \n  \n56  \n  \n57  \n \n58  \nVI.2.12.  Appendix 1. Plants used by inhabitants from Pur\u00e9pecha Plateau for the treatment of dermatological \nconditions: use value, fidelity level, modes of preparation and ethno medicinal studies.  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n59  \n \n60  \n \n61  \n \n62  \n \n63  \n \n64  \n \n65  \n \n66 \n \n67 \n \n68 \n \n69 \n \n70 \n \n71  \n \n72  \n \n73  \n \n74  \n \n \n \n \n \n \n \n \n \nCAP\u00cdTULO 2.  Extracto etan\u00f3lico, fracciones y bio -aceites de \npartes a\u00e9reas de Urtica subincisa : un an\u00e1lisis comparativo de su \ncomposici\u00f3n qu\u00edmica, toxicidad y actividad anti -IL17 en \nquerati nocitos HaCaT  \n \n \n \n \n \n \n \n \n \n \n \n  \n75 VI.3.  PREFACIO  \n \nEste cap\u00edtulo es el tema de l art\u00edculo titulado: \u201cEthanolic extract, solvent fractions and bio -oils \nfrom Urtica subincisa  aerial parts: a comparative analysis of their chemical composition, \ntoxicity and anti -IL-17 acti vity on HaCaT keratinocytes\u201d. El cual  se encuentra en el proceso de  \nrevisi\u00f3n de una revista cient\u00edfica.  \n \nEl presente cap\u00edtulo se dirige a dar respuesta a los objetivos particulares #  2 y 3. Al contar con \nel cat\u00e1logo etnofarmacol\u00f3gico presentado  en el cap\u00edt ulo 1, se seleccion\u00f3 a Urtica subincisa  \ncomo la planta herb\u00e1cea  que ser\u00eda considerada como candidata terap\u00e9utica para estudios  \nsubsecuentes . Esta planta, nativa de M\u00e9xico, present\u00f3 un alto valor de uso (0.17), adem\u00e1s de \nque hasta el presente no cuenta con  estudios fitoqu\u00edmicos , toxicol\u00f3gicos  y farmacol\u00f3gicos, lo \nque garantiz \u00f3 la novedad de la investigaci\u00f3n. L a extracci\u00f3n convencional de las partes a\u00e9reas \nde la planta  se realiz\u00f3 con una mezcla etanol/agua (90:10 v/v), simulando el uso tradicional \nreportado e n la etnomedicina Pur\u00e9pecha. El extracto crudo obtenido  fue posteriormente \nfraccionado por extracci\u00f3n l\u00edquido/l\u00edquido  con vistas a realizar una caracterizaci\u00f3n m\u00e1s \nexhaustiva de las mol\u00e9culas contenidas en el extracto crudo . La biomasa residual , libre de \nextractivos,  fue subsecuentemente sometida a un proceso de pir \u00f3lisis para obtener aceites \npirol\u00edticos. El extracto etan\u00f3lico, sus fracciones y los  aceites  pirol\u00edticos  se caracterizaron \nqu\u00edmicamente , se realizaron pruebas para conocer su toxicidad en un cultivo de c\u00e9lulas HaCaT, \ny finalmente se prob\u00f3 su capacida d para inhibir la producci\u00f3n de IL -8, a trav\u00e9s  de la inducci\u00f3n \nde su s\u00edntesis por IL -17. \n \n \n \n \n \n \n \n  \n76 VI.4.  ART\u00cdCULO  \n \nEthanolic extract, solvent fractions,  and bio -oils from Urtica \nsubincisa aerial parts: a compa rative analysis of their chemical \ncomposition, toxicity and anti -IL-17 activity on HaCaT \nkeratinocytes  \n \nRoberto Esquivel -Garc\u00edaa,b, Ayca Sekerc, Nehal Abu -Laild, Manuel Garc\u00eda -P\u00e9rezc, Alejandra \nOchoa -Zarzosab, Martha -Estrella Garc\u00eda -P\u00e9reza* \n \nAffilations:  \n \naInstituto de Investigaciones Qu\u00edm ico-Biol\u00f3gicas. Universidad Michoacana de San Nicol\u00e1s de \nHidalgo . Morelia,  Michoac\u00e1n,  Mexico.  bCentro Multidisciplinario de Estudios en \nBiotecnolog\u00eda -FMVZ, Universidad Michoacana de San Nicol\u00e1s de Hidalgo. Tar\u00edmbaro, \nMicho ac\u00e1n, Mexico.  cDeparment of B iological Systems Engineering, Washington State \nUniversity, Pullman, WA, USA.  dDepartment of Biomedi cal Engineering, University of Texas \nat San Antonio, TX, USA.  \n \nAddress for reprint requests:  \nMartha Estrella Garc\u00eda -P\u00e9rez, PhD  \naInstituto de Investigaciones Qu\u00edmico -Biol\u00f3gicas.  Universidad Michoacana de San Nicol\u00e1s de \nHidalgo . Avenida  Universidad  S/N. Edificio  B3 Ciudad  Universitaria , Morelia,  Michoac\u00e1n  \n58030,  Mexico . Phone  number:  (+52)  443 142 9280 . E-mail: margar@live.ca   \n77 VI.4.1.  Abstra ct \nEthnopharmacological relevance: Urtica subincisa  Benth. has been used to treat \ninflammatory skin conditions for centuries by Pur\u00e9pecha traditional medicine, an ancient culture \nthat has left an important legacy to the knowledge of Mexican medicinal plant s. \nAim of the study: This study compares and chemic ally characterizes the ethanolic extract, its \nsolvent fractions and bio -oils from U. subincisa  aerial parts and analyzes their toxicity and anti -\nIL17 properties on HaCaT keratinocytes in order to propose f uture applications for treating \npsoriasis, an incur able, inflammatory, dermatological disorder.  \nMethods : The aerial parts from  U. subincisa  were extracted by maceration using 90:10 v/v \nethanol/water and the crude extract (CE) fractionated with hexane, ethy l acetate and water to \nobtain phases A, B and C, respectively. The extracted biomass was then pyrolyzed to produce \nbio-oils 1 and 2. U. subincisa  raw materials, CE, phases A -C, and the two bio-oils were \ncharacterized by Py -GC-MS, proximate , elemental analy sis, FTIR, UV -fluorescence and GC -\nMS to have an overview of their chemical composition. Toxicity of all samples on HaCaT  \nkeratinocytes was assessed by the MTT assay  and the non-cytotoxic concentrations were used \nto determine their inhibito ry activity on IL -8 production in HaCaT keratinocytes stimulated with \nIL-17. \nResults:  FTIR spectra showed a higher diversity of functional groups in CE and its fractions \nthan in bio -oils. On the other hand, UV -fluorescence spectra indicated that solvent ex tracts are \nricher  in simple phenols, while bio -oils contained a higher number of conjugated and \npolycondensed molecules. According to GC -MS, CE and phases A and B were rich in esters, \nwhereas in phase C and bio -oil-2, nitrogen -containing compounds prevaile d. In contrast, b io-\noil-1 showed a preponderance of phenols. CE was characterized by the lowest toxicity on \nkeratinocytes, followed, in an increasing order, by phase C, bio -oil-1, phases B -A, and bio -oil-\n2, respectively. Bio -oil-2 showed a significant inhi bitory effect on IL-8 production comparable \nto that of dexamethasone at 7.5 \u03bcg/mL.  \nConclusions : Bio -oil-2 obtained from the extracted biomass, usually considered as a waste, \ndemonstrated to be the most promising anti-inflammatory sample. Further evaluation  of its key \ncomponents and the elucidation of the relevant pathways involved  in this activity are needed to \nconfirm its therapeutic potential for psoriasis.   \nKeywords : bio-oils; psoriasis; pyrazole; toxicity; solvent -extracts; Urtica subincisa .   \n78 VI.4.2.  Introduction  \nIn Mexico, the inherited knowledge about the medicinal plants converges w ith a great floristic \nwealth that has been exploited for health purposes since the pre -Columbian times. Several \nancestral cultures have left important legacies to the cur rent information about Mexican \nmedicinal plants such as the Maya in the southeast, the  Mixtec and Zapotec in the south as well \nas the Teotihuacan and the Pur\u00e9pecha in the center (Chavarr\u00eda and Espinosa, 2019).  \nPur\u00e9pechas live nowadays in the highlands of Central Michoac\u00e1n, a state located in the center -\nwest of Mexico , where they preserve t heir language and traditions, including an excellent \nancestral inherited knowledge on medicinal plants (Esquivel -Garc\u00eda et al., 2018) . A recent \nethnopharmacological study  conducted at the Pur\u00e9pecha Plateau, a zone characterized by an \nimportant presence of Pur\u00e9pechas (78.86% of its inhabitants), identified 97 promising plants for \ntreating dermatological conditions (Esquivel -Garc\u00eda et al., 2018). Native plants were preferred  \nby Pur\u00e9pechas (56.7%) over the introduced ones. Urtica subincisa  Benth. ( Urticaceae) is one of \nthe most representative native plants which has been widely employed by this population to treat \nskin inflammation, skin bumps, and varicose veins (Esquivel -Garc\u00eda et al., 2018). To the best \nof our knowledge, this herbaceous Mexican plant has not  been analyzed, neither from a \nphytochemical point of view nor regarding its toxicological and anti -inflammatory properties \non the skin cells. Consequently, further phyto chemical, toxicological, and pharmacological \nstudies are warranted to support its folk  use for dermatological conditions.  \nPsoriasis is one of the most prevalent inflammatory skin diseases, affecting about 3 million \nMexicans (Thorpe and Pandya, 2014) . Alth ough its etiology is not fully elucidated, \ninflammatory mediators crucially involved i n its pathogenesis have been recently identified. \nOne of the most critical is the interleukin 17 (IL -17), which exacerbates inflammation, \nstimulating the hyperproliferati on and aberrant differentiation of keratinocytes within the \nepidermis (Ekman et al., 2 019). IL-17 is known to upregulate the release of pro -inflammatory \nchemokines by keratinocytes such as interleukin -8 (IL -8), leading to the recruitment of \nmacrophages and  neutrophils into the epidermis with the consequent flare -up of skin \ninflammation (Blauvelt and Chiricozzi, 2018) . The discovery of biologicals targeting the IL -17 \nor its receptor such as secukinumab, ixekizumab, and brodalumab  offers significant psoriasis  \nimprovement; although adverse events, high -costs, and the lack of response in some pa tients  \n79 can limit their use (Bissonnette et al., 2014; Lv et al., 2018). Therefore, the quest for more \naffordable, effective, and safe therapeutic anti -IL17 agents is ongo ing. The development of \nnovel topical natural products showing anti -IL-17 effects offe rs several advantages compared \nto biologicals regarding their administration, as biotech agents unlike natural molecules, cannot \ncross the stratum corneum which prevent t heir use in topical formulations, preferred by patients \nhaving mild -to-moderate psoria sis (Claudia et al., 2020).  \nThe sub -cosmopolitan genus Urtica  has around 80 species (Steinmann, 2005) ; some of which \nhave medicinal properties such as Urtica dioica  L., Urtica massaica  Mildbr., Urtica parviflora  \nRoxb., Urtica pilulifera L., and Urtica uren s L. (Kopyt\u2019ko et al., 2012) . Phenolic compounds \nsuch as quercetin, isorhamnetin, kaempferol, vicenin -2, isolated from plants of this genus have \nshown promising results f or treating autoimmune diseases due to their immunomodulatory and \nanti-inflammatory pr operties (Ibrahim et al., 2018) .  \nPhenols and other bioactive molecules can be classically obtained by conventional solvent \nextraction but also, they are available as monomers, dimers, and oligomers in bio -oils as a result \nof lignin degradation during pyro lysis (Esquivel -Garc\u00eda et al., 202 0). The pyrolysis involves the \ndegradation of biomass by heat in the absence of oxygen and has the advantage that can be \nperformed after conventional extraction, allowing the integral use of the vegetable matrix. In \nour pr evious study bio -oils derived from  Amphipterygium adstringens  (Schltdl.) Standl. bark, \nmainly constituted of phenols, was shown to have an anti -inflammatory potential to be explored \nfor psoriasis (Esquivel -Garc\u00eda et al., 2020) . Moreover, pyrolytic products , especially the coal \ntar, a dark,  oily material produced by slow pyrolysis of coal, have been used for more than 100 \nyears for this disease (Zeichner, 2010) . However, much remains to be known about the pathways \ninvolved in the anti -inflammatory properties  of these products, the molecules responsible for \nsuch effects, and their safety profiles on the skin. Furthermore, the identification of new natural \nsources of active bio -oils is crucial in the search for new promising pyrolytic products as \nantipsoriatic agents.  \nAlthough the ethanolic mac erates of U. subincisa  have been extensively used by Pur\u00e9pechas for \ndermatological conditions, to the best of our knowledge no research has been carried out to \ncharacterize the chemical, toxicological and anti -inflammatory  properties of the solvent extract s \nor bio -oils from this plant. Therefore, this study aims to compare and chemically characterize  \n80 the ethanolic extract, its fractions, and the bio -oils from U. subincisa  aerial parts and to analyze \ntheir toxicity and anti -inflammatory properties on HaCaT k eratinocytes. We hypothesized that \ndifferences in the chemical compositions of bio -oils and the solvent extracts will significantly \naffect their toxicity and/or anti -inflammatory properties related to the production of IL -8 in IL -\n17 stimulated HaCaT kerati nocytes.  \n \nVI.4.3.  Material and methods  \nFig. 10 shows the major stages described in this paper. Firstly, the botanical identification and \nextraction by macerati on of the aerial parts of U. subincisa  were carried out. The residual \nbiomass resulting from the extraction was then pyrolyzed, to obtain bio -oils (oil -1 and 2). \nSubsequently, the crude extract was fractionated by liquid/liquid extraction to achieve phases  \nA-C. The crude extract, its fractions, and bio -oils were analyzed using a set of analytical \ntechniques (proximate, elemental analysis, FTIR, UV -fluorescence, GC -MS) to have an \noverview of their chemical composition. Finally, an analysis of their toxicity and inhibitory \nactivity on th e IL-8 production in HaCaT keratinocytes stimulated with IL -17 was performed. \nA detailed explanation of each major step is provided in the following sections.   \n81  \nFig. 10. Major steps depicted in this paper.  \n \nVI.4.3.1.  Botanical Analysis, extrac tion, and solvent fractionation  \nBotanical analysis. The aerial parts of U. subincisa  (flowers+seeds+leaves+stems) were \ncollected at Michoac\u00e1n state, Mexico. The plant was botanically identified by Dr. Emmanuel \nP\u00e9rez -Calix and deposited in IEB herbarium at  P\u00e1tzcuaro, Michoac\u00e1n (voucher number: \n256906). Before used, the plant material was w ashed and oven -dried (temperature 40\u00b12 \u00b0C for \n48 h).  \n \n82 Maceration.  Aerial parts from U. subincisa  were extracted by maceration. The choice of the \naerial parts and the extrac tion method was made to simulate the ethnomedicinal use of U. \nsubincisa  as reported b y Pur\u00e9pechas which use the alcoholic extract from the aerial parts as \nfomentations for skin inflammation (Esquivel -Garc\u00eda et al., 2018) . Fifteen grams of dry aerial \nparts powder (DAPP) was grounded to a particle size of \u2264800 \u00b5m. Then DAPP was extracted \nby maceration using Lab Companion SI -600 Benchtop Shaker (25 \u00b0C) with 90% aqueous \nethanol (150 mL) in two 48 -hour rounds. The residual biomass (RB) was separated by filtratio n \nwith a Whatman No. 4 filter paper and washed with an additional 150 mL of 90% aqueo us \nethanol. The crude extract (CE) was concentrated under vacuum (35 \u00b0C, 29 kPa) while the RB) \nwas recovered for pyrolysis experiments.  \nSolvent fractionation : Thirty gram s of CE were resuspended in 300 mL water. Liquid -liquid \nextraction was performed with hexane, ethyl acetate, and water as previously described (Garc\u00eda -\nP\u00e9rez et al., 2018)  to obtain the phases A, B and C, respectively. The CE and its fractions we re \nkept und er refrigeration (4 \u00b0C) until further analysis.  \n \nVI.4.3.2.  Pyrolysis experiments  \nPyrolysis was performed in a quartz -tube furnace reactor of 50 mm outer diameter \u00d7 44 mm \ninner diameter \u00d7 1000 mm length. Sixteen grams of the oven -dried RB were introduced i nto the \nfurnace under nitrogen flow for 5 min at 25 oC where the slow pyrolysis at 500 \u00b0C was performed \nas previously described (Esquivel -Garc\u00eda et al., 2020)  to obtain oils 1 and 2. The oils were kept \nunder refrigeration (4 \u00b0C) until further analysis.  \n \nVI.4.3.3.  Chemical anal ysis \nPyrolysis was performed in a quartz -tube furnace reactor of 50 mm outer diameter \u00d7 44 \nmm inner diameter \u00d7 1000 mm length. Sixteen grams of the oven -dried RB were  introduced \ninto the furnace under nitrogen flow for 5 min at 25 oC where the s low pyrolys is at 500 \u00b0C was \nperformed as previously described (Esquivel -Garc\u00eda et al., 2020)  to obtain oils 1 and 2. The oils \nwere kept under refrigeration (4 \u00b0C) until further analysis.   \n83 2.1 Chemical analys es \nPyrolysis gas chromatography mass spectrometry (Py -GC/MS) . Con sidering that the DAPP and \nRB were the starting materials for obtaining the solvent extracts and bio -oils respectively, a \nchemical characterization of both samples was carried out by Py -GC-MS using an Agilent \nTechnologies 6890N gas chromatograph linked to the Agilent 5975B mass selective detector \n(column: 30 m \u00d7 250 \u00b5m \u00d7 0.25 \u00b5m; mass spectral search program NIST 2.0 f). Both samples \n(\u22480.5 mg) were introduced into the probe interface using a CDS Analytical Pyroprobe 5000 \nfollowin g the method described by Ay ania et al. (Ayiania et al., 2019) . The compounds were \nidentified by combining the data from the Mass Spectra Library and the literature and classified \ninto different chemical groups as previously described (Esquivel -Garc\u00eda et a l., 2020) . \nProximate and ele mental analyses. The proximate analysis of the bio -oils, CE, and phases A -C \nwas performed to determine the fixed carbon, volatiles, and ash content with a Mettler Toledo \nthermogravimetric analyzer (SDTA851e) equipped with the ST ARe data analysis software t o \nobtain thermogravimetric (TGA)/derivative of thermogravimetric curve (DTG) data curves. The \ntotal contents of carbon (C), hydrogen (H), nitrogen (N), and sulfur (S) in the samples were \ndetermined using a Leco TruSpec Micro ele mental analyzer. The oxygen (O) content was \nobtained by difference after considering the dry ash content. Both analyses were performed \naccording to the methods previously described (Esquivel -Garc\u00eda et al., 2020) . \nFourier transform infrared spectroscopy (FT IR) analysis . Small amounts of pyrolytic oils, CE, \nand phases A -C were deposited in the sample container and FTIR spectra were obtained using \na Shimadzu IRPrestige 21 spectrometer. For the analysis of the functional groups, background \ncorrection was perfor med on each spectrum as prev iously described (Esquivel -Garc\u00eda et al., \n2020) . \nUltraviolet (UV) fluorescence . The UV fluorescence analysis was performed based on a \nprevious methodology (Garc\u00eda -P\u00e9rez et al., 2018). Briefly, bio -oils, CE, and phases A -C were \ndiluted in high performance l iquid chromatography  (HPLC) grade methanol at 10 ppm and \nanalyzed on the Shimadzu RF 5301 pc spectrometer with Panorama Fluorescence 2.1 software.  \nGas chromatography mass spectrometry (GC -MS).  The 1% (w/w) ethanolic solutions o f the \nbio-oils, CE and phase s A-C were analyzed by GC -MS using an Agilent Technologies 7890 A  \n84 GC set up (Agilent 19091S -433 HP -5MS column: 325 \u00b0C: 30 m\u00d7250 \u00b5m\u00d70.25 \u00b5m, Agilent \n5975 C MS with NIST 2.0 f Mass Spectral Search Program) and following a method p reviously \ndescribed (Esquive l-Garc\u00eda et al., 2020) .  \nDetermination of total phenols . Total phenol contents of bio -oils, CE, and phases A -C were \ndetermined using Folin -Ciocalteu method with some modifications as previously described \n(Garc\u00eda -P\u00e9rez et al., 20 10). The absorbance was meas ured at 750 nm on a Spectronic 20 Genesys \ninstrument. Results were expressed as mg gallic acid equivalents (GAE)/g of pyrolytic oils, CE, \nand phases A -C, respectively.  \n \nVI.4.3.4.  Toxicity on HaCaT keratinocytes  \nThe toxicity of CE, phases  A-C and bio -oils was evalua ted by (3-(4,5-dimethylthiazol -2-yl)-\n2,5-diphenyltetrazolium bromide  (MTT) assay. Human HaCaT keratinocyte cell line was \npurchased from AddexBio and cultured in DMEM high glucose with sodium pyruvate (Sigma \nAldrich) and suppleme nted with 100 U/mL penicilli n (Sigma Aldrich), 100 \u00b5g/mL streptomycin \n(Sigma Aldrich), and 10% fetal bovine serum (Thermo Fisher Scientific) in a humidified \nincubator containing 5% CO 2 at 37 \u00b0C. MTT assay was performed with cells at 80% confluence. \nBio-oils, CE and phases A -C (25 -1600 \u00b5g/mL) were diluted in DMEM medium with 0.2% \nethanol and the MTT assay performed as previously described (Esquivel -Garc\u00eda et al., 2020; \nGarc\u00eda -P\u00e9rez et al., 2010) . The toxicity was evaluated through the determination of the in itial \ntoxicity value (IC 90) which represents the minimal toxic dose of extract causing a 10% reduction \nof cell viability compared to untreated cells (Esquivel -Garc\u00eda et al., 2020) . \n \nVI.4.3.5.  Anti -inflammatory effects on IL -17-induced IL -8 production  \nHaCaT cells were seeded into 24 -well plat es and cultured under the aforementioned conditions \nuntil 80% of confluence. Subsequently, the cells were synchronized by serum deprivation during \n12 h. After this time, the cells were pre -treated or not for 10 h with dex amethasone (dex, 5 \u00b5M, \nSigma Aldric h), bio -oils, CE, and phases A -C at concentrations lower than IC 90 predetermined \nvalues. Later, IL -17 (50 ng/mL, Thermo Fisher Scientific) was added to cell cultures for 14 h to \ninduce IL -8 production. IL -8 amounts in IL -17 HaCaT supernatants were measured  using  \n85 Human IL -8/CXCL8 DuoSet ELISA kit (R&D Systems) according to the manufacturer\u2019s \nprotocol. The detection limit for IL -8 production was 30 pg/mL.  \n \nVI.4.3.6.  Statistical analyses  \nThe Shapiro -Wilk and Levene tests were conducted  to compare the analyzed variables.  \nAfterward, variables were analyzed by one -way analysis of variance (ANOVA) followed by a \nTukey post -hoc test or Kruskal \u2013Wallis and Holm -Bonferroni tests. The non -parametric \nSpearman\u2019s correlation test was used for establ ishing the association between the phenol content \nand the IC 90 values at p<0.05. The statistical analyses were performed employing R and RStudio \nusing the R commander package.  \n \nVI.4.4.  Results and Discussion  \nThe composition of the raw materials determines the qual ity, reproducibility, and chemical \ncharacteristics of the derived extracts and bio -oils to be used for therapeutic purposes. \nConsidering that the aerial parts of U. subincisa  constitutes the starting material for obtaining \nthe crude extract and its fractio ns, while the residual biomass was used for pyrolysis, the \nchemical characterization of these materials was first performed by Py -GC-MS. This technique \nis rapid, sensitive, and widely used for simultaneous mass spectrometric detection and \nidentification of  pyrolysis products in a vegetable matrix employing small amounts of sample \nand has been used to evaluate the quality of U. dioca  raw material for pharmaceutical purposes \n(Cuinica and Mac\u00eado, 2018) . \nFig. 11 shows the obtained pyrograms of the dried aerial parts and residual biomass of U. \nsubincisa . The names of the identified compounds are reported in  Table 4. As expected, a higher \ndiversity of compounds was found in the dried aerial parts powder (DAPP) than in the residual \nbiomass (RB). Pred ominantly identified compounds from DAPP were aromatics ( ~34 %), acids \n(~14 %), and ketones (~14 %), while in the RB, the aromatics (~36 %) and the acids (~18 %) \nwere also the main identified molecules. Among the aromatics, phenols were the major \ncompounds  in both samples (62 -66 %). Py -GC-MS was used in previous studies to as sign the \ndetected compounds to their biochemical origin (Biller and Ross, 2014; Kebelmann et al., 2013).  \n86 For example, indole and toluene (compounds 22 and 7 in Table 4 respectively) have been linked \nto the proteins, whereas the alkanes (compounds 28 and 33, in Table 4) have been related to \nboth fatty acids and triglycerides. Moreover, levoglucosan (compound 27 in Table 4) is linked \nwith carbohydrates and phenols with lignin (Biller and Ross, 2014). The hexadecanoic and \noctadecanoic acids (compounds 32 and 36, Table 4) were the main ident ified molecular \nfragments from the dried aerial parts and residual biomass of U. subincisa , which is consistent \nwith a previous study that used Py -GC-MS to chemically characterize U. dioica (Cuinica and \nMac\u00eado, 2018).   \n \nFig. 11. Pyrograms of the dried aerial parts and residual biomass of U. subincisa . \nList of compounds are in Table 4. \n \nTable 4. Compounds identified by Py -GC/MS in U. subincisa  aerial parts and residual biomass . \nNo. Identified compounds  RT (min)  DAPP  RB Group s \n1 Carbon dioxide  1.69 \u2713 \u2713 O \n \n87 No. Identified compounds  RT (min)  DAPP  RB Group s \n2 2,3-Butanedione  2.04 \u2713  K \n3 Acetic acid  2.34 \u2713  AC \n4 2-Propanone, 1 -hydroxy - 2.55 \u2713  K \n5 2-Butenal  3.09 \u2713 \u2713 AD \n6 Pyridine  3.54 \u2713  N \n7 Toluene  4.11 \u2713 \u2713 * \n8 3-Furaldehyde  5.01 \u2713  AD \n9 1,2-Ethanediol, diacetate  5.77 \u2713  A \n10 Unknown  6.31 \u2713 \u2713 - \n11 Cyclohexanone  7.09 \u2713  K \n12 Benzaldehyde  8.05 \u2713 \u2713 AD*  \n13 Phenol  8.57 \u2713 \u2713 P* \n14 Limonene  9.50 \u2713 \u2713 O \n15 Phenol, 4 -methyl - 10.87  \u2713 \u2713 P* \n16 Phenol, 2 -methoxy - 11.08  \u2713  P* \n17 Mequinol  11.17  \u2713 \u2713 P* \n18 Maltol  11.74  \u2713  K \n19 Phenol, 2 -methoxy -4-methyl - 13.61  \u2713 \u2713 P* \n20 Catecholborane  14.48  \u2713  O \n21 Phenol, 4-ethyl -2-methoxy - 15.62  \u2713  P* \n22 Indole  16.02  \u2713 \u2713 N \n23 2-Methoxy -4-vinylphenol  16.42  \u2713 \u2713 P* \n24 Phenol, 2,6 -dimethoxy - 17.26  \u2713  P* \n25 1H-Indole, 3 -methyl - 18.05  \u2713 \u2713 N \n26 Benzoic acid, 4 -hydroxy -3-methoxy - 19.30  \u2713  P* \n27 1,6-Anhydro -\u03b2-D-glucopyranose  20.49  \u2713 \u2713 S \n28 Hexadecane  21.68  \u2713 \u2713 AK \n29 Unknown  24.24  \u2713  - \n30 9-Dodecenol  26.52  \u2713 \u2713 A \n31 2-Heptadecanone  27.59  \u2713 \u2713 K \n32 n-Hexadecanoic acid  28.68  \u2713 \u2713 AC \n33 Cyclopentade cane 30.46  \u2713 \u2713 AK \n34 Unknown  31.24  \u2713 \u2713 - \n35 14-Pentadecenoic acid  31.36  \u2713 \u2713 AC \n36 Octadecanoic acid  31.81  \u2713 \u2713 AC \n37 Methyl salicylate  33.82  \u2713 \u2713 E* \n38 Eicosanoic acid  34.51  \u2713 \u2713 AC \nDry aerial parts powder (DAPP); residual biomass (RB); retention time ( RT). Groups: Alcohol (A); Ketone (K); \nAlkanes (AK); Phenol (P); Aromatic (*); Sugar (S); Acid (AC); Aldehyde (AD); Ester (E); Nitrogen -containing \nCompound  (N); Others (O).   \n88 Table 5 shows the yields of CE, its fractions, and the pyro lytic products (bio -oils and char) with \nrespect to the dried powder from U. subincisa  aerial parts. The extractive free bio mass, which \nrepresents an important component of the initial vegetable matrix (73.5\u00b13.3 wt.%), was used to \nobtain the pyrolytic produ cts (chars and bio -oils). As observed, the char, the crude extract, and \noil-2 exhibited higher yields compared to other sam ples. The recovery of char was higher than \nthat reported for nine other herbaceous plants such as Bromus marginatus  Nees and Trifoliu m \npratense L., whereas lower yields of pyrolytic bio -oils (oil -1 + oil -2) were obtained compared \nto the plants mentioned ab ove (Hlavsov\u00e1 et al., 2016) which can be explained both, by the lack \nof filters and electrostatic precipitators to collect aerosols i n our pyrolytic system, but also by \ndifferences in the chemical composition among plants. It is known that cellulose and \nhemicellulose are the primary components responsible to produce bio -oils, whereas lignin is \nassociated with the char yield (Stefanidis et al., 2014). Therefore, differences in the chemical \ncomposition of the feedstock and secondary reactions of bio -oils and char account for the \nrecovery of pyrolytic products (Hlavsov\u00e1 et al., 2016). Regarding the yield of the crude extract, \nit was similar  to that reported for the ethanolic extract of Urtica circularis (Hicken) Sorar\u00fa \n(Gorzalczany et al., 2011).  \n \nTable 5. Yields of the crude extract, its fractions, and pyrolytic products from aerial parts from U. \nsubincisa.  \nSample  Recovery (%) *  \nCrude extract  13.4\u00b10.6b \nPhase A  5.5\u00b10.1d \nPhase B  1.6\u00b10.2e \nPhase C  6.2\u00b10.5d \nChar  31.1\u00b12.1a \nOil-1 5.0\u00b10.5d \nOil-2 10.0\u00b10.6c \n*Percentages determined from the dry powder of aerial parts (wt.%). Data represent the Mean \u00b1 SD of three \nexperimen ts. Statistical: one -way ANOVA followed by Tukey`s post hoc test. Means without a common letter \ndiffer (p<0.05).  \n \nTable 6 illustrates the proximate and elemental analyses of all samples. Bio -oils showed the \nhighest water content (1 7-25 wt.%) compared to the crude extract and its fractions (0.5 -3.4 \nwt.%). This  finding can be explained by the dehydration of carbohydrate fractions during  \n89 pyrolysis (Mohan et al., 2006) . On the contrary, the content of volatiles was similar for all \nsampl es, but not the fixed carbon, which was higher for phase B and bio -oils than fo r the \nreminder of samples. A previous study also showed a high content of fixed carbon for the ethyl \nacetate fraction obtained from Petiveria alliacea L. aerial parts (Garc\u00eda -P\u00e9rez et al., 2018) . On \nthe other hand, the ash content was higher in phase C than that in the other samples.  \nThe elemental analysis revealed higher contents of carbon, nitrogen, and sulfur in bio -oils than \nin the crude extract and its fractions. Conversely , a higher conten t of hydrogen was constated in \nphase A, while the oxygen was significantly higher in the crude extract and its fractions than in \nthe bio -oils. The oxygen content is related to the contribution of oxygen to the total mass of the \nsample and indicates an impo rtant presence of oxygenated metabolites likely polyphenols, \noxygenated fatty acids, carotenoids. In bio -oils, oxygen has been linked to the presence of water, \nphenols, carboxylic acids, hydroxy ketones, and hydroxy aldehydes (Han et al., 2017) . \n \nTable 6. Proximate and elemental analysis of the crude extract, its fractions, and pyrolytic products from \nU. subincisa.  \nProximate analysis (wt. %)  \nSample  Moisture* Volatiles** Fixed carbon** Ash** \nCrude extract  3.4\u00b11.2 b,c 94.8\u00b11.1 a 1.3\u00b10.6 b 3.9\u00b11.7 b \nPhase A  0.5\u00b10.3 c 95.6\u00b10.9 a 2.8\u00b10.0 a,b 1.6\u00b10.8 b \nPhase B  2.4\u00b10.6 c 86.6\u00b15.5 a 8.7\u00b13.2 a 4.7\u00b12.3 b \nPhase C  4.2\u00b11.1 b,c 85.9\u00b12.1 a 0.2\u00b10.1 b 13.9\u00b12.1 a \nOil 1  17.6\u00b15.2 a,b 96.5\u00b12.9 a 4.9\u00b11.2 a,b 0.9\u00b10.8 b \nOil 2  25.5\u00b16.9 a 94.4\u00b10.7 a 4.9\u00b11.2 a,b 0.7\u00b10.5 b \nElemental analysis (wt. %)  \nSample  C** H** N** S** O*** \nCrude extract  34.4\u00b10.2 c 6.9\u00b10.07 c 4.7\u00b10. 00 d 0.06\u00b10.01 c 50.04 \u00b11.5 a \nPhase A  68.0\u00b10.3 a,b 10.4\u00b10.3 a 1.0\u00b10.09 f 0.06\u00b10.00 c 18.94\u00b10.8 b \nPhase B  60.7\u00b12.9 b 8.6\u00b10.53 b 2.4\u00b10.05 e 0.00\u00b10.00 c 23.6\u00b11.2 b \nPhase C  18.4\u00b10.1 d 3.8\u00b10.15 d 7.7\u00b10.21 c 0.03\u00b10.04 c 56.17\u00b11.9 a \nOil 1  77.4\u00b13.2 a 7.5\u00b10.15 b,c 10.4\u00b10.23 a 0.34\u00b10.03 a 3.46\u00b12.8 c \nOil 2  76.8\u00b13.9 a 8.5\u00b10.18 b 9.4\u00b10.54 b 0.18\u00b10.01 b 4.42\u00b13.5 c \n* As-received basis . ** Dry basis. *** By difference. Data represent Mean \u00b1 SD of two experiments. Statistical: one -\nway ANOVA followed by Tukey`s post hoc test. Means without a common letter differ (p<0.05).  \n  \n90 The thermogravimetric analyses of all samples are presented in Fig. 12. TGA and DTG provide \ninformation about the volatility and thermal stability of a sample. As observed, bio -oils had \nlower thermal stability than solvent extracts, as the evaporation and thermal  degradation of their \ncomponents o ccurred faster at lower temperatures. It is worth noting that the crude extract and \nphase C showed the highest thermal stability, which can be observed from the presence of three \nmain decomposition steps. The first step at  <200 \u25e6C corresponds to dehydration. In the second \nstep (200 -450 oC) the devolatilization and decomposition of organic matter occurs, whereas at \ntemperatures higher than 450 oC, the decomposition of residues resulting from the previous steps \ntakes place (M arcill a et al., 2009).  \n \n \nFig. 12. TGA (A) and DTG (B) curves of the crude extract, its fractions, and pyrolytic products from U. \nsubincisa.  \n \nFTIR has been used to analyze the presence of functional groups in natural extracts and its \nfindi ngs complement data obtained using other analytical assessments (dos Santos Grasel et al., \n2016; Esquivel -Garc\u00eda et al., 2020; Nunes Oliveira et al., 2016). Fig. 13 shows the infrared \nspectrum of the crude extract, its fractions, a nd pyrolytic oils from U. subincisa . Stretching \nvibrations of the O -H bond (3600 -3100 cm-1), usually assigned to water, carboxylic acids, \nalcohols, and phenols (Stankovikj and Garcia -Perez, 2017)  were more intense for oil -1 followed \nby phase A  than the rem inder of samples . GC/MS, UV -fluorescence, and the total phenol \ncontent results show ed that oil-1 is abundant in phenols . As such, vibrations observed in the \nspectrum are likely related  to the presence of phenols . Stretching signals for the C-H bond \n \n91 (3000 -2800 cm-1) could be linked to saturated and unsaturated aliphatic and aromatic \ncompounds. These records were more intense for the ethyl acetate fraction (phase B). Similarly, \nthe carbon yl stretching signal (C=O, 1780 -1680 cm-1) typically related to aldehyde s, ketones, \ncarboxylic acids, and esters was also more intense for phase B, which agrees with the analysis \nof this fraction by GC -MS. The stretch signal for C=C (1680 -1530 cm-1), is linked to conjugated \naromatic systems (Esquivel -Garc\u00eda et al., 2020) . This  signal  was more dominant in  phases A \nand C likely due to the presence of flavonoids or even proanthocyanidins which are widely \ndistributed in the plant kingdom and characterized by their aromatic conjugated structures \n(Kumar and Pandey, 2013) . It is worth  noting that the intense sig nal between 1520 -1250 cm-1 \nassociated with the C-O bond, observed for both bio -oils and the crude extract , could indicate \nthe presence of terpenes and acetates, while the signal at 1050 cm-1 could be related to the \noccurrence  of anhydrides (Stankovikj and Garcia -Perez, 2017) . The vibrations observed \nbetween 900 -800 cm-1 could be considered complementary to those of C -O and C -N (Esquivel -\nGarc\u00eda et al., 2020) . Overall, FTIR spectra show ed a higher diversity of functional groups in the \ncrude extract and its fr actions than that of the  bio-oils, although the O -H and C -O signals suggest \nthat the latter are rich in phenols, terpenes, and acetates.    \n92  \nFig. 13. FTIR spectra of  the crude extract, its fractions, and bi o-oils from U. subincisa.   \n \nUV-fluorescence has been used to characterize natural extracts and bio -oils (Bolea et al., 2016; \nGarc\u00eda -P\u00e9rez et al., 2018; Mourant et al., 2013)  as molecules such as phenols that are wide ly \ndistributed in the plant kingdom are fluorescent. Phenols occur in nature as simple phenols, short \nconjugated systems, and polycondensed structures. In a previous study, it was demonstrated that \nconformers having different dihedral angles between aromat ic rings related to the presence of \nsimp le structures, dimers, oligomers, and polymeric molecules have their own contribution to \nthe absorption in the fluorescence spectra (Barsotti et al., 2016) . Thus, as the number of aromatic \nrings in the molecule incre ases, the wavelength of fluorescence emi ssion also raises (Dieguez -\nAlonso et al., 2015) . Fig. 14 shows the UV -fluorescence spectra of all samples. In the range \nfrom 260 -300 nm, the crude extract showed a more intense peak, followed by phase C, and then \noils 1 and 2. The intensity of the peak reveals that crude extract is rich in monophenols. At an \n \n93 excitation wavelength of around 310 nm, dimers and short conjugated structu res can be \nobserved, whereas around 323 nm, large conjugated systems occur (Stankovikj et al., 2017) . \nAccording to Fig. 14, the presence of these compounds is higher in oil -1 than in the other \nsamples. In summary, these results indicate that solvent extracts are generally richer in simple \nphenols, while bio -oils contain a higher nu mber of conjugated molecules and polycondense d \nstructures, likely related to lignin decomposition during pyrolysis. Further studies using nuclear \nmagnetic resonance  (NMR) spectroscopy should be performed to determine the chemical \nstructure of these molecul es in the studied samples.  \n \n \nFig. 14. UV-Fluorescence spectra of the  crude extract, its fractions, and bio -oils from U. subincisa.  \n \n \n94 GC-MS has been used to perform the phytochemical analysis of volatile compounds from \nsolvent extract s and bio -oils (Ezhilan and Neelamegam, 2012; Mourant et al., 2013). GC-MS \nchromatograms of all samples are presented in Fig. 15, whereas the list of the numbered \ncompounds is shown in Table 7. The number o f identified molecules was high er in CE, followed \nby phase B and then the bio-oils. As observed, depending on the solvent extraction or pyrolysis, \nthe relative composition s of samples changed. The crude extract and phases A and B showed a \nhigher concentrat ion of esters (25, 56, and 20% of the identified molecules, respectively) \nwhereas, in phase C and oil -2, nitrogen -contain ing compounds prevailed (26 and 40%, \nrespectively). In contrast, oil -1 showed a preponderance of phenols (33%) and nitrogenous \ncompound s (28%). These results agree wi th the elemental analysis which demonstrated that \noxygen was significantly higher in the crude extract and its fractions than in the bio -oils, whereas \nthe nitrogen was higher in bio -oils than in solvent extracts. These findin gs are in good agreement \nwith t he previously reported FTIR results.  \nAs expected, the nature of the main compounds in each sample changed. Linoleic acid ethyl \nester was the dominant compound in CE and phase A, while 2-cyclohexen -1-one, 4-hydroxy -\n3,5,5 -trime thyl-4-3-oxo-1-butenyl - was the major molecule within phase B. Acetamide N -(3-\nmethyl -2-buten -1-yl)- on the other hand, predominated in phase C. Indole and phenol were \nprevalent within oil -1, while oil -2 proved to be rich in 3,4,5 -trime thylpyrazole and phen ol. The \npresence of fatty acids in the form of ethyl esters, as linoleic acid ethyl ester has been \ndocumented in U. dioica  (Lapinskaya and Kopyt\u2019ko, 2008) . \nIt is worth noting the significant occurrence of nitrogenous compounds in both solvent extracts \nand pyrolytic oils. Although to the best of our knowledge this study is the first to analyse the \nchemical composition of U. subincisa , it is known that other species of this genus such as U. \ndioica  and U. urens  are nitrophilic weeds (Garme ndia et al., 2018; Ro snitschek -Schimmel, \n1985a) as they compete with most other herbal plants for nitrogen. It has been documented that \nthe excess of nitrogen supply led to the accumulation of nitrogenous compounds such as nitrate \nand free amino acid in th ose plants. Proteins can function as nitrogen stores too, particularly in \nseeds (Rosnitschek -Schimmel, 1985b). Our results suggest that U. subincisa  could also be \nconsidered a nitrophilic species, but further studies should be accomplished to determine its  \ncapacity to store th is compound and the impact of seasonal variations on this process.   \n95  \nFig. 15. GC-MS chromatograms of the crude extract, its fractions, and bio -oils from Urtica subincisa . \nPhase A (hexane); B (ethyl acetate) and C (aqueous fraction ) (the list of numbered compounds is provided in Table \n7).  \n \nTable 7. Compounds identified by GC -MS in the crude extract, phases A -C and bio -oils obtained from \naerial parts of U. subincisa . \nNo. Identified compounds  RT \n(min)  Crude \nextract  Phase \nA Phase \nB Phase\nC Oil \n1 Oil \n2 Groups  \n1 Acetic acid  12.30  \u2713   \u2713 \u2713 \u2713 AC \n2 Propanoic acid, 2 -oxo- 14.12  \u2713   \u2713   AC \n3 Pyrrole  21.32      \u2713 \u2713 N \n4 Pyruvic acid  24.11  \u2713   \u2713   AC \n \n96 No. Identified compounds  RT \n(min)  Crude \nextract  Phase \nA Phase \nB Phase\nC Oil \n1 Oil \n2 Groups  \n5 4-Methyl -2-hexene  26.37      \u2713 \u2713 HD \n6 Acetamide  27.32      \u2713 \u2713 N \n7 2-Furanmethanol  27.65      \u2713 \u2713 F \n8 2-Cyclopenten -1-one, 2 -methyl - 28.12      \u2713  K \n9 Propanenitrile, 2 -hydroxy - 32.18       \u2713 N \n10 2-Cyclopenten -1-one, 3 -methyl - 33.65      \u2713 \u2713 K \n11 Butyrolactone  34.02      \u2713 \u2713 E \n12 1-Methyl-2-piperidinemethanol  35.21       \u2713 N \n13 1H-1,2,4 -Triazol -3-amine, 5 -methyl  35.24      \u2713  N \n14 Glycolaldehyde dimer  36.14  \u2713   \u2713   AD \n15 2-Cyclopenten -1-one, 2,3 -dimethyl - 36.62      \u2713 \u2713 K \n16 Phenol  38.54      \u2713 \u2713 P* \n17 Phenol, 2 -methoxy - 39.17      \u2713 \u2713 P* \n18 2-Cyclohexen -1-one, 4 -(2-\noxopropyl) - 39.25       \u2713 K \n19 Cyclohexanone, 3 -methyl - 39.50      \u2713 \u2713 K \n20 dl-Glycerldehyde  40.52  \u2713  \u2713 \u2713   AD \n21 Phenol, 2 -methyl - 40.87      \u2713 \u2713 P* \n22 2-Hydroxy -gamma -butyrolactone  41.45  \u2713   \u2713   E \n23 Benzeneacetic acid, methyl ester  42.29  \u2713  \u2713    AC*  \n24 Phenol, 4 -methyl - 42.60      \u2713 \u2713 P* \n25 Phenol, 3-methyl - 42.70      \u2713 \u2713 P* \n26 Ethanol, 2 -(2-butoxyethoxy) - 43.10  \u2713  \u2713    A \n27 Vinyl butyrate  43.53  \u2713  \u2713 \u2713   E \n28 Cyclobutanol  44.33  \u2713   \u2713   A \n29 1H-Imidazole, 2,4 -dimethy l- 44.54      \u2713 \u2713 N \n30 L-Prolinamide  44.73  \u2713   \u2713   N \n31 Tetradecane  46.45       \u2713 HD \n32 Phenol, 4 -ethyl - 46.62      \u2713 \u2713 P* \n33 Unknown  47.42  \u2713   \u2713   - \n34 Phenol, 4 -ethyl -2-methoxy - 47.99      \u2713  P* \n35 3,4,5 -Trimethylpyrazole  48.06      \u2713 \u2713 N \n36 1,3-Benzen ediamine  48.62       \u2713 N* \n37 1H-Pyrrole -2,5-dione, 3-ethyl -4-\nmethyl - 49.20  \u2713  \u2713    N \n38 Benzenepropanenitrile  49.27       \u2713 N* \n39 2,3,5 -Trimethylanisole  50.50  \u2713  \u2713 \u2713   * \n40 Unknown  50.54      \u2713 \u2713 - \n41 Pyrazine, 2,5 -dimethyl - 51.56       \u2713 N \n42 Indole  53.04 \u2713  \u2713  \u2713 \u2713 N \n43 Unknown  56.23       \u2713 - \n44 Vanillin  56.95  \u2713  \u2713    P* \n45 Benzeneacetamide  58.84  \u2713  \u2713    N* \n46 Acetamide, N -(3-methyl -2-buten -1-\nyl)- 61.72  \u2713  \u2713 \u2713   N \n47 Unknown  63.11  \u2713 \u2713 \u2713    - \n48 Mannitol, 1,4 -anhydro - 63.20  \u2713   \u2713   A \n49 2-Hexadecen e, 2,6,10,14 -\nteramethyl - 63.37  \u2713 \u2713     HD \n50 2-Hexadecene, 3,7,11,15 -\ntetramethyl  63.74  \u2713 \u2713 \u2713    HD \n51 3-Eicosyne  64.07  \u2713 \u2713 \u2713    HD \n52 Tetradecanoic acid, ethyl ester  64.31  \u2713 \u2713     E \n53 7-Octadecyne, 2 -methyl - 64.89  \u2713 \u2713 \u2713    HD  \n97 No. Identified compounds  RT \n(min)  Crude \nextract  Phase \nA Phase \nB Phase\nC Oil \n1 Oil \n2 Groups  \n54 Propanoic acid, 2 -methyl-, 2-\nphenylethyl ester  64.99  \u2713  \u2713    E* \n55 2-Cyclopenten -1-one, 4 -hydroxy -3-\nmethyl -2-(2-propenyl) - 65.48  \u2713  \u2713    K \n56 \u03b2-D-Glucopyranose, 1,6 -anhydro - 65.55  \u2713   \u2713   S \n57 1,4-Eicosadiene  65.67  \u2713 \u2713 \u2713    HD \n58 Unknown  66.33  \u2713  \u2713    - \n59 Unknown  66.99  \u2713   \u2713   - \n60 3-(1-Methylhept -1-enyl) -5-methyl -\n2,5-dihydrofuran -2-one 67.06  \u2713  \u2713    F \n61 2-Pentadecanone, 6,10,14 -\ntrimethyl - 67.14  \u2713 \u2713     K \n62 3-Buten -2-one, 4 -(5-hydroxy -2,6,6 -\ntrimethyl -1-cyclohexen -1-yl)- 67.95  \u2713  \u2713    K \n63 3-Buten -2-one, 4-(4-hydroxy -2,2,6 -\ntrimethyl -7-oxabicyclo[4.1.0]hept -\n1-yl)- 68.30  \u2713  \u2713    K \n64 Hexadecanoic acid, methyl ester  68.77  \u2713 \u2713 \u2713    E \n65 3,7-Cyclodecadiene -1-methanol, \n4,8-tetramethyl - 69.90  \u2713  \u2713    A \n66 Unknown  70.43  \u2713   \u2713   - \n67 4-3-Hydroxy -1-propenyl) -2-\nmethoxyphenol  70.58  \u2713  \u2713    P* \n68 Hexadecanoic acid, ethyl ester  70.80  \u2713 \u2713 \u2713    E \n69 2-Propanone, 1 -hydroxy -3-(4-\nhydroxy -3-methoxyphen yl)- 71.38  \u2713  \u2713    P* \n70 Benzamide, N -(2-hydroxyethyl) - 72.05  \u2713  \u2713 \u2713   N* \n71 11,14 -Eicosadienoic acid, methyl \nester  74.65  \u2713 \u2713     E \n72 Adenine  74.69  \u2713   \u2713   N \n73 Phenethyl alcohol, 2,5 -dihydroxy -\n\u03b1-methyl, ( -)- 74.70  \u2713  \u2713    P* \n74 Phytol  75.56  \u2713 \u2713 \u2713    A \n75 2-Cyclohexen -1-one, 4-hydroxy -\n3,5,5 -trimethyl -4-3-oxo-1-butenyl) - 75.77  \u2713  \u2713    K \n76 Ethyl oleate  76.32  \u2713 \u2713     E \n77 Linoleic acid ethyl ester  76.49  \u2713 \u2713 \u2713    E \n78 Methyl 17 -methyl -octanoate  76.73  \u2713 \u2713     E \n79 9,12,15 -Octadecatrienoic acid, ethyl  \nester  76.99  \u2713 \u2713 \u2713    E \n80 Eicosanoic acid, ethyl ester  82.18  \u2713 \u2713     E \nRetention time (RT). Groups: Alcohol (A); Furans (F); Ketone (K); Phenol (P), Aromatic (*); Sugar (S); \nHydrocarbon (HD); Acid (AC); Aldehyde (AD); Ester (E); Nitrogen -containing Comp ound  (N). \n \nThe preponderance of nitrogenous compounds in bio-oils, determined by elemental analysis and \nGC-MS, among which indole and 3,4,5 -trimethylpyrazole distinguish, could be related to \nprotein pyrolysis (Biller and Ross, 2014) . Phenols, also identifi ed as major compounds in these \noils, could result from li gnin pyrolysis (Fu et al., 2014) . Indeed, bio-oils were found to be \nsignificantly richer in total phenols than solvent extracts as determined by the Folin -Ciocalteu \nmethod  (see Table 8).  \n98 Table 8. Total phenols and initial toxicity values (IC 90) of different fractions of U. subincisa . \nSample  Total phenols (mg GAE/g)  IC90 (\u00b5g/mL)  \nCrude extract  13.5\u00b10.1d 1614.8 \u00b167.0a \nPhase A  13.9\u00b10.1d 116.7 \u00b13.5e \nPhase B  18.5\u00b10.5c 194.9 \u00b15.8d \nPhase C  13.4\u00b10.2d 443.9 \u00b15.0b \nOil-1 30.6\u00b11.2a 284.2 \u00b15.6c \nOil-2 25.4\u00b11.3b 33.8\u00b13.0f \nStatistical: one -way ANOVA followed by Tukey\u2019s post hoc test. Means without a common letter in the same \ncolumn differ (p<0.05).  \n \nAlthough the GC -MS p rovides valuable information on the chemical composition of the studied \nsamples, it could be considered as a preliminary phytochemical study as it only determines the \nnature of volatile  molecules. Further in -depth chemical analyses (HPLC, NMR) should be \nperformed to provide more information about other non -volatile compounds present in U. \nsubincisa  extracts and bio -oils.  \nTo evaluate the potential of the samples as anti -inflammatory agen ts, it is not only indispensable \nto determine their capacity to inhibit  the production of crucial mediators involved in psoriasis, \nbut it is also imperative to assess their toxicity on keratinocytes in advance as they should \ndemonstrate low toxicity at pha rmacological concentrations. In this study, the toxicity of all \nsamples  was evaluated through the determination of the initial toxicity value (IC 90) which \nrepresents the minimum toxic dose causing a 10% reduction of the cell viability compared with \nuntreat ed keratinocytes (Garc\u00eda -P\u00e9rez et al., 2010; Teepe et al., 1993). MTT a ssay has been \nconsidered as a sensitive test to evaluate the toxicity of natural extracts, drugs, and excipients \nused for pharmaceutical goals (Garc\u00eda -P\u00e9rez et al., 2010; Hundie et al.,  2016; Scherlie\u00df, 2011).  \nTable 8 shows the IC 90 values obtained for all samples. The crude extract had the lowest \ntoxicity, followed in increasing toxicity order by phas e C, oil -1, phases B -A, and oil -2, \nrespectively. In rationalizing the initial toxicity of the samples in terms of the total phenol \ncontent, it became clear from the Spearman\u2019s correlation data that higher content of phenols in \nsamples, the lower IC 90 value s and higher toxicity on keratinocytes (r= -0.5209; p=0.0266). It is \nwell known that phenols used in household and pharmaceutical form ulations can produce a rash, \ndermal inflammation, and contact dermatitis (Murray et al., 2007). The toxicity of phenol on \nkeratinocyte s depends not only on its concentration and hydrophobicity  (Newby et al., 2000) \nbut also on the generation of organic radi cals and reactive oxygen species (Gami, 2014). One of  \n99 the main compounds identified by GC -MS in oil -2 (the most toxic sample) was phenol \n(compound 16, Table 7) The metabolism of phenol in the skin results in the formation o f the \nphenoxyl radicals which can modify proteins, DNA, and lipids. A potential mechanism for \nphenol\u2019 cutaneous toxicity is also linked to the glutathione and protein thiols oxidation. \nMoreover, this compound decreases vitamin E, thereby reducing the antio xidant c apacity of the \nskin (Murray et al., 2007).  \nAlthough the presence of phenols could impact the toxicity, their sole occurrence cannot explain \nthe overall observed toxic effects of samples. Indeed, oil -1 which shows a preponderance of \nthese compounds accordin g to the total phenol content assessment, GC -MS, FTIR, and UV -\nfluorescence analyses, was less toxic on keratinocytes than the phases A -B and oil -2. Thus, we \nhypothesized that the toxicity on keratinocytes is also related to the relative proportion of the \nchemical compounds within the sample, which could lead to interactions between molecules \nthat would ultimately translate into harmful effects on cells. Our hypothesis was tested though \nexploration of the GC -MS data ( Fig. 15, Table 7). GC -MS analysis showed the important \noccurrence of nitrogenous compounds in the samples. The CE ( the sample with the least \ntoxicity) showed a relatively low proportion of nitrogenous compounds (14%), while oil -2 (the \nmost toxic s ample) showed the highest proportion of these compounds (36%). On the contrary, \nthe CE presented a high proportion of esters  (25%), while oil -2 showed the lowest proportion \n(4%) of these molecules. The major ester in CE was linoleic acid ethyl ester (compo und 77, \nTable 3), which is a neutral, lipid -soluble form of linoleic acid. In the skin epidermis, mainly \ncomposed of keratin ocytes, linoleic acid is transformed in 13 -hydroxyoctadecadienoic acid \nwhich exerts antiproliferative and anti -inflammatory activiti es (Ziboh et al., 2000)  thereby \nprotecting skin against toxicity. The dominant nitrogenous compound in oil -2 was 3,4,5 -\ntrime thylpyrazole  (compound 35, Table 7). Although the toxicity of this compound on \nkeratinocytes is not documen ted, the pyrazole derivative 3,4 -dimethyl -1-H-pyrazole has been \ndemonstrated to be irritant for the skin (J\u00edrov\u00e1 et al.,  2010) and other pyrazole -based compounds \nhave been shown to have slight toxicity to dermal fibroblasts (Nada et al., 2018). More in vit ro \nand in vivo  toxicological studies should be carried out to accurately determine the nature of the \nmolecules impacting  the toxicity on keratinocytes and their threshold doses.  \nThe critical role of IL -17 is now recognized in psoriasis and the impact of k eratinocytes as \ncrucial targets for its inflammatory effects on the skin is also documented (Moos et al., 2019) .  \n100 The pro duction of IL -8, a potent neutrophil chemoattractant, was found to be higher in the serum \nand skin of psoriasis patients compared to hea lthy ones (Bai et al., 2017)  and its levels were \ncorrelated with psoriasis severity (Arican et al., 2005) . Consequently,  in this work, it was \nconsidered that the inhibition of IL -8 production by IL -17 stimulated HaCaT keratinocytes \nwould be a good in vitro  model for screening the anti -inflammatory potential of the solvent \nextracts and bio -oils and their possible application  for psoriasis. For this, all samples were tested \nat non -cytotoxic concentrations, under their respective IC 90 values . Fig. 16 shows the ir effect \non IL-8 production.  \n \n \nFig. 16. Effect of the crude extract, phases A -C, and bio -oils on the IL -8 production in keratinocytes \nHaCaT stimulated with IL -17.  \nA) Solvent extracts, B) Bio -oils. The con fluent HaCaT cells were pre -treated or  not with the crude extract (400 -\n1600 \u00b5g/mL), phase A (27.5 -110 \u00b5g/mL), phase B (47.5 -190 \u00b5g/mL), phase C (110 -440 \u00b5g/mL), oil -1 (70 -280 \n\u00b5g/mL), oil -2 (7.5 -30 \u00b5g/mL) or Dex (5 \u03bcM) for 10h, then cells were stimulated with IL -17 (50 ng/mL) for 14 h. \nIL-8 pro duction in HaCaT supernatants was assessed by ELISA. Results are expressed in pg/mL and correspond \nto 106 cells. Histograms represent the mean \u00b1 SD. A) statistical: Kruskal -Wallis followed by Holm\u2019s post hoc test. \nB) statistical: one -way ANOVA followed by Tukey\u2019s post hoc test. In all cases, means without a common letter \ndiffer (p < 0.05).  \n \nAs observed, the solvent extracts did not inhibit the IL -8 production, except when phase A was \nused at the lowest concentration, which decreased IL -8 to basal concentrations. Conversely, a \nsignificant and unexpected proinflammatory effect of phase B was no ted, whereas \ndexamethasone, a corticoid used for psoriasis (Le and Howard, 2013)  signific antly decreased \nthe IL -8 under basal levels. In the case of bio -oils, oil -1 failed to induce an anti -inflammatory \neffect, while oil -2 at 15 and 7.5 \u03bcg/mL significantly  decreased the IL -8 production. It should be \n \n101 noted, that, unlike solvent extracts, this e ffect at 7.5 \u03bcg/mL was comparable to that of \ndexamethasone. Interestingly, oil -2 at intermediate and higher concentrations (15 and 30 \u03bcg/mL, \nrespectively) showed lesse r anti -IL17 activity than did the lowest tested concentration (7.5 \n\u03bcg/mL). This opposite effect was also observed for the anti -inflammatory activity of pyrolytic \noils from A. adstringens  bark (Esquivel -Garc\u00eda et al., 2020) . A possible explanation could be \nrelated to the fact that at higher concentrations close to the minimum toxic concentratio n, the \nbio-oils trigger cellular defense mechanisms, which counteract the anti -inflammatory effect, but \nfurther research is needed to prove it.  \nOur results demonstrate that differences in chemical composition, as observed between phase B \nand oil 2 (the sam ples with highest pro -inflammatory and anti -inflammatory effects, \nrespectively) could be associated with changes in the anti -IL17 activity. The most important \ndifferences in the relative composition of phase B and oil -2 according to GC -MS data are related \nto the presence of esters (20 vs. 4%); nitrogenous compounds (16 vs. 36%), hydrocarbons (13 \nvs. 8%) and phenols (13 vs. 24%), respectively. One of the major identified compounds in phase \nB is phytol (compound 74, Table 7) which has  been shown to have pro -inflammatory and tumor -\npromoting activities on mouse skin (Kagoura et al., 1999) . Phytol derivatives are strong inducers \nof cytokines such as IL -17 (Roy Chowdhury et al., 2013)  and can stimulate the NF -kappaB \ntranscription factor (Ghosh and Chowdhury, 2013)  linked to the IL -8 production. Phytol -based \nimmunostimul ants can boost the expression of CXCL 1, a murine equivalent of IL -8 (Chowdhury \nand Ghosh, 2012)  so we think that the important presence of phytol in Phase B could explain, \nat least partially, the unexpected pro -inflammatory activity. Furthermore, the signi ficant \noccurrence of hydrocarbons in this phase compared to oil -2 is striking. Hydrocarbons have been \nassociated with immune activation and development of autoimmune disease (Yau et al., 2017) , \nso it is likely that these compounds act alone or in synergism  with phytol to stimulate the IL -8 \nproduction, but further research is warranted to confirm it.  \nCurrently, the main utilization of bio -oils is related to fuel\u2019s development, while their use as \nvaluable sources of bioactive molecules has been largely neglec ted. However, the tar\u2019s use as a \ntreatment for dermatological conditions dates back to over 2000 years, whereas coal tar has been \nused precisely for psoriasis for more than 1 00 years (Zeichner, 2010) . The Goeckerman \nregimen, presently used for this illness , which consists of the ultraviolet B exposure combined \nwith the coal tar application is an example of the importance of pyrolytic products as effective  \n102 antipsoriatic therapi es. Nevertheless, the mechanism of action of coal tar in psoriasis remains to \nbe elucidated and it is unknown whether other pyrolytic products derived from new natural \nsources, as U. subincisa,  could have an anti -inflammatory potential for this cutaneous c ondition. \nResults here presented demonstrate that oil -2 has an inhibitory effect on the IL -8 production \ntriggered by IL -17 comparable to that of dexamethasone. The m ajor compound detected by GC -\nMS in oil -2 was 3,4,5 -trimethylpyrazole . The pyrazole scaffold  provides varied stereochemical \ncomplexity and functionality due to the presence of two nitrogen atoms and aromaticity. This \ncomplexity explains its wide range of drug -like properties including  anti-inflammatory activity \n(Ansari et al., 2017) . Pyrazole der ivatives can ameliorate psoriasis -like dermatitis in mice by \ninhibiting IL -17 mRNA expression (Seki et al., 2014). Moreover, these compounds can inhibit \nNF-kappaB (Fu et al., 2017) linked to IL -8 production. Another bioactive nitrogenous \ncompound present i n oil -2 is pyrrole (compound 3, Table 7). Pyrrole derivatives have been \nproposed for the prophylaxis and t reatment of inflammatory diseases involving the over -\nproduction of cytokines such as IL -8 (Zablocki et al., 2003). Moreover, the significant \nproportion of phenols in oil -2 could also be linked to its anti -inflammatory potential as these \nmolecules are recog nized by their anti -psoriatic activity (Dzia\u0142o et al., 2016) . \nEven though our results show the potential of oil -2 as an anti -IL-17 agent for psoriasis, \nadditional research should be performed to elucidate the mechanisms involved in this activity. \nAlso, sin ce this oil at concentrations higher th an those showing anti -inflammatory activity \nproved to be toxic on keratinocytes, further studies should be carried out to comprehensively \nevaluate its pharmacodynamic and toxicity -related compositions to ensure its ef ficacy and safety \non skin.  \n \nVI.4.5.  Conclusions  \nOverall, results here presented allowed for the first time to compare the chemical composition, \ntoxicity, and anti -inflammatory character of the crude extract, its fractions, and bio -oils from U. \nsubincisa . The use o f aerial parts of the plant and the ext racted residual biomass to obtain solvent \nextracts and bio -oils allowed the integral use of this medicinal plant employed by Pur\u00e9pechas \nfor dermatological conditions. The relative chemical compositions of the samples were assessed \nusing a set of analytical  techniques. FTIR spectra showed a higher diversity of functional groups  \n103 in the crude extract and its fractions than in bio -oils. UV -fluorescence indicated that solvent \nextracts were generally richer in simple phenols , while bio -oils contained a higher num ber of \nconjugated molecules and polycondensed structures. According to GC -MS, the crude extract \nand phases A and B showed a higher concentration of esters (25, 56, and 20% of the identified \nmolecules, respectively) wh ereas, in phase C and oil -2, nitrogen -containing compounds \nprevailed (26 and 40%, respectively). In contrast, oil -1 showed a preponderance of phenols \n(33%). These results agree with the elemental analysis which demonstrated that the oxygen was \nsignificantl y higher in the crude extract and its f ractions than in bio -oils, whereas the nitrogen \nwas higher in bio -oils than in solvent extracts. As to the toxicity, the crude extract had the lowest \ntoxicity on HaCaT keratinocytes, followed in increasing toxicity or der by phase C, oil -1, phases \nB-A, and oil-2, respectively. Regarding the anti -IL-17 activity, only oil -2 showed a significant \ninhibitory effect on IL -8 production and this effect,  at 7.5 \u03bcg/mL, was comparable to that of \ndexamethasone.  \nThe evidence presented in this work does not support the traditional topical use of the ethanolic \nextract from aerial parts of U. subincisa  by Pur\u00e9pechas as an anti -inflammatory agent for \ntreating psoriasis. However, this folk preparation could possess oth er anti -inflammatory \nproperties not linked to IL -17\u2019s inhibition useful for other cutaneous conditions, but further \ninvestigations should be performed to prove it. Our results demonstrate for the first time t hat \noil-2 obtained from the extracted biomass, u sually considered as a waste, has anti -IL-17 \nproperties that deserve to be studied in detail in the future to elucidate the involved mechanisms. \nThe significant proportion of nitrogenous compounds in this bio -oil, particularly 3,4,5 -\ntrimethylpyrazole , open s the door for a more exhaustive analysis of the anti -IL17 effects of this \nmolecule and its possible application in psoriasis. As the toxic effects linked to the use of oil -2 \non the skin could be a concern, i t is expected that preclinical dermal toxicologi cal evaluations \ncan be performed to asses any complication arising during its topical exposition to anticipate \nadverse events in humans.  \n \nVI.4.6.  Author  contribution s \nREG : investigation, formal analysis, writing orig inal draft. AS: investigation, formal analysis. \nNAL : investigation, visualization, writing, review & editing. MGP : investigation,  \n104 methodology, resources, writing, review, and editing. AOZ : investigation, formal analysis, \nwriting, review, and editing. MEGP : conceptualization, methodology, formal analysis , \nresources, supervision, writing, review, and editing.  \n \nVI.4.7.  Conflict of i nterest  \nThe authors declare that they have no competing interests.  \n \nVI.4.8.  Acknowledgements  \nThe \u201cConsejo Nacional de Ciencia y Tecnolo g\u00eda\u201d (CONA CYT, Mexico) for the financial \nsupport of Roberto Esquivel -Garc\u00eda (Doctoral Fellowship No.285764).  \n \nVI.4.9.  References  \nAnsari, A., Ali, A., Asif, M., Shamsuzzaman, 2017. Review: biologically active pyrazole derivatives. New. J. \nChem. 41, 16 \u201341. https://doi.org/10. 1039/C6NJ03181A  \nArican, O., Aral, M., Sasm az, S., Ciragil, P., 2005. Serum levels of TNF -alpha, IFN -gamma, IL -6, IL -8, IL -12, IL -\n17, and IL -18 in patients with active psoriasis and correlation with disease severity. Mediat. Inflamm. \n2005, 273 \u2013279. https:// doi.org/10.1155/MI.2005.273  \nAyiania, M., T errell, E., Dunsmoor, A., Carbajal -Gamarra, F.M., Garcia -Perez, M., 2019. Characterization of solid \nand vapor products from thermochemical conversion of municipal solid waste woody fractions. Waste \nManag. 84, 277 \u2013285. https://doi.org/10.1016/j.wasman.2018. 11.042  \nBai, F., Zheng, W., Dong, Y., Wang, J., Garstka, M.A., Li, R., An, J., Ma, H., 2017. Serum levels of adipokines \nand cytokines in psoriasis patients: a systematic review and meta -analysis. Oncotarget 9, 1266 \u20131278. \nhttps://doi.org/10.18632/oncotarget. 22260  \nBarsotti, F., Ghigo, G., Vione, D., 2016. Computational assessment of the fluorescence emission of phenol \noligomers: a possible insight into the fluorescence properties of humic -like substances (HULIS). J \nPhotochem. Photobiol. A. 315, 87 \u201393. https:// doi.org/10.1016/j.jphotochem.2015.09.012  \nBiller, P., Ross, A.B., 2014. Pyrolysis GC \u2013MS as a novel analysis technique to determine the biochemical \ncomposition of microalgae. Algal Res. 6, 91 \u201397. https://doi.org/10.1 016/j.algal.2014.09.009  \nBissonnette, R., N igen, S., Langley, R.G., Lynde, C.W., Tan, J., Fuentes\u2010Duculan, J., Krueger, J.G., 2014. \nIncreased expression of IL -17A and limited involvement of IL -23 in patients with palmo -plantar (PP) \npustular psoriasis or PP pustulosis; results from a randomised cont rolled trial. J. Eur. Acad. Dermatol. \nVenereol. 28, 1298 \u20131305. https://doi.org/10.1111/jdv.12272  \nBlauvelt, A., Chiricozzi, A., 2018. The immunologic role of IL -17 in psoriasis and psoriatic arthritis pathogenesis. \nClin. Rev. Allergy Immunol. 55, 379\u2013390. https://doi.org/10.1007/s12016 -018-8702 -3 \nBolea, C., Turturic\u0103, M., St\u0103nciuc, N., Vizireanu, C., 2016. Thermal degradation kinetics of bioactive compounds \nfrom black rice flour ( Oryza sativa  L.) extracts. J. Cereal Sci. 71, 160 \u2013166. \nhttps://doi.or g/10.1016/j.jcs.2016.08.010  \nChavarr\u00eda, A., Espinosa , G., 2019. Cruz -Badiano Codex and the importance of the Mexican medicinal plants. J. \nPharm. Technol. Res. Manag. 7, 15 \u201322. \nChowdhury, R.R., Ghosh, S.K., 2012. Phytol -derived novel isoprenoid immunostimula nts. Front. Immunol. 3. \nhttps://doi.org/10.3389/fim mu.2012.00049   \n105 Claudia, C. -D., Mar\u00eda -Elena, V. -H., Josu\u00e9, V. -E., Mar\u00eda -Carmen, B. -C., Alain -Raimundo, R. -O., Martha -Estrella, \nG.-P., 2020. Small molecules under development for psoriasis: on the road to the  individualized therapies. \nArch. Dermatol. Res. htt ps://doi.org/10.1007/s00403 -020-02056 -3 \nCuinica, L.G., Mac\u00eado, R.O., 2018. Thermoanalytical characterization of plant drug and extract of Urtica dioica  \nL. and kinetic parameters analysis. J. Therm. Anal. Calorim. 133, 591 \u2013602. \nhttps://doi.org/10.1007/s1097 3-018-6986 -4 \nDieguez -Alonso, A., Anca -Couce, A., Zobel, N., Behrendt, F., 2015. Understanding the primary and secondary \nslow pyrolysis mechanisms of holocellulose, lignin and wood with laser -induced fluorescence. Fuel 153, \n102\u2013109. https://doi.org/10.1016/ j.fuel.2015.02.097  \ndos Santos Grasel, F. , Fl\u00f4res Ferr\u00e3o, M., Wolf, C.R., 2016. Development of methodology for identification the \nnature of the polyphenolic extracts by FTIR associated with multivariate analysis. Spectrochim. Acta A. \nMol. Biomol. Spectrosc.  153, 94 \u2013101. https://doi.org/10.1016/j. saa.2015.08.020  \nDzia\u0142o, M., Mierziak, J., Korzun, U., Preisner, M., Szopa, J., Kulma, A., 2016. The potential of plant phenolics in \nprevention and therapy of skin disorders. Int. J. Mol. Sci. 17. https://doi.org/10.3 390/ijms17020160  \nEkman, A. -K., Bivik Edi ng, C., Rundquis t, I., Enerb\u00e4ck, C., 2019. IL -17 and IL -22 Promote Keratinocyte Stemness \nin the Germinative Compartment in Psoriasis. J. Invest. Dermatol. 139, 1564 -1573.e8. \nhttps://doi.org/10.1016/j.jid.2019.01.014  \nEsquivel -Garc\u00eda, R., Ayiania, M., Abu -Lail, N., L\u00f3pez -Meza, J.E., del R\u00edo, R.E., Garc\u00eda -P\u00e9rez, M., Ochoa -Zarzosa, \nA., Garc\u00eda -P\u00e9rez, M. -E., 2020. Pyrolytic oils from Amphipterygium adstringens  bark inhibit IL -8 \nproduction of IL -17-stimulated HaCaT keratinocytes. J. Anal. Appl. Pyrol. 145, 104749.  \nhttps://doi.org /10.1016/j.jaap.2019.104749  \nEsquivel -Garc\u00eda, R., P\u00e9rez -Calix, E., Ochoa -Zarzosa, A., Garc\u00eda -P\u00e9rez, M. -E., 2018. Ethnomedicinal plants used \nfor the treatment of dermatological affections on the Pur\u00e9pecha Plateau, Michoac\u00e1n, Mexico. Acta Bot \nMex 125, 95 \u2013132. https://doi.org/10.21829/abm125.2018.1339  \nEzhilan, B.P., Neelamegam, R., 2012. GC -MS analysis of phytocomponents in the ethanol extract of Polygonum \nchinense  L. Pharmacognosy Res 4, 11 \u201314. https://doi.org/10.4103/0974 -8490.91028  \nFu, D., Fa rag, S., Chaouki , J., Jessop, P.G., 2014. Extraction of phenols from lignin microwave -pyrolysis oil using \na switchable hydrophilicity solvent. Bioresour. Technol. 154, 101 \u2013108. \nhttps://doi.org/10.1016/j.biortech.2013.11.091  \nFu, Y., Ma, J., Shi, X., Song, X .-Y., Yang, Y., Xiao, S., Li, J., Gu, W. -J., Huang, Z., Zhang, J., Chen, J., 2017. A \nnovel pyrazole -containing indolizine derivative suppresses NF -\u03baB activation and protects against TNBS -\ninduced colitis via a PPAR -\u03b3-dependent pathway. Biochem. Pharmacol. 1 35, 126 \u2013138. \nhttps://doi.org/10.1016/j.bcp.2017.03.013  \nGami, A.A., 2014. Phenol and its toxicity. Journal of Environmental Microbiology and Toxicol ogy 2.  \nGarc\u00eda -P\u00e9rez, M. -E., Alfonso -Castillo, A., Fong Lores, O., Batista -Duharte, A., Lemus -Rodr\u00edguez, Z., 2 018. \nToxicological evaluation of an aqueous suspension from leaves and stems of Petiveria alliacea  L. \n(Phytolaccaceae). J. Ethnopharmacol. 211, 29 \u201337. https://doi.org/10.1016/j.jep.2017.09.022  \nGarc\u00eda -P\u00e9rez, M. -E., Royer, M., Duque -Fernandez, A., Diouf, P.N ., Stevanovic, T., Pouliot, R., 2010. Antioxidant, \ntoxicological and antiproliferative properties of Canadian polyphenolic extracts on normal and p soriatic \nkeratinocytes. J. Ethnopharmacol. 132, 251 \u2013258. https://doi.org/10.1016/j.jep.2010.08.030  \nGarmendia,  A., Raig\u00f3n, M.D., Marques, O., Ferriol, M., Royo, J., Merle, H., 2018. Effects of nettle slurry ( Urtica \ndioica  L.) used as foliar fertilizer on po tato ( Solanum tuberosum  L.) yield and plant growth. PeerJ 6, \ne4729. https://doi.org/10.7717/peerj.4729  \nGhosh,  S.K., Chowdhury, R.R., 2013. Synthetic adjuvants for vaccine formulations: phytol derivatives. Expert \nOpin. Drug Deliv. 10, 437 \u2013450. https://doi.o rg/10.1517/17425247.2013.757591  \nGorzalczany, S., Marrassini, C., Mi\u00f1o, J., Acevedo, C., Ferraro, G., 2011. An tinociceptive activity of ethanolic \nextract and isolated compounds of Urtica circularis . J. Ethnopharmacol. 134, 733 \u2013738. \nhttps://doi.org/10.1016/j .jep.2011.01.025  \nHan, Y., Stankovikj, F., Garcia -Perez, M., 2017. Co-hydrotreatment of tire pyrolysis oil and  vegetable oil for the \nproduction of transportation fuels. Fuel Process Technol. 159, 328 \u2013339. \nhttps://doi.org/10.1016/j.fuproc.2017.01.048  \nHlavsov \u00e1, A., Corsaro, A., Raclavsk\u00e1, H., Vallov\u00e1, S., Juchelkov\u00e1, D., 2016. The effect of feedstock composition \nand taxonomy on the products distribution from pyrolysis of nine herbaceous plants. Fuel Process \nTechnol. 144, 27 \u201336. https://doi.org/10.1016/j.fuproc .2015.11.022   \n106 Hundie, G.B., Woldemeskel, D., Gessesse, A., 2016. Evaluation of direct colorimetric MTT assay f or rapid \ndetection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis . PLoS ONE 11, e0169188. \nhttps://doi.org/10.1371/journal.pon e.0169188  \nIbrahim, M., Rehman, K., Razzaq, A., Hussain, I., Farooq, T., Hussain, A., Akash, M.S.H., 2018. Investigations of \nphytochemical constituents and their pharmacological properties isolated from the genus Urtica : critical \nreview and analysis. Crit. Rev. Eukar yot. Gene Expr. 28, 25 \u201366. \nhttps://doi.org/10.1615/CritRevEukaryotGeneExpr.2018020389  \nJ\u00edrov\u00e1, D., Basketter, D., Liebsch, M., Bendov\u00e1, H., Kejlov\u00e1, K., Marriott, M., Kand\u00e1rov\u00e1, H., 2010. Comparison \nof human skin irritation patch test data with in  vitro ski n irritation assays and animal data. Contact \nDermatitis 62, 109 \u2013116. https://doi.org/10.1111/j.1600 -0536.2009.01640.x  \nKagoura, M., Matsui, C., Morohashi, M., 1999. Phytol is a novel tumor promoter on ICR mouse skin. Jpn. J. Cancer \nRes. 90, 377 \u2013384. https:/ /doi.org/10.1111/j.1349 -7006.1999.tb00758.x  \nKebelmann, K., Hornung, A., Karsten, U., Griffiths, G., 2013. Intermediate pyrolysis and product identification by \nTGA and Py -GC/MS of green microalgae and their extracted protein and lipid components. Biomass \nBioenergy 49, 38 \u201348. https://doi.org/10.1016/j.biombioe.2012.12.006  \nKopyt\u2019ko, Ya.F., Lapinskaya, E.S., Sokol\u2019skaya, T.A., 2012. Application, chemical composition, and \nstandardization of nettle raw material and related drugs (review). Pharm. Chem. J . 45, 622\u2013631. \nhttps://doi.org/10.1007/s11094 -012-0690 -7 \nKumar, S., Pandey, A.K., 2013. Chemistry and biological activities of flavonoids: an overview. Sci. World J. 2013, \ne162750. https://doi.org/10.1155/2013/162750  \nLapinskaya, E.S., Kopyt\u2019ko, Ya.F., 2008 . Comp osition of the lipophilic fraction of stinging nettle ( Urtica dioica  \nL. and U. urens  L.) homeopathic matrix tinctures. Pharm. Chem. J. 42, 699 \u2013702. \nhttps://doi.org/10.1007/s11094 -009-0204 -4 \nLe, Q.V., Howard, A., 2013. Dexamethasone iontophoresis for the tr eatment of nail psoriasis. Australas. J. \nDermatol. 54, 115 \u2013119. https://doi.org/10.1111/ajd.12029  \nLv, J., Zhou, D., Wang, Y., Zhao, J., Chen, Z., Zhang, J., Di, T., Hu, J., Li, B., Li, P., Huang, F., 2018. Quantitative \nevaluation to efficacy and safe ty of therapies for psoriasis: a network meta -analysis. Mol. Pain 14, \n1744806918762205. https://doi.org/10.1177/1744806918762205  \nMarcilla, A., G\u00f3mez -Siurana, A., Gomis, C., Ch\u00e1puli, E., Catal\u00e1, M.C., Vald\u00e9s, F.J., 2009. Characterization of \nmicroalgal speci es thr ough TGA/FTIR analysis: application to Nannochloropsis sp.  Thermochim. Acta \n484, 41 \u201347. https://doi.org/10.1016/j.tca.2008.12.005  \nMohan, D., Pittman, Charles U., Steele, P.H., 2006. Pyrolysis of wood/biomass for bio -oil:\u2009 a critical review. \nEnergy Fu els 20 , 848 \u2013889. https://doi.org/10.1021/ef0502397  \nMoos, S., Mohebiany, A.N., Waisman, A., Kurschus, F.C., 2019. Imiquimod -induced psori asis in mice depends on \nthe IL -17 signaling of keratinocytes. J. Invest. Dermatol. 139, 1110 \u20131117. \nhttps://doi.org/10.1016/j.j id.2019.01.006  \nMourant, D., Lievens, C., Gunawan, R., Wang, Y., Hu, X., Wu, L., Syed -Hassan, S.S.A., Li, C. -Z., 2013. Effects \nof temperature on the yields and properties of bio -oil from the fast pyrolysis of mallee bark. Fuel 108, \n400\u2013408. https://doi.org/ 10.1016/j.fuel.2012.12.018  \nMurray, A.R., Kisin, E., Castranova, V., Kommineni, C., Gunther, M.R., Shvedova, A.A., 2007. Phenol -induced \nin vivo  oxidative stress in skin: evidence for enhanced free radical generation, thiol oxidation, and \nantioxidant depleti on. Chem. Res. Toxicol. 20, 1769 \u20131777. https://doi.org/10.1021/tx700201z  \nNada, A., Al -Moghazy, M., Soliman, A.A.F., Rashwan, G.M.T ., Eldawy, T.H.A., Hassan, A.A.E., Sayed, G.H., \n2018. Pyrazole -based compounds in chitosan liposomal emulsion for antimicrobia l cotton fabrics. Int. J. \nBiol. Macromol. 107, 585 \u2013594. https://doi.org/10.1016/j.ijbiomac.2017.09.031  \nNewby, C.S., Barr, R.M., Gr eaves, M.W., Mallet, A.I., 2000. Cytokine release and cytotoxicity in human \nkeratinocytes and fibroblasts induced by phenols a nd sodium dodecyl sulfate. J. Invest. Dermatol. 115, \n292\u2013298. https://doi.org/10.1046/j.1523 -1747.2000.00056.x  \nNunes Oliveira, R.,  Cordeiro Mancini, M., Cabral Salles de Oliveira, F., Passos, T., Quilty, B., da Silva Moreira \nThir\u00e9, R.M., McGuinness, G.B., 2016. FTIR analysis and quantification of phenols and flavonoids of five \ncommercially available plants extracts used in wound heal ing. Mat\u00e9ria (Rio J.) 21, 767 \u2013779. \nhttps://doi.org/10.1590/S1517 -707620160003.0072  \nRosnitschek -Schimmel, I., 1985a. Seasonal d ynamics of nitrogenous compounds in a nitrophilic weed I. Changes \nin inorganic and organic nitrogen fractions of the different pla nt parts of Urtica dioica . Plant Cell Physiol. \n26, 169 \u2013176. https://doi.org/10.1093/oxfordjournals.pcp.a076885   \n107 Rosnitschek -Schimmel, I., 1985b. Seasonal dynamics of nitrogenous compounds in a nitrophilic weed II. The role \nof free amino acids and proteins a s nitrogen store in Urtica dioica . Plant Cell Physiol. 26, 177 \u2013183. \nhttps://doi.org/10.1093/oxfordjournals.pcp.a076886  \nRoy Chowdhury, R., Fitch, R.W., Ghosh, S.K., 2013. Efficacy of phytol -derived diterpenoid immunoadjuvants \nover alum in shaping the murine  host\u2019s immune response to Staphylococcus aureus . Vaccine 31, 1178 \u2013\n1186. https://doi.org/10.1016/j.vaccine.2012.12.069  \nScherlie\u00df, R., 2011. The MTT assay as tool to evaluate and compare excipient toxicity in vitro  on respiratory \nepithelial cells. Int. J. P harm. 411, 98 \u2013105. https://doi.org/10.1016/j.ijpharm.2011.03.053  \nSeki, N., Shimano, K., Kondou, T., Murase, M., Mitamur a, M., Kataoka, H., Sugahara, K., Nakamura, H., Yamada, \nM., 2014. OP0105 Pyrazole -anilide derivatives, a new class of immunomodulator whi ch inhibits IL -17 \nproduction, ameliorate CIA and psoriasis -like dermatitis in mice. Ann. Rheum. Dis. 73, 100 \u2013101. \nhttps ://doi.org/10.1136/annrheumdis -2014 -eular.3054  \nStankovikj, F., Garcia -Perez, M., 2017. TG-FTIR method for the characterization of bio -oils in chemical families. \nEnergy Fuels 31, 1689 \u20131701. https://doi.org/10.1021/acs.energyfuels.6b03132  \nStankovikj, F., McD onald, A.G., Helms, G.L., Olarte, M.V., Garcia -Perez, M., 2017. Characterization of the water -\nsoluble fraction of woody biomass pyrolysis  oils. Energy Fuels 31, 1650 \u20131664. \nhttps://doi.org/htpps://doi.org/10.1021/acs.energyfuels.6b02950  \nStefanidis, S.D., Ka logiannis, K.G., Iliopoulou, E.F., Michailof, C.M., Pilavachi, P.A., Lappas, A.A., 2014. A study \nof lignocellulosic biomass pyrolysis via  the pyrolysis of cellulose, hemicellulose and lignin. J. Anal. Appl. \nPyrol. 105, 143 \u2013150. https://doi.org/10.1016/j.ja ap.2013.10.013  \nSteinmann, V.W., 2005. Urticaceae. Flora del Baj\u00edo y de Regiones Adyacentes 134, 1 \u201374. \nTeepe, R.G., Koebrugge, E.J., L\u00f6wik , C.W., Petit, P.L., Bosboom, R.W., Twiss, I.M., Boxma, H., Vermeer, B.J., \nPonec, M., 1993. Cytotoxic effects of topica l antimicrobial and antiseptic agents on human keratinocytes \nin vitro . J. Trauma 35, 8 \u201319. https://doi.org/10.1097/00005373 -199307000 -00002 \nThorpe, R., Pandya, A.G., 2014. Psoriasis, in: Jackson -Richards, D., Pandya, A.G. (Eds.), Dermatology Atlas for \nSkin of Color. Springer, Berlin, Heidelberg, pp. 131 \u2013138. https://doi.org/10.1007/978 -3-642-54446 -0_25  \nYau, A.C.Y., L\u00f6nnblom, E., Zhong, J., Holmdahl, R., 2017. Influence of hydrocarbon oil structure on adjuvanticity \nand autoimmunity. Sci. Rep. 7, 14998. https ://doi.org/10.1038/s41598 -017-15096 -z \nZablocki, J.A., Tarlton, E., Rizzi, J.P., Mantlo, N.B., 2003. Aryl and heteroaryl substituted fused  pyrrole anti -\ninflammatory agents. US6605634B2.  \nZeichner, J.A., 2010. Use of topical coal tar foam for the treatment of  psoriasis in difficult -to-treat areas. J. Clin. \nAesthet. Dermatol. 3, 37 \u201340. \nZiboh, V.A., Miller, C.C., Cho, Y., 2000. Metabolism of pol yunsaturated fatty acids by skin epidermal enzymes: \ngeneration of antiinflammatory and antiproliferative metabolites. A m J. Clin. Nutr. 71, 361s \u2013366s. \nhttps://doi.org/10.1093/ajcn/71.1.361s  \n  \n108  \n \n \n \n \n \n \n \n \n \nCAP\u00cdTULO 3. Los a ceites pirol\u00edticos de  la corteza de  \nAmphipterygium adstringens  inhiben la producci\u00f3n de IL -8 en \nqueratinocitos HaCaT estimulados con IL-17. \n \n \n \n \n \n \n \n \n \n \n \n  \n109 VI.5.  PREFACIO  \n \nEste cap\u00edtulo es el tema de un art\u00edculo titulado: \u201cPyrolytic oils from Amphipterygium \nadstringens  bark inhibit IL -8 production o f IL-17-stimulated HaCaT keratinocytes \u201d. El cual fue \npublicado en Journal of Analytical and Applied Pyrolysis , 145: 104749 . Su identificador de \nobjeto digital es: https://doi.org/10.1016/j.jaap.2019 .104749  \n \nEl presente cap\u00edtulo se dirige a dar respuesta a los objetivos particulares # 2 y 3. La especie, \nnativa de M\u00e9xico, Amphipterygium adstringens  fue es cogida como un \u00e1rbol prometedor, dado \nsu valor alto valor de uso por la etnomedicina Pur\u00e9pecha  (0.15), que se demostr\u00f3 durante el \nestudio etnofarmacol\u00f3gico . La especie fue sometida a una extracci\u00f3n con agua caliente, \nsiguiendo el uso tradicional reportado y poste riormente la biomasa residual fue sometida a un \nproceso de pir \u00f3lisis para obtener aceites p irol\u00edticos. Estos aceites fueron caracterizados \nqu\u00edmicamente , se hizo un an\u00e1lisis de  su toxicidad en un cultivo de queratinocitos  HaCaT, y \nfinalmente se prob\u00f3 su cap acidad para inhibir la producci\u00f3n de IL -8 en queratinocitos \nestimulados con  IL-17. \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \n110  \nVI.6.  ART\u00cdCULO  \n \n \n \n \n \n \n \nVI.6.1.  Abstract  \n \n \n \n \nVI.6.2.  Introduction  \n \n \n \n \n \n \n \n \n \n \n111  \n \n \n \n \n \n \n \n \nSchematic representation  of mayor tasks described in this paper.  \n \n \n \n \n \nVI.6.3.  Material and methods  \n \nVI.6.3.1.  Materials  \n \nVI.6.3.2.  Pyrolysis experiments  \n \nVI.6.3.3.  Chemical characterization of residual biomass and pyrolytic f ractions  \n \n \n \n112  \n \n \n \nSystem used for pyrolytic collection of oil -1 and oil -2. \n \nPyrolytic products yield of residual biomass from  A. adstringens . \n \n \n \n \n \n \nProximate and elemental analyses of A. adstringens  samples.  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nTGA (A) and DTG (B) curv es for the residual biomass and pyrolytic products from A. adstringens bark.  \n \n \n \n113  \n \n \n \n \n \n \n \n \nFTIR spectra of residual biomass and pyrolytic fractions from A. adstringens  bark. \n \nVI.6.3.4.  Toxicity of pyrolytic oils on HaCaT cells and effects on IL -17-induced IL -8 \nproduct ion. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nPy-GC-MS analysis chromatogram of residual biomass from A. adstringens . \nLlist of the numbered compounds is shown in . \n \n \n \n114 Py-GC-MS characterization of the main compounds found in the residual b iomass from A. adstringens . \n \n \n \n \n \nVI.6.4.  Results and Discussion  \nVI.6.4.1.  Recovered pyrolytic fractions  \n \n \n \nVI.6.4.2.  Chemical characterization of the pyrolytic fractions and the residual \nbiomass  \n \n \n \n \n \n \n \n \n \n115  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nGC-MS analysis chromatograms of pyrolytic oils from A. ad stringens . \nList of the numbered compounds is shown in \u00a1Error! No se encuentra el origen de la referencia. . \n \n \n \n \n \n \n \n \n \n \n \n \n116  \nGC-MS characterization of the main compounds found in the pyrolytic oils from A. adstringens . \nGroups: (Alcohol (A); Furans (F); Ketone (K); Phenol (P), Aromatic (*); Amine (AM); Sugar (S); Ester (E); Acid \n(AC); Polycyclic aromatic compound (PAC).  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nUV-fluorescence spectra of the oil samples from A. adstringens.  \n \n \n \n \n \n \n \n \n117  \n \n \n \n \n \n \n \nHPLC -DAD profiles of liquid pyrolysis samples from A. adstringens . \nDotted lines represent the standards used and the list of numbered compounds is shown in \u00a1Error! No se encuentra \nel orige n de la referencia. . \n \nHPLC -DAD quali -quantitative an alysis of phenolic compounds in A. adstringens  oils. \n \n \n \n \n \nEffect of pyrolytic oils on the IL -17-induced production of IL -8 on HaCaT keratinocytes.  \n \n \nVI.6.4.3.  Toxicity of oils on HaCaT cells and effects on IL -17-induced IL -8 production  \n \n \n \n \n \n118  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nVI.6.5.  Conclusi ons \nVI.6.6.  Credit authorship contribution statement  \nVI.6.7.  Declaration of Competing Interest  \nVI.6.8.  Acknowledgements  \nVI.6.9.  References  \n \n \n \n \n119 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n   \n120  \n \n \n \n \n \n \n \n \n CAP\u00cdTULO 4. Caracterizaci\u00f3n qu\u00edmica, toxicolog\u00eda y \nactividad antiinflamatoria del extracto acuoso de la corteza de  \nAmphipterygium adstringens  y sus fracciones en queratinocitos \nHaCaT.  \n \n \n \n \n \n \n \n \n \n \n \n  \n121 VI.7.  PREFACIO  \n \nEste cap\u00edtulo es el tema de l art\u00edculo titulado: \u201cChemical characterization, toxicology and anti -\ninflammatory activity of the Amphipterygium adstringens  aqueous bark  extract and its solvent \nfractions on HaCaT keratinocytes\u201d. El cual  se enviar\u00e1 pr\u00f3ximamente a  una revista cient\u00edfica.  \n \nEl presente cap\u00edtulo se dirige a dar respuesta a los objetivos particulares # 2  y 3. Como se explic\u00f3 \nen el cap\u00edtulo anterior, l a especie nativa de M\u00e9xico Amphipterygium adstringens  fue es cogida \ncomo un \u00e1rbol prometedor.  Las cortez as del \u00e1rbol  fueron sometidas a una extracci\u00f3n con agua \ncaliente, siguiendo el uso tradicional reportado, y el extracto acuoso  fue fraccionado por \nextracci\u00f3n l\u00edqui do/l\u00edquido  para una caracterizaci\u00f3n m\u00e1s exhaustiva de su composici\u00f3n  qu\u00edmica . \nEl extracto y s us fracciones fueron qu\u00edmicamente caracterizad os, se determin\u00f3 su toxicidad en \nqueratinocitos HaCaT y se evalu\u00f3 su capacidad para inhibir la producci\u00f3n de IL -8 en un modelo \nde inducci\u00f3n p or IL-17. Los resultados mostraron un  alto rendimiento de extracci\u00f3n,  potente \nefecto an ti-IL17 y una baja toxicidad del extracto crudo, por lo que fue considerado el candidato  \nm\u00e1s prometedor.  \n \n \nFig. 17. Grap hical abstract.  \n \n \n \n \n \n122 VI.8.  ART\u00cdCULO  \n \nChemical characterization, toxicology and anti -inflammatory \nactivity of the Amphipterygium adstringens  aqueous bark extract \nand its solvent fractions on HaCaT keratinocytes  \n \nRoberto Esquivel -Garc\u00eda 1,2, Jos\u00e9 Salom\u00f3n Mart\u00ednez -Fern\u00e1ndez 3, Nehal Abu -Lail 4, Manuel \nGarc\u00eda -P\u00e9rez 3, Alejandra Ochoa -Zarzosa 2, Martha -Estrella Garc\u00eda -P\u00e9rez 1 \n \nAffilations:  \n \n1 Instituto de Investigaciones Qu\u00edmico -Biol\u00f3gicas, Universidad Michoacana de San Nicol\u00e1s de \nHidalgo . Morelia,  Michoac\u00e1n,  Mexico.  2 Centro Multidisciplinario de Estudios en \nBiotecnolog\u00eda -FMVZ, Universidad Michoacana de San Nicol\u00e1s de Hidalgo. Tar\u00edmbaro, \nMich oac\u00e1n, Mexico. 3 Department of Biological Systems Engineering , Washington State \nUniversity, Pullman, WA, USA. 4 Department of Bio medical Engineering, University of Texas \nat San Antonio, TX, USA.  \n \nAddress for reprint requests:  \n \nMartha Estrella Garc\u00eda -P\u00e9rez, PhD  \naInstituto de Investigaciones Qu\u00edmico -Biol\u00f3gicas. Universidad Michoacana de San Nicol\u00e1s de \nHidalgo. Avenida  Universidad  S/N. Edificio  B3 Ciudad  Universitaria,  Morelia,  Michoac\u00e1n  \n58030,  Mexico.  Phone  number:  (+52)  443 142 9280  \nE-mail: marg ar@live.ca   \n123 VI.8.1.  Abstract  \n \nPrevious ethnophar macological research on the Pur\u00e9pecha Plateau, Michoac\u00e1n, Mexico \ndemonstrated that its indigenous pop ulation used topically the aqueous extract from \nAmphipterygium adstringens  bark to treat dermatological disorders. However, no exhaustive \ninvestigations exist about the chemical characterization of the aqueous extract from the bark of \nthis tree, its toxico logy and anti -inflammatory properties on skin cells.  In this work, this extract \nand its solvent fractions were chem ically characterized by a tandem of analytical techniques \n(proximate, elemental analysis, FTIR, GC -MS and UV -fluorescence). Its toxicity and potential \nanti-inflammatory activity on IL -8 production of IL -17-stimulated HaCaT keratinocytes was \nstudied by MTT and ELISA methods respectively.  Acids and aromatics were the predominant \ncompounds identified in all samples whereas the flamenol was the maj or molecule present in \nthe crude extract, the ethyl acetate, and the aqueous fractions. The crude extract and the a queous \nfraction were less toxic on keratinocytes and exhibited a significantly higher inhibitory activity \non IL -8 production than dexamethaso ne (p<0.01), a drug used for treating inflammatory skin \nconditions such as psoriasis. These results support the tra ditional topical use of A. adstringens  \nbark\u2019 decoctions by Pur\u00e9pechas for treating dermatological inflammatory diseases and open the \ndoor for  a more exhaustive study of its anti -IL17 mechanism.  \nKeywords: Amphipterygium adstringens , Anacardiaceae, aqueous e xtract, IL -17, psoriasis.  \n \n \n \n \n \n \n  \n124 VI.8.2.  Introduction  \nAmphipterygium adstringens  (Schltdl.) Standl. is an endemic tree from Mexico commonly \nknown as \u201ccuachalate\u201d and belongs to the Anacardiaceae family [1]. This medicinal plant is \nwidely prescribed by Mexican traditional healers since, in the pre -Hispanic period, its bark was \nused to treat gastrointestinal disorders, skin affections, and respiratory pr oblems [2].  \nOur recently conducted ethnophar macological survey at the Pur\u00e9pecha Plateau, Michoac\u00e1n, \nMexico demonstrated its ancestral population, locally recognized by its inherited know ledge on \nmedicinal plants, has used the aqueous extract from the bark of this specie orally and topically \nto treat dermatological disorders [3]. This pharmacological potential warrant further chemical \ncharacterization, toxicology and anti -inflammatory evaluation on skin cells.  \nAlthough previous studies report the medi cinal  properties of bark extracts from this tree, most \nof them use organic solvent extraction methodologies with ethanol, hexane or methanol [4 \u20139]. \nThese extraction protocols do not reflect the traditional decoction usage form of this plant by \nthe Mexican popul ation [3,10]. The anti -inflammatory effect of the aqueous extract has been \nreported in two models of acute inflammation: the 12 -O- tetradecanoylphorbol -13-acetate \n(TPA) -induced ear edema and the carrageenan -induced paw edema (CIPE) [11]. The CIPE \nrepresent s a biphasic inflammation reaction where multiple mediators participate, whereas the \nTPA -induced ear edema can be used to study the skin inflammation. The aqueous extract was \ninactive to inhibit the cutaneous inflammation in TPA -model [11] which is co ntrad ictory with \nthe extensive use of the decoctions from the A. adstringens  bark by the Mexican population to \ntreat dermatological conditions. The lack of data about the effects of the extracts from this specie \non the skin prompted us to evaluate the anti -inflammatory potential of the aqueous extract on \nHaCaT keratinocytes.  \nPsoriasis is a common inflammatory skin disease that affects 2.9 % of the Mexican population \n[12]. In a psoriasis context, an intricate interaction occurs between hyperproliferative \nkeratino cytes and the innate and adaptive immune cells [13]. Although the exact cause of this \ncondition is not yet known, the significant role of pro -inflammatory cytokines such as \ninterleukin (IL) -17 is now recognized and psoriasis is currently considered to  be an IL-17 driven \ndisease [14]. When IL -17 binds to its receptor on the keratinocyte surface (IL -17RA), it can \ninduce an accelerated division of these cells, their aberrant differentiation [15], and the release  \n125 of other pro -inflammatory mediators such as  the neutrophil -attracting chemokine IL -8 which \ncontributes to the exacerbation of the cutaneous inflammation [15].  \nBiological agents that neutralize IL -17 (secukinumab and ixekizumab) or antagonize its receptor \n(brodalumab) have been demonstrated to be h ighly  efficacious in clinical studies for psoriasis \n[16]. However, some adverse events have been described with these drugs [17,18], which has \nlead patients to search for complementary and alternative  therapies [19]. Nowadays, the \npharmaceutical industry c ontin ues the pursuit of new therapeutic antipsoriatic candidates \neffective and safe for patients [20].  \nSome phytochemical studies performed with A. adstringens  bark have shown that the \ndichloromethane fraction contains gastroprotective triterpenoids such a s 3\u03b1 -\nhydroxymasticadienonic acid and \u03b2 -sitosterol and 3 -epi-oleanolic acid [ 6]. Masticadienonic, \u03b1 -\nhydroxymasticadienonic and masticadienonic/isomasticadienonic acid mixtures were also \nidentified in the hexanoic bark extract from these species [21]. The pr esence of masticadienonic \nacid and 3 -hydroxymasticadienonic acid has also been reported in the methanolic bark extract \nfrom this tree [22]; whereas anacardic acids, recognized by their anti -inflammatory properties \nhave been identified in the ether fraction  [23]. \nUp to date, most of the phytochemical investigations to characterize the bioactive compounds \npresent in A. adstringens  bark have been made in the nonpolar extracts and little is known about \nthe identity of the major compounds present in the aqueous extract. This constitutes an important \nlimitation since Mexican traditional medicine mostly employs aqueous preparations from this \nplant [3,10] . \nRegarding the toxicology studies, the methanol -chloroform extract (1:1) from A. adstringens  \nbark showed no toxi c effect against Artemia salina  (LC 50>1000 \u03bcg/mL) or against a mice model \n(LD 50>5000 mg/kg) [24]. The toxicity of the aqueous extract from this plant on the skin or \ncutaneous -related cells is unknown.  \nTaking into account the traditiona l dermatological use of A. adstringens  by Pur\u00e9pechas and the \nMexican population and the fact that little is known about t he phytochemistry, toxicology and \nanti-inflammatory character of the aqueous extract on the skin cells, this study aimed to the \nchemica l characterization of the A. adstringens  aqueous bark ext ract and its solvent fractions \nand to analyze their toxicology on HaCaT keratinocytes. Moreover, their capacity to inhibit the  \n126 IL-8 production on IL -17-stimulated HaCaT keratinocytes was also studied  to propose future \napplications for treating inflammatory  skin conditions such as psoriasis.  \n \nVI.8.3.  Material and methods  \nThe experiment procedure of the present work is divided into four major steps. In the first step, \nA. adstringens  bark was subject to a hot wa ter extraction and afterward fractionated with hexane, \nethyl acetate and water to obtain the phases A, B, and C respectively. In the second step, the CE \nand the fractions were chemically characterized by a tandem of analytical techniques to have an \novervie w of the molecules present in each sample. As the DBP is the starting material, and its \ncomposition can affect the chemical composition of the extract and its fractions, it was also \ncharacterized in this step. The third step consisted of the analysis of th e toxicology of the CE \nand its fractions on HaCaT keratin ocytes. Finally, the anti -inflammatory character of the CE \nand the solvent fractions on the IL -8 production on HaCaT keratinocytes stimulated with IL -17 \nwas determined and compared to that of dexamet hasone. Each of these major parts will be more \nexhaustive ly explained in the sections that follow.  \n \nVI.8.3.1.  Botanical identification and solvent extraction  \nBotanical identification: The bark from A. adstringens  was collected from Michoac\u00e1n state, \nMexico. Bark samp les were taken in a single strip approximately 50 cm long  by 8 cm wide and \nless than 3 cm thick from 20 trees that had not been previously barked with an age between 20 \u2013\n25 years (20\u221225 cm diameter) avoiding affecting its viability. Botanical characterizati on was \nperformed by Dr. Emmanuel P\u00e9rez -Calix and a sample  deposited in the IEB herbarium located \nin P\u00e1tzcuaro, Michoac\u00e1n, Mexico (voucher number: 256881) (collection date 07/01/2017). \nBefore extraction, the bark was washed and oven -dried (40\u00b12 \u00b0C) by 48 h,  then it was grounded \nat a particle size of \u2264 800 \u03bcm.  \nSolvent extraction: Considering that the decoction was reported to be used to treat \ndermatological conditions by Pur\u00e9pechas [3], in this work the DBP (40 g) was subjected to hot \nwater extraction (400 mL ) for 1 h to simulate this traditional use. The CE was th en concentrated \nunder vacuum (60 \u00b0C, 29 kPa) and solvent fractionated. Thirty grams of CE were resuspended  \n127 in 300 mL water, decanted through a 100 -mL Gooch crucible (Pyrex\u00ae, 40 \u201360 \u00b5m, coarse \nporosity ) and the filtrate collected in a 500 mL Erlenmeyer flask . In a separation funnel, the \naqueous solution was first extracted with hexane (3 \u00d7 100 mL, phase A) and ethyl acetate (3 \u00d7 \n100 mL, phase B) whereas the remained aqueous solution was called phase C. The three phases \nwere evaporated under vacuum to remove h exane (40 \u00b0C, 23 kPa), ethyl acetate (60 \u00b0C, 21 kPa) \nand water (60 \u00b0C, 29 kPa). The CE and fractions were kept under refrigeration (4 \u00b0C) until \nfurther analyses.  \n \nVI.8.3.2.  Chemical analysis of the starting ma terial, the CE and its fractions  \nPy-GC-MS of the starting  material: The Py-GC-MS analysis was conducted on the DBP using \nan Agilent Technologies 6890N Gas Chromatograph linked to Agilent 5975B Mass Selective \nDetector (column: 30 m\u00d7250 \u00b5m\u00d70.25 \u00b5m) with NIST  2.0 f Mass Spectral Search Program. \nThe DBP sample (\u22480.5  mg) was introduced in the probe interface using a CDS Analytical \nPyroprobe 5000 Series and the analytical method used was described by Ayania et al. [43]. The \ncompounds were identified by combining the data from the Mass Spectral Library and literature \ndata, and these were classified into the different chemical groups as previously described [30].  \nProximate and elemental analyses: Fixed carbon, volatiles, and the ash content of DBP, CE and \nphases A -C were determined with a Mettler Toledo thermogravimetric analyzer (SDTA851e) \nequipped with STARe data analysis software for obtaining TGA/derivative of \nthermogravimetric curve (DTG) data curves. The carbon, hydrogen, nitrogen and sulfur contents \nof the afo rementioned samples were determined using a Leco TruSpec Micro elemental \nanalyzer. The oxygen content was obtained by difference after considering the ash content on a \ndry basis. Both analyses were performed according to the methods previously described [3 0]. \nFTIR analysis: FTIR spectra of DBP, CE, and phases A -C were obtained using a Shimadzu \nIRPrestige 21 spectrometer. For the analysis of functional groups, a background correction was \ndone on each spectrum [30].  \nGC\u2013MS: The CE and phases A -C were analyzed by GC \u2013MS using an Agilent Technologies \n7890 A GC set up ( Agilent 19091S -433 HP -5MS column: 325 \u00b0C: 30 m\u00d7250 \u00b5m\u00d70.25 \u00b5m,  \n128 Agilent 5975 C MS with NIST 2.0 f Mass Spectral Search Program) using a method previously \ndescribed [29].  \nUV-fluorescence: The analysis was based on the methodology described by Garc\u00eda -P\u00e9rez an d \ncollaborators [29]. CE and phases A -C were diluted in HPLC grade methanol at 10 ppm and \nanalyzed on Shimadzu RF 5301 pc spectrometer with the software Panorama F luorescence 2.1.  \n \nVI.8.3.3.  Toxicological evaluation of the CE and its fractions on HaCaT cells  \nCE and phases A -C were evaluated on HaCaT keratinocytes by the MTT method (R&D \nSystems) through the determination of the initial toxicity value (IC 90) [38]. The IC 90 represents \nthe minimal toxic dose of extract causing 10% reduction of cell viability compared wit h \nuntreated cells. MTT test is a measure of toxicity on the mitochondria.  \nCell culture and MTT assay: Human HaCaT keratinocyte cell line was purchased from \nAddexB io. HaCaT cells were cultured in DMEM high glucose with sodium pyruvate (Sigma \nAldrich) and s upplemented with 100 U/mL penicillin (Sigma Aldrich), 100 \u00b5g/mL streptomycin \n(Sigma Aldrich), and 10% fetal bovine serum (Thermo Fisher Scientific) in a humidified  \nincubator containing 5% CO 2 at 37 \u00baC. Only cells at 80% confluence were used in experiments \nas previously described. MTT assay was performed as previously described [30]. CE and phases \nA-C from A. adstringens  (25-1600 \u00b5g/mL) diluted in DMEM medium with 0.2% ethanol was \nadded to HaCa T cells and incubated for 24 h. The cells were washed with PBS an d a solution \nof MTT (1 mg/ml in PBS) was added to each well with fresh medium and incubated for 4 h at \n37 \u00baC. Formazan crystals were dissolved with 0.2 mL of acidic isopropanol and absorbance  was \nread at 570 nm with an Accuris SmartReader 96. The IC 90 values were estimated from the dose -\nresponse curve, using a non -linear regression algorithm.  \n \nVI.8.3.4.  Anti -inflammatory activity on HaCaT cells  \nHaCaT cells were seeded into 24 -well plates until 80% of co nfluence and subsequently \nsynchronized by serum deprivation durin g 12 h. After this time, the cells were pre -treated or not \nfor 10 h with dex (5 \u00b5M, Sigma Aldrich), CE and phases A -C from A. adstringens  bark at  \n129 concentrations lower than IC 90 values. Later,  IL-17 (50 ng/mL, Thermo Fisher Scientific) was \nadded to cell cul tures for 14 h to induce IL -8 production. IL -8 amounts in Il -17 HaCaT \nsupernatants were measured using Human IL -8/CXCL8 DuoSet ELISA kit (R&D Systems) \naccording to the manufacturer\u2019s protocol . The detection limit for IL -8 production was 30 pg/mL.  \n \nVI.8.4.  Results and Discussion  \nThis study presents novel results regarding the chemical characterization, the toxicological and \nanti-inflammatory analyses of the aqueous extract from the A. adstringens bark and its solvent \nfractions  on HaCaT keratinocytes.  \nThe yield of c rude extract (CE) was 28.6\u00b12.1% (w/w respect to the dry bark powder (DBP)). \nThis recovery was higher than that previously reported (14.4%) [11]. As to the liquid -liquid \nfractionation, the pha se C (aqueous fraction) exhibited a higher recovery (10.2\u00b11.9%) t han the \nphase A (hexanoic fraction, 5.3\u00b10.1%) followed by the phase B (ethyl acetate fraction, \n4.9\u00b10.1%). In a previous study in which the methanolic extract from A. adstringens  bark was \nfractionated with hexane, ethyl acetate and water, higher yields were  also observed in the \naqueous phase [6], probably due to the presence of polar molecules with high molecular weight \nsuch as tannins.  \nConsidering that the A. adstringens  bark was the starting material and that biomass composition \nmay change according to the  collection site with the consequent variation of the chemical \ncomposition of the extract and its fractions, a characterization of the DBP by pyrolysis \u2013gas \nchromatography mass spectrometry (p y-GC/MS) was firstly performed. Fig. 18 shows the \npyrogram whereas the list of major identified peaks is presented in Table 9.  \n130  \nFig. 18. Py-GC/MS analysis chromatogram of dry bark powder from A. adstringens.  \nList of  the numbered compounds is shown in Table 9. \n \nTable 9. Py-GC/MS characterization of dry bark from A. adstringens . \nNo. Identified compounds  RT (min)  Groups  \n1 Carbon dioxide  2.10 O \n2 Nitrous o xide 2.12 O \n3 n-Hexylmethylamine  2.24 AM \n4 Butanal  3.11 AD \n5 Toluene  4.12 * \n6 Benzaldehyde  8.06 AD*  \n7 Phenol  8.65 P* \n8 Cyclotetrasiloxane, octamethyl - 8.84 O \n9 Phenol, 2 -methyl - 10.38  P* \n10 Phenol, 4 -methyl - 10.90  P* \n11 Phenol, 2,4 -dimethyl - 12.64  P* \n12 Naphthalene, 2,6 -bis(1,1 -dimethylethyl) - 15.28  * \n13 Phenol, 2,6 -dimethoxy - 16.97  P* \n14 1,6-Anhydro -\u03b2-D-glucopyranose  20.07  S \n15 Ethyl -\u03b1-d-glucopyranoside  20.08  S \n16 Unknown  24.42  - \n17 n-Hexadecanoic acid  28.56  AC \nGroups: Phenol (P), Aromatic (*); Amine (AM); Sugar (S); Acid (AC); Aldehyde (AD); Others (O)  \n \nAromatic compounds related to lignin degradation reached 43% from the total identified \ncompounds with 71% of them being phenols. In contrast, sugars derived from \ncellulose/hemicellulose degr adation represented only 12.5% from the total compounds. This \n \n131 correlates with previous studies that highlighted the importance of lignin content in barks [25]. \nIndeed, the predominant peaks (7 and 10) were phenols.  \nThe pyrogram also showed the presence of  the fatty acid, hexadecanoic acid, in the A. \nadstringens  bark. The anti -inflammatory activity of an ethanolic extract from A. adstringens \nbark has been related to the content of fatty acids [5]. The ethyl -\u03b1-d-glucopyranoside , here \nidentified has been prev iously reported in rice wine and showed photop rotective activity in rat \nskin exposed to UVB -radiation [26] . Similarly, when it was  isolated from Stichopus japonicus  \nSel., it inhibited the activity of tyrosinase, an enzyme that participates in cutaneous \nhyperpigmentation [27] . \nTable 10 presents the proximate and elemental analysis of the A. adstringens  bark, CE, and \nfractions. The volatiles' content of this bark was similar to those reported for pine (68.21%) and \neucalyptus (68.73) barks, whereas the fixed carbon content was comparable to that of pine park \n(25.27%) [28]. In contrast, A. adstringens  bark had a higher ash content than those of the pine \nand eucalyptus bark (1.52 and 4.22%, respectively). In terms of the e lemental analysis, the \ncontent of oxygen was greater in A. adstringens  bark than in the aforementioned barks, which \ncould be related to the presence of oxygenated compounds such as phenols previously described \nin this species [10] . In the A. adstringens  bark, the sulfur content was not detectable while in the \npine and eucalyptus barks a minimal presence of it (0.03 and 0.04, respectivel y) has been \nreported [28]. However, as shown in Table 10 when fractionating the CE with hexane, et hyl \nacetate and water, the sulfur concentration increased compared to t he starting extract and the \nbark. This noted surge in sulfur content after fractionation is in agreement with results \npreviously described for other species such as Petiveria alliacea  L. [29].  \nThermogravimetric analysis (TGA) of the dry bark, the crude aqu eous extract and its fractions \nare presented in Fig. 19. TGA curve represents the weight loss depending on the volatility and \nthermal stability of the c hemical compounds present in the samples [30]. The greater weight \nloss from the DBP could be related to a higher concentration of volatiles as compared with the \nCE and the fractions ( Fig. 19-A). All these sa mples showed a faster change in the range of 200 \nto 300 \u00baC ( Fig. 19-B), which can be related to the presence compounds such as monophenols, \nmonosugars and furans [31], some of them identified in the GC -MS analysis.  \n  \n132 Table 10. Proximate and elemental analysis of  A. adstringens bark,  crude extract and fractions.  \nParameter  Sample  \nDry bark \npowder  Crude \nextract  Phase A  Phase B  Phase C  \nProximate analysis (wt. %)  \nMoisturea 6.7\u00b10.1  3.9\u00b10.5  6.1\u00b10.2  5.5\u00b10.1  6.4\u00b10.3  \nVolatilesb 69.4\u00b10.9  54.5\u00b10.4  56.9\u00b10.4  55.2\u00b10.8  53.3\u00b10.8  \nFixed carbonb 22.1\u00b10.1  36.5\u00b11.0  31.4\u00b13.4  35.5\u00b10.0  33.7\u00b10.5  \nAshb 8.5\u00b11.0  9.0\u00b11.4  11.7\u00b13.0  9.3\u00b10.9  13.0\u00b10.3  \nElemental analysis (wt. %)  \nCb 45.2\u00b10.03  18.6\u00b10.21  42.6\u00b10.08  45.1\u00b10.11  43.3\u00b10.74  \nHb 5.1\u00b10.01  8.4\u00b10.05  4.7\u00b10.00  4.2\u00b10.03  3.9\u00b10.14  \nNb 0.6\u00b10.01  0.1\u00b10.02  0.2\u00b10.00  0.2\u00b10.00  0.2\u00b10.01  \nSb 0.00\u00b10.00  0.01\u00b10.00  0.32\u00b10.02  0.26\u00b10.00  0.24\u00b10.02  \nOc 40.55\u00b11.0  63.85\u00b11.5  40.47\u00b12.8  40.94\u00b11.0  39.28\u00b11.17  \naAs-received basis. bDry basis. cBy diffe rence. Carbon (C), Hydrogen (H), Nitrogen (N), Sulfur (S), Oxygen (O). \nData represent mean \u00b1 SD of two experiments.  \n \n \nFig. 19. TGA (A) and DTG (B) curves for the dry bark, crude aqueous extract and its fractions from A. \nadstringens . \nDBP (dry bark powder), CE (crude aqueous extract), phase A (hexane), phase B (ethyl acetate), and phase C \n(aqueous fraction).  \n \nThe FTIR analysis provi des information on certain functional groups of chemical families in the \nstudied natural samples [31]. Fig. 20 (supporting information) shows the infrared spectrum of \nthe DBP, CE and phases A -C. O -H and N -H bonds generated stretching vibrations between \n3600 -3100 cm-1 which correspond to water, alcohols or some amines [ 31]. Aliphatic and \naromatic compounds presente d stretching signals for the C -H bond in the range of 3000 to 2800 \n \n133 cm-1. These peaks were more intense in phase B, which agrees with the GC -MS analysis that \nshowed a higher proportion of aromatic compounds in t his phase (44.4% of the identified \ncompounds f rom phase B). The C=O signal characteristic for aldehydes, ketones, carboxylic \nacids and esters was less visible in the CE and phases A and B between 1780 -1680 cm-1 \nregarding DBP and phase C. In all samples, th e stretch signal for C=C at 1680 -1530 cm-1 was \nintense and was associated with conjugated aromatic systems. The C -O bond had the most \nintense signals in the spectra between 1520 -1250 cm-1 associated with another signal at 1050 \ncm-1 which could indicate the  presence of oxygenated compounds such as terp enes, acetates or \nanhydrides [31]. Overall, the FTIR spectrum revealed an abundance of functional groups in the \nDBP, CE and fractions linked with the presence of bioactive aromatic or cyclical compounds \nsuch as  phenols or terpenes previously described for this species [5].  \n \n \nFig. 20. FTIR spectra of the dry bark, aqueous crude extract and fractions from A. adstringens . \n \n134 The CE and the A -C phases from A. adstringens  bark were analyzed by GC -MS. Fig. 21 shows \nthe chromatograms of each sample and Table 11 reports the name of the numbered compounds. \nAcids and aromatics were the predominant identified compounds in all samples. Within the \naromatics, phenols represented the most extracted compounds, mainly in CE and phase B (\u2248 \n62%). Flamenol, one of  the major compounds was concentrated in a greater proportion in phases \nB and C. This is the first report for this phenol ic compound in the Amphipterygium  genus, but \nit has also been described in seeds of Terminalia chebula  Retz. [32] and in Sinapis alba  L., a \nplant recognized by its antibacterial activity [33]. Hydroquinone, identified in the CE and phases \nB and C, has been  used for the treatment of various skin hyperpigmentation disorders [34] \nwhereas pyrogallol, present in the CE and phase A has been top ically used for psoriasis \ntreatment [35].  \n \n \nFig. 21. Chromatograms obtained by GC -MS in aqueous b ark extract from A. adstringens  and its solvent \nfractions.  \nPhase A (hexane); B (ethyl acetate) and C (aqueous fraction) (list of the numbered compounds is shown in Table \n11). \n \n135 Table 11. Compounds identified by  GC-MS in the crude aqueous extract from A. adstringens  bark and its \nfractions.  \nNo. Identified compounds  RT \n(min)  Crude \nextract  Phase A  Phase B  Phase C  Groups  \n1 Metil formate  9.56 \u2713 \u2713 \u2713 \u2713 E \n2 Hydrazine, ethyl - 12.41  \u2713    O \n3 Acetic acid, methyl ester  14.15 \u2713 \u2713 \u2713 \u2713 AC \n4 3,3-Dimethylacrylic acid  19.48  \u2713 \u2713 \u2713  AC \n5 Pyruvic acid  21.32  \u2713 \u2713 \u2713 \u2713 AC \n6 Glycoaldehyde dimethyl acetal  23.11  \u2713 \u2713   AD \n7 Propanoic acid, 2 -oxo-, methyl ester  24.11  \u2713 \u2713 \u2713 \u2713 E \n8 Proline, 2-methyl -5-oxo-, methyl ester  31.23  \u2713    E \n9 Acetic acid, hydrazide  33.53  \u2713 \u2713 \u2713 \u2713 AC \n10 2-Propanone, 1,3 -dihydroxy - 36.13  \u2713 \u2713 \u2713 \u2713 K \n11 Picolinic acid N -oxide  38.51  \u2713   \u2713 AC \n12 (S)-(+)-3-Hydroxytetrahydrofuran  41.43  \u2713 \u2713 \u2713 \u2713 F \n13 4H-Pyran -4-one, 2,3 -dihydro -3,5-\ndihydroxy -6-methyl - 43.51  \u2713 \u2713   K \n14 Thiophene -3-ol, tetrahydro -, 1,1-dioxide  44.31  \u2713 \u2713  \u2713 A \n15 7-Octen -2,6-diol, 2,6 -dimethyl - 47.02  \u2713 \u2713   A \n16 Butanedioic acid, methoxy -, dimethyl \nester  50.68   \u2713 \u2713 \u2713 AC \n17 Unknown  50.88  \u2713  \u2713  - \n18 3,5-Dimethyl -1-\ndimethylphenylsilyloxybenzene  53.79  \u2713  \u2713 \u2713 O* \n19 11-Tricosene  54.41  \u2713 \u2713   O \n20 Carbonic acid, ethyl 3 -(1-\nmethylethoxy)phenyl ester  57.26  \u2713  \u2713 \u2713 E* \n21 Hydroquinone  58.48  \u2713  \u2713 \u2713 P* \n22 2-(Methylmercapto) -benzothiazol  59.63  \u2713  \u2713 \u2713 O* \n23 Benzeneethanol, 4 -hydroxy - 61.28  \u2713 \u2713 \u2713 \u2713 P* \n24 Homovanillyl alcohol  62.55   \u2713 \u2713 \u2713 P* \n25 Pyridine, 4 -tert-butyl -2-(tert-butylthio) - 63.21  \u2713 \u2713   O \n26 Unknown  66.12  \u2713  \u2713  - \n27 Flamenol  68.34  \u2713 \u2713 \u2713 \u2713 P* \n28 Pyrogallol  75.74  \u2713 \u2713   P* \nRetention time  (RT, min).  Groups: Alcohol (A); Furans (F); Ketone (K); Phenol (P), A romatic (*); Acid (AC); \nAldehyde (AD); Ester (E); Others (O)   \n \nUV-fluorescence has been used in the analysis of natural extracts to identify compounds capable \nof emitting fluorescence, mainly phenolics [29]. Phenolic compounds can be present in plants \nas m onomers, short conjugated ring systems and as polycondensed str uctures [36]. Fig. 22 \nshows that the spectra of all samples had the highest intensity peak in the range from 260 to 290 \nnm, which could be related to a greater amount of monophenols of a small structure. The higher \nproportion of monophenols in the CE could be explained by the presence of a larger diversity \nof molecules in this CE compared to its fractions. It is worth noting the significantly more \nintense  signal related to the monophenols of phase B as compared with phases A and C ( Fig. \n22). Ethyl acetate has been described as a good solvent to extract phenols of low molecular  \n136 weight [37]. Interestingly, phase C pre sents signals from short conjugated systems and \npolycondensed structures in the range of 290 to 340 nm. It could indicate a higher diversity of \npolyphenolic structures as tannins in this phase as compared with phases A and B.  \n \n \nFig. 22. UV-fluorescence spectra of the crude extract and its frac tions from A. adstringens bark . \n \nThe toxicological MTT test performed on HaCaT cells through the determination of the \nminimum toxic dose (IC 90) showed that phase C had the lowest toxicity with a n \nIC90=911.3\u00b110.8 \u03bcg/mL followed by phase A (IC 90= 283.2\u00b17.2 \u03bcg/mL), the CE (IC 90=223\u00b16 \n\u03bcg/mL) and then phase B (IC 90=74.0\u00b15.5 \u03bcg/mL), respectively. According to the UV -\nfluorescence analysis, phase C presents a higher abundance of dimers, short conjugated \nmolecu les, and polycondensed structures when compar ed to phases A and B. Proanthocyanidins \nare a group of biologically active oligomeric and polymeric bioflavonoids which can be obtained \n \n137 in the aqueous fraction [38]. These compounds have protective effects on ke ratinocyte\u2019s UV -\ninduced oxidative stress and could be related to the lower toxicity observed in phase C compared \nto phases A and B [39]. \nFig. 23 shows the anti -inflammatory activity of CE and its fractions at concen trations lower than \nIC90 on IL -17-induced IL -8 production on HaCaT keratinocytes. Results were compared with \ndexamethasone (dex), a drug used for psoriasis treatment. Dexamethasone has demonstrated to \ndecrease the deleterious Th17 immune response in a mode l of arthritis [40] show ing anti -IL17 \nactivities on articular chondrocytes [41]. As shown in Fig. 23, the CE and all fractions \nsignificantly decreased (p <0.05) the IL -8 release  from keratinocytes. Interestingly, th e CE and \nphase C, at all tested concentrations, demonstrated to be more potent than dexamethasone by \nsignificantly decreasing the IL -8 production under basal concentrations.  \n \n \nFig. 23. Effect of crude extract and phases A -C from A. adstringens  bark on the IL -17-induced production \nof IL -8 on HaCaT keratinocytes.  \nThe confluent HaCaT cells were pretreated or not with crude extract and phases A -C (\u03bcg/mL) or dexamethasone \n(dex, 5 \u03bcM) for 10 h , then cells were stimulated with IL -17 (50 ng/ mL) for 14 h. IL -8 production in HaCaT \nsupernatants was measured by ELISA. Results are expressed in pg/mL and correspond to 106 cells. The histogram \nrepresents the mean \u00b1 standard deviation. Statistical: one -way ANOVA followed by Tukey\u2019s post hoc test. Mea ns \nwithout a common letter differ (p<0.05).  \n \n \n138 In a previous study, it was demonstrated that a pyrolytic oil from the bark of this tree had a \ncomparable anti -inflammatory effect as dexamethasone [30]. However, t he results here \npresented show a more important  anti-inflammatory effect of CE and fraction C on the IL -8 \nproduction (p<0.01). This can be explained by the higher diversity of chemical structures present \nin both samples. Most of the identified compounds wi th variable structures are present in CE, \nwhile  phase C is rich in dimers, small conjugated structures and polycondensed molecules which \ncould significantly contribute to the IL -17 inhibition. It has been reported that proanthocyanidins \ninhibit the IL -17 in human pulmonary epithelial cells by blocking mitogen -activated protein \nkinases and nuclear factor -\u03baB-mediated signaling pathway [42]. Further research is needed to \nelucidate the involved anti -inflammatory mechanism from CE and phase C and the molecules \nresponsible for this activity.  \nOverall, our resu lts demonstrate for the first time the significant anti -inflammatory effect and \nlow toxicity of the CE and aqueous fraction on HaCaT keratinocytes, which supports the \ntraditional topical use of A. adstringens  bark\u2019 decoctions by Pur\u00e9pechas for the treatmen t of \ndermatological diseases and opens the door for an exhaustive study of their anti -IL17 \nmechanism. Acids and aromatics were the predominant compounds identified in all samples. \nMoreover, flamenol, a phenol identified for the first time in the Amphiptery gium  genus, was the \nmajor compound in CE and phases B and C. Other investigations should be performed to \ndetermine the anti -inflammatory properties of flamenol and quantify this molecule into the \nanalyzed samples.  \n \nVI.8.5.  Conflict of interest statement  \nThe author s declare no conflict of interest  \n \nVI.8.6.  Authors\u2019 contributions  \nREG:  investigation, formal analysis, writing -original draft.  JSMF: Investigation, formal \nanalysis.  NAI: Investigation, reviewing and editing.  MGP:  investigation, formal analysis, \nmethodology, resour ces, reviewing and editing. AOZ: investigation, formal analysis,  \n139 methodology, reviewing and editing. MEGP: conceptualization, methodology, formal analysis, \nresources, supervision, reviewing and editing.  \n \nVI.8.7.  References  \n1 Villase\u00f1or JL. Checklist of the native vascular plants of Mexico. Rev Mex Biodivers 2016; 87: 559 \u2013902 \n2 Alonso -Castro AJ, Dom\u00ednguez F, Maldonado -Miranda JJ, Castillo -P\u00e9rez LJ, Carranza -\u00c1lvarez C, Solano E, \nIsiordia -Espinoza MA, Ju\u00e1rez -V\u00e1zquez M del C, Zapata -Morales JR, Argueta -Fuertes MA, Ruiz -Padilla AJ, \nSolorio -Alvarado CR, Rangel -Vel\u00e1zquez JE, Ortiz -Andrade R, Gonz\u00e1lez -S\u00e1nchez I, Cruz -Jim\u00e9nez G, Orozco -\nCastellanos LM. Use of medicinal plants by health professionals in Mexico. J Ethnopharmacol 2017; 198: 81 \u2013\n86 \n3 Esquivel -Garc\u00eda R, P\u00e9rez -Calix  E, Ochoa -Zarzosa A, Garc\u00eda -P\u00e9rez M -E. Ethnomedicinal plants used for the \ntreatment of dermatological affections on the Pur\u00e9pecha Plateau, Michoac\u00e1n, Mexico. Acta Bot Mex 2018; 125: \n95\u2013132 \n4 Rodriguez -Garcia A, Peixoto ITA, Ve rde-Star MJ, De la Torre -Zaval a S, Aviles -Arnaut H, Ruiz ALTG. In \nvitro  antimicrobial and antiproliferative activity of Amphipterygium adstringens . Evid Based Complement \nAlternat Med 2015; 2015: 175497  \n5 Rodriguez -Canales M, Jimenez -Rivas R, Canales -Martin ez MM, Garcia -Lopez AJ, Rivera -Ya\u00f1ez N, Nieto -\nYa\u00f1ez O, Ledesma -Soto Y, Sanchez -Torres LE, Rodriguez -Sosa M, Terrazas LI, Rodriguez -Monroy MA. \nProtective effect of Amphipterygium adstringens  extract on dextran sulphate sodium -induced ulcerative colitis \nin mice. Mediators Inflamm 2016; 2 016: 8543561  \n6 Arrieta J, Benitez J, Flores E, Castillo C, Navarrete A. Purification of gastroprotective triterpenoids from the \nstem bark of Amphipterygium adstringens ; role of prostaglandins, sulfhydryls, nitric oxide and capsaicin -\nsensitive neurons. Plan ta Med 2003; 69 : 905 \u2013909 \n7 Knauth P, Acevedo -Hern\u00e1ndez GJ, Cano ME, Guti\u00e9rrez -Lomel\u00ed M, L\u00f3pez Z. In vitro  bioactivity of methanolic \nextracts from Amphipterygium adstringens  (Schltdl.) Schiede ex Standl., Chenopodium ambrosioides  L., \nCirsium mexicanum  DC., Eryngium carlin ae F. Delaroche, and Pithecellobium dulce  (Roxb.) Benth. used in \ntraditional medicine in Mexico. Evid Based Complement Alternat Med 2018; 2018: 3610364  \n8 Navarrete A, S\u00e1nchez -Mendoza ME, Arrieta J, Cruz -Antonio L, Oliva I, Casta\u00f1eda -Hern\u00e1nde z G. \nGastroprot ection and effect of the simultaneous administration of cuachalalate ( Amphipterygium adstringens ) \non the pharmacokinetics and anti -inflammatory activity of diclofenac in rats. J Pharm Pharmacol 2005; 57: \n1629 \u20131636  \n9 Rosas -Pi\u00f1\u00f3n Y, Mej\u00eda A, D \u00edaz-Ruiz G, Agu ilar MI, S\u00e1nchez -Nieto S, Rivero -Cruz JF. Ethnobotanical survey \nand antibacterial activity of plants used in the Altiplane region of Mexico for the treatment of oral cavity \ninfections. J Ethnopharmacol 2012; 141: 860 \u2013865 \n10 Mata R, Figueroa M, Navarrete A,  Rivero -Cruz I. Chemistry and biology of selected Mexican medicinal plants. \nIn: Kinghorn AD, Falk H, Gibbons S, Kobayashi J, Asakawa Y, Liu J -K (Hrsg.). Progress in the Chemistry of \nOrganic Natural Products. Cham: Springer, 2019: 1 \u2013142 Im In ternet: https:/ /doi.org/10.1007/978 -3-030-01099 -\n7_1 \n11 Oviedo -Ch\u00e1vez I, Ram\u00edrez -Apan T, Soto -Hern\u00e1ndez M, Mart\u00ednez -V\u00e1zquez M. Principles of the bark of \nAmphipterygium adstringens  (Julianaceae) with anti -inflammatory activity. Phytomedicine 2004; 11: 436 \u2013445 \n12 Internatio nal Psoriasis Council. IPC Psoriasis Review. Dallas, Texas: IPC, 2009: 1 \u201312 Im Internet: \nhttp://www.psoriasiscouncil.org/docs/ipcpsoriasisreview_dec_2009_english.pdf?LanguageID=EN -US \n13 Boehncke W -H, Sch\u00f6n MP. Psoriasis. Lancet 2015; 386: 98 3\u2013994 \n14 Blauvelt A, Chiricozzi A. The immunologic role of IL -17 in psoriasis and psoriatic arthritis pathogenesis. Clin \nRev Allergy Immunol 2018; 55: 379 \u2013390 \n15 Nograles KE, Zaba LC, Guttman\u2010Yassky E, Fuentes\u2010Duculan J, Su\u00e1rez\u2010Fari\u00f1as M, Cardinale I, Khat cherian A , \nGonzalez J, Pierson KC, White TR, Pensabene C, Coats I, Novitskaya I, Lowes MA, Krueger JG. Th17 \ncytokines interleukin (IL) -17 and IL -22 modulate distinct inflammatory and keratinocyte -response pathways. \nBr J Dermatol 2008; 159: 1092 \u20131102  \n16 Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin -17 inhibition: role in psoriasis and \ninflammatory bowel disease. J Dermatol Treat 2018; 29: 13 \u201318  \n140 17 Rusta -Sallehy S, Gooderham M, Papp K. Brodalumab: a review of safety. Skin Therapy Lett 2018; 23: 1 \u20133 \n18 van de Kerkhof PCM, Griffiths CEM, Reich K, Leonardi CL, Blauvelt A, Tsai T -F, Gong Y, Huang J, \nPapavassilis C, Fox T. Secukinumab long -term safety experience: a pooled analysis of 10 phase II and III \nclinical studies in patients with moderate t o severe plaque psoriasis. J Am Acad Dermatol 2016; 75: 83 -98.e4  \n19 Murphy EC, Nussbaum D, Prussick R, Friedman AJ. Use of complementary and alternative medicine by \npatients with psoriasis. J Am Acad Dermatol 2019; 81: 280 \u2013283 \n20 Esquivel -Garc\u00eda R, Est\u00e9vez -Delgado G, Rodr\u00edguez -Orozco A -R, Ochoa -Zarzosa A, Garc\u00eda -P\u00e9rez ME. La \npsoriasis: de la investigaci\u00f3n b\u00e1sica y cl\u00ednica al desarrollo de nuevos tratamientos. Gaceta M\u00e9dica de M\u00e9xico \n2018; 154: 502 \u2013508 \n21 Olivera Ortega AG, Soto Hern\u00e1ndez M, Mart \u0131\u0301nez V\u00e1zque z M, Terr azas Salgado T, Solares Arenas F. \nPhytochemical study of cuachalalate ( Amphiptherygium adstringens , Schiede ex Schlecht). J Ethnopharmacol \n1999; 68: 109 \u2013113 \n22 Navarrete A, Avula B, Joshi VC, J i X, Hersh P, Khan IA. Quantitative determination of triterpene s from \nAmphiptherygium adstringens  by liquid chromatography and thin -layer chromatography and morphological \nanalysis of cuachalalate preparations. J AOAC Int 2006; 89: 1 \u20137 \n23 Castillo -Ju\u00e1rez I,  Rivero -Cruz F, Celis H, Romero I. Anti -Helicobacter pylori  activity of anacardic acids from \nAmphipterygium adstringens . J Ethnopharmacol 2007; 114: 72 \u201377 \n24 D\u00e9ciga -Campos M, Rivero -Cruz I, Arriaga -Alba M, Casta\u00f1eda -Corral G, Angeles -L\u00f3pez GE, Navarrete A,  \nMata R. Acute toxicity and mutagenic activity of Mexican plant s used in traditional medicine. J \nEthnopharmacol 2007; 110: 334 \u2013342 \n25 Kersten S, Garcia -Perez M. Recent developments in fast pyrolysis of ligno -cellulosic materials. Curr Opin \nBiotechnol 2013;  24: 414 \u2013420 \n26 Hirotsune M, Haratake A, Komiya A, Sugita J, Ta chihara T, Komai T, Hizume K, Ozeki K, Ikemoto T. Effect \nof ingested concentrate and components of sake on epidermal permeability barrier disruption by UVB \nirradiation. J Agric Food Chem 2005; 53: 948 \u2013952 \n27 Husni A, Jeon J -S, Um B -H, Han NS, Chung D. Tyro sinase inhibition by water and ethanol extracts of a Far \nEastern sea cucumber, Stichopus japonicus . J Sci Food Agric 2011; 91: 1541 \u20131547  \n28 ECN, TNO. Database for the physico -chemical compositi on of (treated) lignocellulosic biomass, micro - and \nmacroalgae, various feedstocks for biogas production and biochar. Phyllis2 2020; Im Internet: \nhttps://phyllis.nl/Browse/Standard/ECN -Phyllis#bark  \n29 Garc\u00eda-P\u00e9rez M -E, Alfonso -Castillo A, Fong Lores O, Bat ista-Duharte A, Lemus -Rodr\u00edguez Z. Toxicological \nevaluation of an aqueous suspension from leaves and stems of Petiveria alliacea  L. (Phytolaccaceae). J \nEthnopharmacol 2018; 211: 29 \u201337 \n30 Esquivel -Garc\u00eda R, Ayiania M, Abu -Lail N, L\u00f3pez -Meza JE, del R\u00edo RE, Garc\u00eda -P\u00e9rez M, Ochoa -Zarzosa A, \nGarc\u00eda -P\u00e9rez M -E. Pyrolytic oils from Amphipterygium adstringens  bark inhibit IL -8 production of IL -17-\nstimulated HaCaT keratinocytes. J Anal Appl Pyrol 2020; 145: 104749  \n31 Stankovikj F, Garcia -Perez M. TG -FTIR method for the characterization of bio -oils in chemical families. \nEnergy Fuels 2017; 31: 1689 \u20131701  \n32 Nandagopal S, Ganesh Kumar A, Dhanalakshmi DP, Prakash P. Bio -prospecting the antibacterial and \nanticancer activ ities of silver nanoparticles synthesized using Termi nalia chebula  seed extract. Int J Pharm \nPharm Sci 2014; 6: 368 \u2013373 \n33 Al-Qudah MA, Al -Jaber HI, Muhaidat R, Hussein EI, Hamid AAA, Al -Samadi ML, Abaza IF, Afifi FU, Abu -\nOrabi ST. Chemical composition and antimicrobial activity of the essential oil from Sinapis alba  L. and Sinapis \narvensis  L. (Brassicaceae) growing wild in Jo rdan. Res J Pharm Biol Chem Sci 2011; 2: 1136 \u20131144  \n34 Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Venereol 2006; 20: \n781\u2013787 \n35 Willsteed E, Regan  W. Psoriasis, pyrogallol and skin cancer. Australas J Dermatol 1985; 26: 144 \u2013145 \n36 Barsotti F, Ghigo G, Vione D. Computational assessment of the fluorescence emission of phenol oligomers: a \npossible insight into the fluorescence properties of humic -like substances (HULIS). J Photochem Photobiol A \n2016; 315: 87 \u201393 \n37 Garc\u00eda -P\u00e9rez M -E, Royer M, Herbette G, Desjardins Y, Pouliot R, Stevanovic T. Picea mariana  bark: a new \nsource of trans -resveratrol and other bioactive polyphenols. Food Chem 2012; 135: 1173 \u20131182 \n38 Garc\u00eda -P\u00e9rez M -E, Royer M, Duque -Fernandez A, Diouf PN, Stevano vic T, Pouliot R. Antioxidant, \ntoxicological and antiproliferative properties of Canadian polyphenolic extracts on normal and psoriatic \nkeratinocytes. J Ethnopharmacol 2010; 132: 251 \u2013258  \n141 39 Mantena SK, Katiyar SK. Grape seed proanthocyanidins inhibit UV -radiation -induced oxidative stress and \nactivation of MAPK and NF -kappaB signaling in human epidermal keratinocytes. Free Radic Biol Med 2006; \n40: 1603 \u20131614  \n40 Pe\u00f1a C, G\u00e1rate D, Contreras -Levicoy J, Aravena O, Catal\u00e1n D, Aguill\u00f3n JC. Dexamethasone preconditioning \nimproves the response of collagen -induced arthritis to treatment with short -term lipopolysaccharide -stimulated \ncollagen -loaded dendritic cells. Clin Dev Immunol 2013; 2013: 296031  \n41 Shalom -Barak T, Quach J, Lotz M. Interleukin -17-induced Gene Expression in Articular Chondrocytes Is \nAssociated with Activation of Mitogen -activated Protein Kinases and NF -\u03baB. J Biol Chem 1998; 273: 27467 \u2013\n27473  \n42 Kim H, Kim JY, Song HS, Park KU, Mun K -C, Ha E. Grape seed proanthocyanidin extract inhibits interleukin -\n17-induced interleukin -6 production via MAPK pathway in human pulmonary epithelial cells. Naunyn \nSchmiedebergs Arch Pharmacol 2011; 383: 555 \u2013562 \n43 Ayiania M, Terrell E, Dunsmoor A, Carbajal -Gama rra FM, Garcia -Perez M. Characterization of solid and vapor \nproducts from thermochemical conversion of municipal solid waste woody fractions. Waste Manag 2019; 84: \n277\u2013285 \n   \n142 VII. DISCUSI\u00d3N GENERAL  \n \nEl presente trabajo se  enmarca en una visi\u00f3n de desarrollo  farmac\u00e9utico,  donde  se sigui\u00f3  un \nenfoque etnofarmacol\u00f3gico para la b\u00fasqueda de candidatos terap\u00e9uticos de origen natural con \nposible actividad antipsori\u00e1sica . La regi\u00f3n de la Meseta Pur\u00e9pecha  se seleccion\u00f3 como \u00e1rea de \nestudio  para la realizaci\u00f3n del estu dio etnofarmacol\u00f3gico de partida (Fig. 1 -Cap\u00edtulo 1 ), ya que  \nlas caracter\u00edsticas culturales de su poblaci\u00f3n y la diversidad biol\u00f3gica de su territorio favorecen  \nque la pr\u00e1ctica de la medicina tradicional contin\u00fae vigente . Adem\u00e1s, ning\u00fan estudio \netnofarmaco l\u00f3gico hab\u00ed a sido reportado c on relaci\u00f3n al tratamiento de enfermedades \ndermatol\u00f3gicas por esta poblaci\u00f3n, lo que garantiz \u00f3 la novedad de la investigaci\u00f3n presentada.  \nSe identificaron 97 plantas medicinales para el trat amiento de afecciones dermatol\u00f3gicas  \nutilizadas por los habitantes de esta regi\u00f3n  (Esquivel -Garc\u00eda et  al., 2018 b) y 19 condiciones \ndermatol\u00f3gicas entre las que destacaron el tratamiento de heridas (40.20%), inflamaci\u00f3n de la \npiel (37.11%) y erupciones cut\u00e1 neas (37.11%)  (Fig. 4 -Cap\u00edtulo 1 , Ap\u00e9ndice -Cap\u00edtulo 1). \nAdem\u00e1s, se constat\u00f3 que  las partes a\u00e9reas, las hojas y las flores son los tejidos m\u00e1s empleados, \nlos que se usan preferentemente por v\u00eda oral en forma de infusiones y cocimientos ( Fig. 5 -\nCap\u00edtulo 1 ). Una observaci\u00f3n interesante es que a diferencia de otros estudios \netnofarmacol\u00f3gicos centrados en enfermedades de la piel (Afolayan et  al., 2014; Njoroge & \nBussmann, 2007; Sharma et  al., 2014)  los Pur\u00e9pecha s prefieren el uso de preparaciones por v\u00eda \noral en lugar de la administraci\u00f3n t\u00f3pica , esto debido a que poseen la creencia de que las \nenfermedades dermatol\u00f3gicas se deben a una contaminaci\u00f3n sangu\u00ednea interna . \nLa comparaci\u00f3n con la literatura etnomedicinal permiti\u00f3 registrar por primera vez 8 nuevas \nplantas utiliza das para tratar afeccion es de la piel ( Eryngium  beecheyanum, T agetes  remotiflora, \nTournefortia mutabilis, Equisetum  hyemale  var. affine , Clinopodium  macrostemum, S alvia  \nleucantha, S ida haenkeana y Urtica  subincisa ). Desde el punto de vista et nofarmacol\u00f3gico, se \ntrata de una  nueva informaci\u00f3n que podr\u00eda servir para el desarrollo de nuevos candidatos \norientados a tratar este tipo de patolog\u00edas . Adem\u00e1s, permite la difusi\u00f3n del conocimiento \nheredado de generaci\u00f3n en gener aci\u00f3n por los Pur\u00e9pecha  sobre las preparaciones herbolarias  \npara enfermedades cut\u00e1neas.  Lo anterior sirvi\u00f3 para confeccionar un cat\u00e1logo  \n143 etnofarmacol\u00f3gico de la zona  con caracter\u00edsticas similares a los ya publicados en otras regiones \ndel mundo  (Prashantkum ar & Vidyasagar, 2008; Sha rma et  al., 2014) .  \nA partir de la informaci\u00f3n etnofarmacol\u00f3gica,  se determinaron  las 10 plantas con mayor valor \nde uso (Fig. 6 -Cap\u00edtulo 1 ). De estas plantas se seleccionaron dos especies mexicanas (una \nherb\u00e1cea y un \u00e1rbol) que se  emplearon en etapas suces ivas de la investigaci\u00f3n para la b\u00fasqueda \nde compuestos prometedores como tratamientos antipsori\u00e1sicos. Tres criterios fundamentales \nse consideraron en la elecci\u00f3n de ambas plantas: 1) ser altamente reportadas por los Pur\u00e9pechas; \n2) ser nativas de M\u00e9xico; 3) no haber sido farmacol\u00f3gicamente estudiadas para el tratamiento \nde enfermedades dermatol\u00f3gicas. La l\u00f3gica tras la elecci\u00f3n de una planta herb\u00e1cea y un \u00e1rbol \nestuvo motivada por las diferencias en cuanto a la composici\u00f3n qu\u00edmica  de ambas especies , \nrespec to al tipo de compuestos extra\u00edbles y lignina, con el consiguiente impacto en la diversidad \nde mol\u00e9culas obtenidas  en los extractos convencionales y aceites pirol\u00edticos,  as\u00ed como  en su \nactividad biol\u00f3gica. En consecuencia, la especie herb\u00e1cea conocida com\u00fa nmente como ortiga \n(Urtica subincisa ), identificada como la quinta planta con mayor valor de uso , y el \u00e1rbol de \ncuachalalate ( Amph ipterygium adstringens ), s\u00e9ptimo reportado con mayor valor de uso, fueron \nselec cionados para etapas subsecuentes de la investi gaci\u00f3n.  \nEl cuachalalate (Fig. 17) se utiliza desde tiempos prehisp\u00e1nicos en el tratamiento de \u00falceras \ng\u00e1stricas y hay registro en la literatura cient\u00edfica de que algunos de sus compuestos tienen acci\u00f3n \nantimicrobia na y antiinflamatoria (Mata et  al., 2019) . En la regi\u00f3n de la Meseta Pur\u00e9pecha su \ncorteza es preparada como cocimiento, tomada oralmente y/o usada para lavar las \u00e1reas de piel \nafectada por cortaduras, inflamaci\u00f3n, quemaduras, sarpullido, infecciones con ab scesos, \npicaduras de insectos (Ap\u00e9ndice-Cap\u00edtulo 1). Con respecto a  la ortiga (Fig. 10) en la literatura \nsolamente se menciona el uso de las partes a\u00e9reas  en la medicina tradicional sin una ap licaci\u00f3n \nen particular (Steinmann, 2005) , y no hay estudios de su composici\u00f3n qu\u00edmica, acciones \nfarmacol\u00f3gicas o toxicol\u00f3gicas . En la etnomedicina Pur\u00e9pecha se describe que el extracto \netan\u00f3lico de sus parte s a\u00e9rea s es utilizado  por v\u00eda t\u00f3pica en forma de fomentos , mientras que  la \ninfusi\u00f3n se admi nistra oralmente para el tratamiento de inflamaci ones cut\u00e1neas , v\u00e1rices y \nerupciones (Ap\u00e9ndice -Cap\u00edtulo 1). \nPosterior a la recolecci\u00f3n , preparaci\u00f3n de las muestras  y dep\u00f3sito en el herbario  del Instituto de \nEcolog\u00eda d el Baj\u00edo  (IEB) de ambas plantas  se obtuvieron los extractos crudos convencionales  \n144 apeg\u00e1ndose a l a forma de uso tradicional , los que fueron fraccionados utilizando tres solventes \nde menor a mayor polaridad  (hexano, acetato de etilo y agua ) con vistas a caracterizar los m\u00e1s \nexhaustivamente desde el punto de vista qu\u00edmico . Las fracciones resultantes fueron \ndenominadas fases A, B y C , respectivamente . La biomasa residual libre de extractivos  (m\u00e1s del \n60% de la muestra in icial)  fue sometida a un proceso de pir \u00f3lisis lenta (Fig. 2-Cap\u00edtulo 3). Este \nprocedimiento  permiti\u00f3  el aprovechamiento  integral  del material biol\u00f3gico  y se ampli\u00f3  la \ncantidad de compuestos bioactivos obtenidos , ya que los aceites pirol\u00edticos presenta ron en su \ncomposici\u00f3n compuestos  provenientes de la degradaci\u00f3n de la celulosa, hemicelulosa y lignina , \nimposibles de obtener con m\u00e9todos convencionales de extracci\u00f3n  (Mohan et  al., 2006) . Los \nextractos crudos, sus fracciones y los aceites pirol\u00edticos de ambas plantas fueron caracterizados \nqu\u00edmicamente, adem\u00e1s de que se determin\u00f3 su toxicidad y efec to sobre la producci\u00f3n de IL -8 \nen queratinocitos HaCaT estimulados con IL -17. \nCon respecto al rendimiento de extracci\u00f3n, el extracto crudo de A. adstringens  present\u00f3  el mayor \nrendimiento de extracci\u00f3n (28.6 %) comparativamente a 13.4 % del extracto etan\u00f3li co de U. \nsubincisa . Con re laci\u00f3n  a la extracci\u00f3n l\u00edquido/l\u00edquido en ambos casos, la fracci\u00f3n acuosa \ngener\u00f3 los mayores rendimientos, mientras que el aceite pirol\u00edtico  2 comparativamente al aceite \npirol\u00edtico 1  fue el que se obtuvo en mayores cantidades (13. 8 y 10.0 % para A. adstringens  y U. \nsubincisa  respectivamente) . El an\u00e1lisis realizado por GC -MS permiti\u00f3 constatar que l a \ncomposici\u00f3n qu\u00edmica de los extractos convenc ionales de ambas plantas fue variable  tal y como \nse esperaba dada su naturaleza  (Stevanovic, 2005) . \nEl extracto etan\u00f3lico de U. subincisa  present\u00f3 una alta concentraci\u00f3n de esteres (25% de las \nmol\u00e9culas  identificadas), mientras que los compuestos fen\u00f3licos y \u00e1cidos prevalecieron en el \nextracto acuoso de A. adstringens  (19 % de las mol \u00e9culas reportadas  para ambos grupos ). \nAdem\u00e1s de las varia ciones en las proporciones relativas de los compuestos identificados, los \ncompuestos mayoritarios fueron diferentes en ambos extractos convencionales . El extracto \netan\u00f3lico de U. subincisa  demostr\u00f3 s er rico en linoleato de etilo, mientras que el extracto a cuoso \nderivado de cortezas de A. adstringens  mostr\u00f3 altas concentraciones del compuesto fen\u00f3lico \nflamenol. La presencia de esta mol\u00e9cula es documentada por vez primera  para el g\u00e9nero \nAmphipterygium .  \n145 Las mol\u00e9culas mayoritarias de los aceites pirol\u00edticos tambi\u00e9n mostraron variaciones  \nrelacionadas con la especie analizada. En el caso de U. subincisa , el indol y el fenol mostraron \nuna prevalencia en el aceite pirol\u00edtico -1, mientras que el aceite pirol\u00edtic o-2 demostr\u00f3 ser rico en \n3,4,5 trimetilpirazol y fenol. En el caso de A. adstringens  existe una gran similitud entre los \ncompuestos presentes en el a ceite  pirol\u00edtico -1 y el aceite  pirol\u00edtico -2, aunque las \u00e1reas de los \npicos difi rieron  cuando se compara ron ambos aceites. Por ejemplo, el guaiacol, un producto de  \ndegradaci\u00f3n de la  lignina (Mohan et al., 2006) est uvo presente en mayor proporci\u00f3n en el acei te \npirol\u00edtico -2, mientras que ocurre lo contrario con el siringol  que estuvo  presente en una \nconcentraci\u00f3n m\u00e1s alta en el aceite  pirol\u00edtico -1. \nLas diferencias observadas en cuanto a la composici\u00f3n qu\u00edmica de los extractos convencionales  \ny aceites pirol\u00edtic os de U. subincisa  y A. adstringens  podr\u00e1n explicarse por la propia naturaleza \nde las plantas estudiadas. E n general se considera que las plantas le\u00f1osas tienen un contenido \nelevado de compuestos fen\u00f3licos como taninos, lignanos y estilbenos, mientras que las \nherb\u00e1ceas suelen ser ricas en flavonoides y \u00e1cidos fen\u00f3licos  (G\u00f3mez -Fuentes -Galindo et  al., \n2017) . Adem \u00e1s, los aceites pirol\u00edticos pueden contener compuestos diferentes dadas las \ndiferencias en cuanto a la composici\u00f3n de la lignina, el tipo de planta , la etapa de desarrollo, \nlugar de crecimiento y anatom\u00eda  propia de la especie analizada  (Sykes et  al., 2009) . \nEl an\u00e1lisis de la toxicidad de las muestras analizadas sobre los queratinocitos HaCaT se realiz\u00f3 \nsiguiendo el m\u00e9todo de MTT mediante la determinaci \u00f3n de la concentraci\u00f3n  toxica m\u00ednima \n(IC 90). Tanto para U. subincisa , como  para A. adstringens  la muestra c on mayor toxicidad estuvo \nrepresentada por el  aceite pirol\u00edtico -2. \nComparando la toxicidad de las muestras con el contenido de compuestos fen\u00f3licos \nidentificados por las distintas t\u00e9cnicas anal\u00edticas se puede apreciar  que a mayor concentraci\u00f3n \nde fenoles se constat\u00f3  una mayor toxicidad  sobre  los queratinocitos. De hecho, en el caso de U \nsubincisa  se encontr\u00f3 una correlaci\u00f3n indirecta  entre el contenido de fenoles totales y el valor \nde la IC 90, representativo de una mayor toxicidad (r=-0.5209; p=0.0266) . De igual manera, para \nA. adstringens , pud o apreciarse que l as muestras  con mayor toxicidad correspond \u00edan a aquellas \ncon altos contenidos de fenoles, seg\u00fan el an\u00e1lisis por GC -MS y FTIR. Es conocido que fenoles \nutilizados en formulaciones tradicionales y farmac \u00e9uticas pueden producir erupciones cut\u00e1neas, \ninflamaci\u00f3n d\u00e9rmica y dermatitis de contacto (Murray et  al., 2007) . La toxicidad de estos  \n146 compuesto s fen\u00f3licos depender\u00e1 no solo de su concentraci\u00f3n e hidrofobicidad (Newby et  al., \n2000) , sino tambi\u00e9n de la gene raci\u00f3n de radicales libres y especies reactivas de ox\u00edgeno (Gami, \n2014) . \nAunque la presencia de fenoles podr\u00eda afectar la toxicidad, su sola aparici\u00f3n no es suficiente \npara explicar en su totalidad  los efectos t\u00f3xicos observados en las muestras  analizadas . Si bien \nen el caso de A. adstringens  la mayor toxicidad estuvo en la fase B y los aceites 1 -2, que \nmostraron el mayor contenido fen\u00f3lico, el aceite  pirol\u00edtico -1 de U. subincisa  que m ostr\u00f3 una \npreponderancia de estos compuestos de acuerdo con la evaluaci\u00f3n  del contenido de fenol es \ntotales, GC -MS, FTIR y an\u00e1lisis de UV fluorescencia, fue menos t\u00f3xico que las fases A -B y el \naceite  pirol\u00edtico -2 de esta misma planta . Por lo tanto, se propuso  la hip\u00f3tesis de que la toxicidad \nen los quera tinocitos pudiera tambi\u00e9n  estar  relacionada con la proporci\u00f3n relativa de los \ncompuestos qu\u00edmicos dentro de la muestra, lo que podr\u00eda conducir a interacciones entre las \nmol\u00e9culas que finalmente se traducir\u00edan en efectos nocivos para las c\u00e9lulas.  Otros estu dios \ntoxicol\u00f3gicos in vit ro e in vivo  deben ser realizados para determinar con precisi\u00f3n la naturaleza \nde las mol\u00e9culas que impactan sobre la toxicidad  en los queratinocitos y sus dosis umbral.  \nLos extracto s crudo s de ambas plantas , sus respectivas fracciones (fases A, B y C ), as\u00ed como los \naceites pirol\u00edticos 1 y 2 de cada una de las especies analizadas  fueron evaluados a \nconcentraciones no citot\u00f3xicas con relaci\u00f3n a  su efecto inhibitorio sobre  la producci\u00f3n de IL -8 \nen un modelo in vitro de inducci\u00f3n por IL -17 en queratinocitos HaC aT. Se escogi\u00f3 este modelo \npor varias razones: a) el reconocimiento del papel significativo de la IL -17 en la patog\u00e9nesis de \nla psoriasis; b) el papel  de los queratinocitos como c\u00e9lulas cruciales que promueve n los efectos \nproinflamatorios de esta citocina a nivel epid\u00e9rmico  (Moos et  al., 2019) ; c) la correlaci\u00f3n de los \nniveles de IL -8 con la gravedad de la psoriasis  (Arican et  al., 2005) . En consecuencia,  para el \ncribado farmacol\u00f3gico , se consider\u00f3 que la inhi bici\u00f3n de la producci\u00f3n de IL -8 por los \nqueratin ocitos HaCaT estimulados por IL -17 ser\u00eda un buen modelo in vitro  para detectar el \npotencial antiinflamatorio de los extractos solventes y bio -aceites y su posible aplicaci\u00f3n para \nla psoriasis . Lo anterior con  el objetivo de seleccionar la especie m\u00e1s prome tedora.  \nLa producci\u00f3n basal de IL -8 en c\u00e9lulas HaCaT fue de 252\u00b14 pg/ml, mientras que  la IL-17 \nestimul\u00f3 1.54 veces la producci\u00f3n de IL -8 despu\u00e9s de 14 horas de tratamiento (p <0.05).  En el \ncaso de U. subincisa  (Fig. 16), los extra\u00edbles mostraron un efecto proinflamatorio y no  \n147 inhibieron la producci\u00f3n de IL -8, excepto cuando la fase C fue probada a la concentraci\u00f3n m\u00e1s \nbaja de 27.5  \u03bcg/m L, generando una disminuci\u00f3n en los niveles de  IL-8 hasta las concentraciones \nbasales; mientras que  el aceite -2 a una concentraci\u00f3n de 7.5 \u03bcg/m L provoc\u00f3 una  disminuci\u00f3n  \nsignificativa  de IL -8 inferior a las concentraciones  basales en forma comparable a la \ndexametasona.  Uno de los resultados m\u00e1s inesperados fue el significativo efecto  proinflamatorio \nobservado  en la fase B  de U. subincisa . Uno de los principales compuestos identificados en esta \nfase es el fitol, al que se le han demostrado actividades proinflamatorias y promotoras de \ntumores en piel de rat\u00f3n  (Kagoura et  al., 1999) . Los der ivados de fitol son inductores potentes \nde citocinas como la IL-17 (Roy Chowdhury et  al., 2013)  y pueden estimular al factor de \ntranscrip ci\u00f3n NF-\u03baB (Ghosh & Chowdhury, 2013)  vinculado a la producci\u00f3n de IL -8. Los \ninmunoestimulantes basados en fitol pueden aumentar la expresi\u00f3n de CXCL1, un equivalente \nmurino de IL -8 (Chowdhury & Ghosh, 2012) , por lo que creemos que la importante presencia  \nde fito l en la Fase B podr\u00eda explicar, al menos parcialmente, la actividad proinflamatoria \nencontrada . Adem\u00e1s, la presencia  significativa de hidrocarburos  en esta fase pueden generar  \nactivaci\u00f3n inmun itaria  (Yau et  al., 2017) , que podr\u00eda estar relacionada con los efectos \nobservados ya  que estos compuestos podr\u00edan actuar solos o en sinergia con el fitol para estimular \nla producci\u00f3n de IL -8, pero nuevas investigaci ones deben a\u00fan ser realizadas para confirmar tales \nefectos . El efecto antinflamatorio mostrado p or el ac eite pirol\u00edtico -2 de U. subincisa  sugiere que \neste bioaceite  posee  un potencial  farmacol\u00f3gio  a ser explorado en el tratamiento de la psoriasis . \nEl compuesto mayoritario  detectado por GC -MS en el mismo  fue el 3,4,5 -trimetilpirazol. Se ha \ndemostrado que derivados piraz\u00f3licos  pueden mejorar la psoriasis  inducida  en ratones al inhibir \nla expresi\u00f3n de l ARNm de la IL-17 (Seki et  al., 2014) . Adem\u00e1s, estos compuestos pueden inhibir \nla activaci\u00f3n de  NF-\u03baB (Fu et  al., 2 017), factor de transcripci\u00f3n  vinculado a la producci\u00f3n de \nIL-8. Otro compuesto nitrogenado bioactivo presente en el aceite -2 es el pirrol , quien se ha \nsugerido  para la profilaxis y el tratamiento de enfermedades inflamatorias que implican la \nsobreproducci \u00f3n de citocinas como IL -8 (Zablocki et  al., 2003) . \nA diferencia de los resultados presentados para U. subincisa , las muestras m\u00e1s antiinflamatorias  \nen el caso de A. adstringens  resultaron provenientes de la extracci\u00f3n convencional, aunque l os \naceites pirol \u00edticos mostraron tambi\u00e9n efectos anti -IL17. De hecho, el extracto crudo  y las fases \nA-C disminuyeron significativamente la liberaci\u00f3n de IL -8 (p<0.05).  Un resultado notable fue \nel constatar que e l extracto crudo  y la fase C, a todas las con centraciones pro badas, demostraron  \n148 ser significativamente m\u00e1s potentes que la dexametasona (p <0.05 ). El an\u00e1lisis realizado por \nfluorescencia UV mostr\u00f3 que la  fase C presenta ba se\u00f1ales de sistemas conjugados y estructuras \npolicondensadas en el rango de 290  a 340 nm , lo que p odr\u00eda indicar una mayor diversidad de \nestructuras polifen\u00f3licas como las proantocianidinas  en esta fase en comparaci\u00f3n con las fases \nA y B.  Se ha reportado  que las proantocianidinas tienen actividad anti -IL17 en el epitelio \npulmonar huma no (H. Kim et  al., 2011) , por lo que podr\u00edan estar relacionadas con esta actividad.  \nEl aceite  pirol\u00edtico -1 de A. adstringens  a una concentraci\u00f3n de 17.5  \u03bcg/m L disminuy \u00f3 la \nproducci\u00f3n de IL -8 hasta el valor basal (p <0.05) , mientras que el efecto antiinflam atorio fue \nmayor en el aceite  pirol\u00edtico  2, pues a una concentraci\u00f3n de 15  \u03bcg/m L provoc\u00f3 la disminuci\u00f3n \nde la producci\u00f3n de IL -8 por debajo de l os valores  iniciales  y en forma comparable a la  \ndexametasona  (p <0.05) . Algunos de los compuestos fen\u00f3licos iden tificados  por HPLC  en los \naceites pir\u00f3licos  de A. adstringens , como la epigalocatequina, la catequina y la quercetina, \nposeen  propiedades antiinflamatorias  (Vijayalakshmi et al., 2012) . Adem\u00e1s, otras mol\u00e9culas  \ntambi\u00e9n identificad as, como el \u00e1cido docosahex aenoico, pueden inhibir la secreci\u00f3n de la IL -8 \nen las c\u00e9lulas HaCaT estimuladas por TNF  (Storey et  al., 2005) . Nuevas investigaciones son \nnecesarias  para dilucidar el mec anismo por el cual los aceites pirol\u00edticos inhiben la producci\u00f3n \nde IL -8 al bloquear las v\u00edas de IL -17 y las mol\u00e9culas responsables de estos efectos.  \nLos resultados anteriormente presentados  permitieron seleccionar la muestra m\u00e1s prometedora . \nDicha  selecci \u00f3n se realiz\u00f3 considerando tres elementos principales: a) baja toxicidad sobre los \nqueratinocitos HaCaT ; b) alto rendimiento de extracci\u00f3n  y 3) efecto anti -IL17  (Fig. 24). Estos \ntres elementos llevaron a considerar como el candidato  m\u00e1s prometedor  para continuar con \nestudios farmacodin\u00e1micos, toxicol\u00f3gicos y farmac ocin\u00e9ticos  al extracto acuoso de A. \nadstringens . \n \n  \n149  \nFig. 24. Esquema representativo de los resultados obtenidos en este trabajo.  \nLos extractos  crudos  de A. adstringens  y U. subincisa  se obtuvieron  simulando  su uso tradicional  por la \netnomedicina  Pur\u00e9pecha  y fueron  fraccionados  por extracci\u00f3n  l\u00edquido/l\u00edqu ido en las fases  A-C. La biomasa  residual  \nlibre de extractivos  de ambas  plantas  fue pirolizada,  permitiendo  la obtenci\u00f3n  de los aceites  pirol\u00edticos  1 y 2. \nDespu\u00e9s  de conocer  la compos ici\u00f3n  qu\u00edmica  y la concentraci\u00f3n  m\u00ednima  t\u00f3xica  (IC 90) de cada una de las muestras  \nestudiadas,  se evalu\u00f3  el potencial  antiinflamatorio  de las muestras  en un modelo  de inducci\u00f3n  de inflamaci\u00f3n  por \nIL-17 en queratinocitos  HaCaT.  El aceite  pirol\u00edtico -2 de U.subincisa , as\u00ed como  el extracto  crudo,  las fases  A-C y \nlos aceites  pirol\u00edti cos 1 y 2 de A. adstringens  mostraron  un efecto  antiinflamatorio.  El alto rendimiento  de \nextracci\u00f3n,  la baja toxicidad  y el efecto  antiinflamatorio  mostrado  por el extracto  crudo  de A. \nadstringens  permitieron  seleccionarlo  como  la muestra  m\u00e1s prometedora.  \n \n150 VIII.  CONCLUSI\u00d3N GENERAL  \n \nEl extracto acuoso, las fracciones y el aceite pirol\u00edtico -2 derivados de la corteza de A. \nadstringens , as\u00ed como el aceite pirol\u00edtico -2 de U. subincisa  mostraron e fectos anti -IL17  en el \nmodelo de inducci\u00f3n en queratinocitos humanos HaCaT . El extracto acuoso de A. adstringens  \nfue considerado el candidato m\u00e1s prometedor dado su alto rendimiento de extracci\u00f3n, baja \ntoxicidad y acci\u00f3n anti -IL17; lo que respalda su uso t radicional  por v\u00eda t\u00f3pica  reportado por la \npoblaci\u00f3n Pur\u00e9pecha, al menos en el modelo in vitro  empleado.  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \n151 IX. PERSPECTIVAS  \n \nLa investigaci\u00f3n presentada podr \u00e1 probablemente  contribuir al desarrollo de nuevas terapias \nutilizando extractos convenc ionales y aceites pirol\u00edticos de especies utilizadas en la \netnomedicina Pur\u00e9pecha para tratar la psoriasis , lo que podr\u00eda tener repercusiones significativas \nen la calidad de vida y la salud de los pacientes  afectados con esta enfermedad. \n152 X. BIBLIOGRAF\u00cdA  \n \nAbre u Guirado, O. A., & Cu\u00e9llar Cu\u00e9llar, A. (2008). Estrategias en la selecci\u00f3n de las plantas medicinales a \ninvestigar. Revista Cubana de Plantas Medicinales , 13(3), 0 -0. \nAdami, S., Cavani, A., Rossi, F., & Girolomoni, G. (2014). The role of interleukin -17A i n psoriatic diseas e. \nBioDrugs , 28(6), 487 -497. https://doi.org/10.1007/s40259 -014-0098 -x \nAfolayan, A. J., Grierson, D. S., & Mbeng, W. O. (2014). Ethnobotanical survey of medicinal plants used in the \nmanagement of skin disorders among the Xhosa communities  of the Amathole District, Eastern Cape, \nSouth Africa. Journal of Ethnopharmacology , 153(1), 220 -232. https://doi.org/10.1016/j.jep.2014.02.023  \nAlonso -Castro, A. J., Dom\u00ednguez, F., Maldonado -Miranda, J. J., Castillo -P\u00e9rez, L. J., Carranza -\u00c1lvarez, C., \nSolano, E., Isiordia -Espinoza, M. A., del Carmen Ju\u00e1rez -V\u00e1zquez, M., Zapata -Morales, J. R., A rgueta -\nFuertes, M. A., Ruiz -Padilla, A. J., Solorio -Alvarado, C. R., Rangel -Vel\u00e1zquez, J. E., Ortiz -Andrade, R., \nGonz\u00e1lez -S\u00e1nchez, I., Cruz -Jim\u00e9nez, G., & Orozco -Caste llanos, L. M. (2017). Use of medicinal plants by \nhealth professionals in Mexico. Journal of Ethnopharmacology , 198, 81 -86. \nhttps://doi.org/10.1016/j.jep.2016.12.038  \nAmatya, N., Garg A. V., Gaffen S. L. (2017). IL -17 signaling: the yin and the yang. Trends in immunology, 38 (5), \n310-322. https://doi.org/10.1016/j.it.2017.01.006  \nArican, O., Aral, M., Sasmaz, S., & Ciragil, P. (2005). Serum levels of TNF -alpha, IFN -gamma, IL -6, IL -8, IL -12, \nIL-17, and IL -18 in patients with active psoriasis and correlation with  disease severity. Mediators of  \nInflammation , 2005 (5), 273 -279. https://doi.org/10.1155/MI.2005.273  \nArmstrong, A. W., Robertson, A. D., Wu, J., Schupp, C., & Lebwohl, M. G. (2013). Undertreatment, treatment \ntrends, and treatment dissatisfaction among patie nts with psoriasis and psoriati c arthritis in the United \nStates: Findings from the National Psoriasis Foundation surveys, 2003 -2011. JAMA Dermatology , \n149(10), 1180 -1185. https://doi.org/10.1001/jamadermatol.2013.5264  \nArora, N., Shah, K., & Pandey -Rai, S. (2016). Inhibition of imiquimod -induced psoriasis -like dermatitis in mice \nby herbal extracts from some Indian medicinal plants. Protoplasma , 253(2), 503 -515. \nhttps://doi.org/10.1007/s00709 -015-0829 -y \nBai, F., Zheng, W., Dong, Y., Wang, J., Garstka, M. A., Li, R., An, J., & Ma, H. (2017) . Serum levels of adipokines \nand cytokines in psoriasis patients: A systematic review and meta -analysis. Oncotarget , 9(1), 1266 -1278. \nhttps://doi.org/10.18632/oncotarget.22260  \nBDMTM. (2009). Biblioteca Digital de la Medicina Tradicional Mexicana  [Base de datos]. Biblioteca Digital de \nla Medicina Tradicional Mexicana - Universidad Nacional Aut\u00f3noma de M\u00e9xico. \nhttp://www.medicinatradicionalmexicana.unam.mx/index.php  \nBello -Gonz\u00e1lez, M. \u00c1., Hern\u00e1ndez -Mu\u00f1oz, S., Lara -Ch\u00e1vez, M. B. N., & Salgado -Garcig lia, R. (2015). Plantas \n\u00fatiles de la comunidad ind\u00edgena Nuevo San Juan Parangaricutiro, Michoac\u00e1n, M\u00e9xico. Polibot\u00e1nica , 39, \n175-215. https://doi.org/10.18387/polibotanica.39.10  \nBissonnette, R., Nigen, S., Langley, R. G., Lynde, C. W., Tan, J., Fuentes\u2010Duc ulan, J., & Krueger, J. G. (2014). \nIncreased expression of IL -17A and limited involvement of IL -23 in patients with palmo -plantar (PP) \npustular psoriasis or PP pustulosis; results from a randomised controlled trial. Journal of the Europ ean \nAcademy of Derma tology and Venereology , 28(10), 1298 -1305. https://doi.org/10.1111/jdv.12272  \nBoehncke, W. -H., & Sch\u00f6n, M. P. (2015). Psoriasis. The Lancet , 386(9997), 983 -994. \nhttps://doi.org/10.1016/S0140 -6736(14)61909 -7 \nBogaard, E. H. van den, Bergbo er, J. G. M., Vonk -Bergers, M., Vlijmen -Willems, I. M. J. J. van, Hato, S. V., Valk, \nP. G. M. van der, Schr\u00f6der, J. M., Joosten, I., Zeeuwen, P. L. J. M., & Schalkwijk, J. (2013). Coal tar \ninduces AHR -dependent skin barrier repair in atopic dermatitis. The Journal of Clinical  Investigation , \n123(2), 917 -927. https://doi.org/10.1172/JCI65642  \nBruhn, J. G., & Helmstedt, B. (1981). Ethnopharmacology: Objectives, principles and perspectives. Natural \nproducts as medicinal agents . \nCai, Y., Fleming, C., & Yan, J. (2 012). New insights o f T cells in the pathogenesis of psoriasis. Cellular and \nMolecular Immunology , 9(4), 302 -309. https://doi.org/10.1038/cmi.2012.15  \nCalvo, M. I., Akerreta, S., & Cavero, R. Y. (2011). Pharmaceutical ethnobotany in the Riverside of Navarra  (Iberian \nPeninsula) . Journal of Ethnopharmacology , 135(1), 22 -33. https://doi.org/10.1016/j.jep.2011.02.016  \nCervantes -Dur\u00e1n, C., Vel\u00e1zquez -Hern\u00e1ndez, M. -E., Valent\u00edn -Escalera, J., Bartolom\u00e9 -Camacho, M., Rodr\u00edguez -\nOrozco, A. -R., & Garc\u00eda -P\u00e9rez, M. -E. (2020 ). Small molecules u nder development for psoriasis: On the  \n153 road to the individualized therapies. Archives of Dermatological Research . \nhttps://doi.org/10.1007/s00403 -020-02056 -3 \nCh\u00e1vez -Sifontes, M., & Domine, M. E. (2013). Lignina, estructura y aplicaciones : M\u00e9todos de despoli merizaci\u00f3n \npara la obtenci\u00f3n de derivados arom\u00e1ticos de inter\u00e9s industrial. Avances en Ciencias e Ingenier\u00eda , 4(4), \n15-46. \nChern, E., Yau, D., Ho, J. -C., Wu, W. -M., Wang, C. -Y., Chang, H. -W., & Cheng, Y. -W. (2011). Positive effect of \nmodified Goeckerman re gimen on quality of life and psychosocial distress in moderate and severe \npsoriasis. Acta Dermato -Venereologica , 91(4), 447 -451. https://doi.org/10.2340/00015555 -1096  \nChiricozzi, A., Guttman -Yassky, E., Su\u00e1rez -Fari\u00f1as, M., Nograles, K. E., Tian, S., Cardin ale, I., Chimenti, S., & \nKrueger, J. G. (2011). Integrative responses to IL -17 and TNF -\u03b1 in human keratinocytes account for key \ninflammatory pathogenic circuits in psoriasis. The Journal of Investigative Dermatology , 131(3), 677 -687. \nhttps://doi.org/10.103 8/jid.2010.340  \nChowdhury, R. R., & Ghosh, S. K. (2012). Phytol -derived novel isoprenoid immunostimulants. Frontiers in \nImmunology , 3. https://doi.org/10.3389/fimmu.2012.00049  \nCzernik, S., & Bridgwater, A. V. (2004). Overview of applicat ions of biomass fast pyrolysis oil. Energy & Fuels , \n18(2), 590 -598. https://doi.org/10.1021/ef034067u  \nDhanabal, S. P., Dwarampudi, L. P., Muruganantham, N., & Vadivelan, R. (2012). Evaluation of the antipsoriatic \nactivity of Aloe vera  leaf extract using a mouse tail model of psoriasis. Phytotherapy Research , 26(4), \n617-619. https://doi.org/10.1002/ptr.3589  \nDi Meglio, P., Duarte, J. H., Ahlfors, H., Owens, N. D. L., Li, Y., Villanova, F., Tosi, I.,  Hirota, K., Nestle, F. O., \nMrowietz, U., Gilchrist, M. J., &  Stockinger, B. (2014). Activation of the Aryl Hydrocarbon Receptor \nDampens the Severity of Inflammatory Skin Conditions. Immunity , 40(6), 989 -1001. \nhttps://doi.org/10.1016/j.immuni.2014.04.019  \nDimitris, D., Ekaterina -Michaela, T., Christina, K., Ioannis, S., Ioanna, S. K., Aggeliki, L., Sophia, H., Michael, \nR., & Helen, S. (2020). Melissa officinalis  ssp. Altissima extracts: A therapeutic approach targeting \npsoriasis in mice. Journal of Ethnophar macology , 246, 112208. https://doi.org/10.1016/j.jep.2019.112 208 \nDuan, H., Koga, T., Kohda, F., Hara, H., Urabe, K., & Furue, M. (2001). Interleukin -8-positive neutrophils in \npsoriasis. Journal of Dermatological Science , 26(2), 119 -124. https://doi.org/10. 1016/s0923 -\n1811(00)00167 -5 \nEdeas, M. (2008). Les polyph\u00e9nols et les polyph\u00e9nols de th\u00e9. Phytoth\u00e9rapie , 5(5), 264 -270. \nhttps://doi.org/10.1007/s10298 -007-0268 -9 \nEkman, A. -K., Bivik Eding, C., Rundquist, I., & Enerb\u00e4ck, C. (2019). IL -17 and IL -22 Promote Ker atinocyte \nStemness in the Germinative Compartment in Psoriasi s. Journal of Investigative Dermatology , 139(7), \n1564 -1573.e8. https://doi.org/10.1016/j.jid.2019.01.014  \nEsquivel -Garc\u00eda, R., Est\u00e9vez -Delgado, G., Rodr\u00edguez -Orozco, A. -R., Ochoa -Zarzosa, A., & Ga rc\u00eda-P\u00e9rez, M. E. \n(2018 a). La psoriasis: De la investigaci\u00f3n b\u00e1sica y cl\u00ednica al desarrollo de nuevos tratamientos. Gaceta \nM\u00e9dica de M\u00e9xico , 154(4), 502 -508. https://doi.org/10.24875/GMM.17003182  \nEsquivel -Garc\u00eda, R., P\u00e9rez -Calix, E., Ochoa -Zarzosa, A., & G arc\u00eda -P\u00e9rez, M. -E. (2018 b). Ethnomedicinal plants \nused for th e treatment of dermatological affections on the Pur\u00e9pecha Plateau, Michoac\u00e1n, Mexico. Acta \nBotanica Mexicana , 125, 95-132. https://doi.org/10.21829/abm125.2018.1339  \nFabricant, D. S., & Farnsworth, N. R. (2001). The value of plants used in traditional medic ine for drug discovery. \nEnvironmental Health Perspectives , 109(Suppl 1), 69 -75. \nFleischer, A. B., Feldman, S. R., Rapp, S. R., Reboussin, D. M., Exum, M. L., & Clark , A. R. (1996). Alternative \ntherapies commonly used within a population of patients with ps oriasis. Cutis , 58(3), 216 -220. \nFu, Y., Ma, J., Shi, X., Song, X. -Y., Yang, Y., Xiao, S., Li, J., Gu, W. -J., Huang, Z., Zhang, J., & Chen, J. (2017). \nA novel pyrazole -containing indolizine derivative suppresses NF -\u03baB activation and protects against \nTNBS -induced colitis via a PPAR -\u03b3-dependent pathway. Biochemical Pharmacology , 135, 126 -138. \nhttps://doi.org/10.1016/j.bcp.2017.03.013  \nGallardo Ruiz, J. (2002). Medi cina tradicional P\u2019urh\u00e9pecha . El Colegio de Michoac\u00e1n A. C. \nGami, A. A. (2014). Phenol and its toxicity. Journal of Environmental Microbiology and Toxicology , 2(1), Article \n1. https://journal.hibiscuspublisher.com/index.php/JEMAT/article/view/89  \nGarc\u00eda, A. \u00c1., & Carril, E. P. -U. (2011). Metabolismo secundario de  plantas. REDUCA (Biolog\u00eda) , 2(3), Article 3. \nhttp://revistareduca.es/index.php/biologia/article/view/798  \nGarc\u00eda -P\u00e9rez, M. E., Allaeys, I., Rusu, D., Pouliot, R., Janezic, T. S., & Poubelle, P. E. (20 14). Picea mariana \npolyphenolic extract inhibits phlogog enic mediators produced by TNF -\u03b1-activated psoriatic keratinocytes:  \n154 Impact on NF -\u03baB pathway. Journal of Ethnopharmacology , 151(1), 265 -278. \nhttps://doi.org/10.1016/j.jep.2013.10.034  \nGarc\u00eda -P\u00e9rez, M. E ., Jean, J., & Pouliot, R. (2012). Antipsoriatic drug de velopment: Challenges and new emerging \ntherapies. Recent Patents on Inflammation & Allergy Drug Discovery , 6(1), 3 -21. \nhttps://doi.org/10.2174/187221312798889248  \nGellerstedt, G., & Henriksson, G. (200 8). Chapter 9 - Lignins: Major sources, structure and pr operties. En M. N. \nBelgacem & A. Gandini (Eds.), Monomers, Polymers and Composites from Renewable Resources  (pp. \n201-224). Elsevier. https://doi.org/10.1016/B978 -0-08-045316 -3.00009 -0 \nGendrisch, F., N ov\u00e1\u010dkov\u00e1, A., Sochorov\u00e1, M., Haarhaus, B., V\u00e1vrov\u00e1, K., Schempp, C. M., & W\u00f6lfle, U. (2020). \nGentiana lutea  extract modulates ceramide synthesis in primary and psoriasis -Like keratinocytes. \nMolecules , 25(8). https://doi.org/10.3390/molecules25081832  \nGertsc h, J. (2009). How scientific is the science in ethnopharmacology? Historical perspectives and \nepistemological problems. Journal of Ethnopharmacology , 122(2), 177 -183. \nhttps://doi.org/10.1016/j.jep.2009.01.010  \nGhosh, S. K., & Chowdhury, R. R. (2013). Synthe tic adjuvants for vaccine formulations: Phytol derivatives. Expert \nOpinion on Drug Delivery , 10(4), 437 -450. https://doi.org/10.1517/17425247.2013.757591  \nG\u00f3mez -Fuentes -Galindo, T., Gonz\u00e1lez -Rebeles, C., L\u00f3pez -Ortiz, S., Ku -Vera, J. C., Albor -Pinto, C. de J ., \nSangines -Garc\u00eda, J. R., G\u00f3mez -Fuentes -Galindo, T., Gonz\u00e1lez -Rebeles, C., L\u00f3pez -Ortiz, S., Ku -Vera, J. \nC., Albor -Pinto, C. de J., & Sangines -Garc\u00eda, J. R. (2017). Dominancia, composici\u00f3n qu\u00edmica -nutritiva \nde especies forrajearas y fitomasa potencial en u na selva secundaria. Agricultura, sociedad y desarrollo , \n14(4), 617 -634. \nGriffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus -Gort, R., Yeilding, N., Guzzo, C., Xia, Y., \nZhou, B., Li, S., Dooley, L. T., Goldstein, N. H., Menter, A., & A CCEPT Study Group. (2010). \nComparison of ustekinumab and etanercept for m oderate -to-severe psoriasis. The New England Journal \nof Medicine , 362(2), 118 -128. https://doi.org/10.1056/NEJMoa0810652  \nGulliver, W. P., & Donsky, H. J. (2005). A report on three rec ent clinical trials using Mahonia aquifolium  10% \ntopical cream and a revi ew of the worldwide clinical experience with Mahonia aquifolium  for the \ntreatment of plaque psoriasis. American Journal of Therapeutics , 12(5), 398 -406. \nhttps://doi.org/10.1097/01.mjt.0000174350.82270.da  \nGupta, A., Nagariya, A. K., Mishra, A. K., Bansal, P ., Kumar, S., Gupta, V., & Singh, A. K. (2010). Ethno -potential \nof medicinal herbs in skin diseases: An overview. Journal of Pharmacy Resea rch, 3(3), 435 -441. \nGuttman -Yassky, E., & Krueger, J. G. (2007). Psoriasis: Evolution of pathogenic concepts and new therapies \nthrough phases of translational research. The British Journal of Dermatology , 157(6), 1103 -1115. \nhttps://doi.org/10.1111/j.1365 -2133.2007.08135.x  \nHarvey, A. L., Edrada -Ebel, R., & Quinn, R. J. (2015). The re -emergence of natural products for drug  discovery in \nthe genomics era. Nature Reviews Drug Discovery , 14(2), 111 -129. https://doi.org/10.1038/nrd4510  \nHeinrich, M., Edwards, S., M oerman, D. E., & Leonti, M. (2009). Ethnopharmacological field studies: A critical \nassessment of their conceptual bas is and methods. Journal of Ethnopharmacology , 124(1), 1 -17. \nhttps://doi.org/10.1016/j.jep.2009.03.043  \nHeinrich, M., Frei Haller, B., & Leon ti, M. (2014). A perspective on natural products research and \nethnopharmacology in Mexico: The eagle and the serpent on the prickly pear cactus. Journal of Natural \nProducts , 77(3), 678 -689. https://doi.org/10.1021/np4009927  \nHeinrich, M., & Gibbons, S. (200 1). Ethnopharmacology in drug discovery: An analysis of its role and potential \ncontribution. Journal of Pharmacy and Pharmacology , 53(4), 425. \nhttps://doi.org/10.1211/0022357011775712  \nHert, J., Irwin, J. J., Laggner, C., Keiser, M. J., & Shoichet, B. K. (2 009). Quantifying biogenic bias in screening \nlibraries. Nature chemical biology , 5(7), 479 -483. https://doi.org/10.10 38/nchembio.180  \nHsu, S., Dickinson, D., Borke, J., Walsh, D. S., Wood, J., Qin, H., Winger, J., Pearl, H., Schuster, G., & Bollag, \nW. B. (2 007). Green tea polyphenol induces caspase 14 in epidermal keratinocytes via MAPK pathways \nand reduces psoriasiform l esions in the flaky skin mouse model. Experimental Dermatology , 16(8), 678 -\n684. https://doi.org/10.1111/j.1600 -0625.2007.00585.x  \nInternatio nal Psoriasis Council. (2009). IPC Psoriasis Review . 5, 1 -12. \nhttp://www.psoriasiscouncil.org/docs/ipcpsoriasisreview _dec_2009_english.pdf?LanguageID=EN -US \nJ\u00edrov\u00e1, D., Basketter, D., Liebsch, M., Bendov\u00e1, H., Kejlov\u00e1, K., Marriott, M., & Kand\u00e1rov\u00e1, H. (201 0). \nComparison of human skin irritation patch test data with in vitro skin irritation assays and animal data. \nContact  Dermatitis , 62(2), 109 -116. https://doi.org/10.1111/j.1600 -0536.2009.01640.x   \n155 Johansen, C., Usher, P. A., Kjellerup, R. B., Lundsgaard, D.,  Iversen, L., & Kragballe, K. (2009). Characterization \nof the interleukin -17 isoforms and receptors in lesional psori atic skin. The British Journal of Dermatology , \n160(2), 319 -324. https://doi.org/10.1111/j.1365 -2133.2008.08902.x  \nKagoura, M., Matsui, C., &  Morohashi, M. (1999). Phytol is a novel tumor promoter on ICR mouse skin. Japanese \nJournal of Cancer Research: Gann , 90(4), 377 -384. https://doi.org/10.1111/j.1349 -7006.1999.tb00758.x  \nKim, H., Kim, J. Y., Song, H. S., Park, K. U. , Mun, K. -C., & Ha, E. (20 11). Grape seed proanthocyanidin extract \ninhibits interleukin -17-induced interleukin -6 production via MAPK pathway in human pulmonary \nepithelial cells. Naunyn -Schmiedeberg\u2019s Archives of Pharmacology , 383(6), 555 -562. \nhttps://doi.o rg/10.1007/s00210 -011-0633 -y \nKim, W. B., Jerome, D., & Yeung, J. (2017). Diagnosis and management of psoriasis. Canadian Family Physician , \n63(4), 278 -285. \nKing, L., Jurima\u2010Romet, M., & Ichhpurani, N. (2010). Biomarkers in pharmaceutical development: The essential \nrole of project ma nagement and teamwork. En Pharmaceutical Sciences Encyclopedia  (pp. 1 -22). \nAmerican Cancer Society. https://doi.org/10.1002/97804 70571224.pse278  \nKoo, J., & Lebwohl, M. (1999). Duration of remission of psoriasis therapies. Journal of the American Academy of \nDermatology , 41(1), 51 -59. https://doi.org/10.1016/s0190 -9622(99)70406 -8 \nKviecinski, M. R., David, I. M. B., Fernandes, F. de S. , Correa, M. dos R., Clarinda, M. M., Freitas, A. F., da Silva, \nJ., Gava, M., M\u00fcller, S. D., Florentino, D., Petronilho, F., Moterle, D., Kanis, L. A., & Pedrosa, R. C. \n(2016). Healing effect of Dillenia indica  fruit extracts standardized to betulinic acid  on ultraviolet \nradiation -induced psoriasis -like wounds in rats. Pharmaceutical Biology , 55(1), 641 -648. \nhttps://doi.org/10.1080/13880209.2016.1266672  \nLapolla, W., Yentzer, B. A., Bagel, J., Halvorson, C. R., & Feldman, S. R. (2011). A review of photothera py \nprotocols for psoriasis treatment. Journal of the American Academy of Dermatology , 64(5), 936 -949. \nhttps://doi.org/10.1016/j.jaad.2009.12.054  \nLebwohl, M. (2016). Psoriasis therapy: Breakthroughs in  pharmacogenomics or in pharmacology? Journal of \nInvesti gative Dermatology , 136(12), 2339 -2340. https://doi.org/10.1016/j.jid.2016.07.019  \nLee, D. H., & Lee, C. S. (2016). Flavonoid myricetin inhibits TNF -\u03b1-stimulated production of inflammatory \nmediators by suppressing the Akt, mTOR and NF -\u03baB pathways in human k eratinocytes. European Journal \nof Pharmacology , 784, 164 -172. https://doi.org/10.1016/j.ejphar.2016.05.025  \nLee, E., & Koo, J. (2005). Modern modified \u2018ultra\u2019 Goeckerman therapy: A PASI assessment of a very effective \ntherapy for psoriasis resistant to both prebiologic and biologic therapies. Journal of Dermatological \nTreatment , 16(2), 102 -107. https://doi.org/10.1080/09546630510033140  \nLee, S. Y., Nam, S., Hong, I. K., Kim, H., Yang, H., & Cho, H. -J. (2018). Antiproliferation of keratinocytes and \nalleviation of psoriasis by the ethanol extract of Artemisia capillaris . Phytotherapy Research , 32(5), 923 -\n932. https://doi.org/10.1002/ptr.6032  \nLiaw, S. -S., Zhou, S., Wu, H., & Garcia -Perez, M. (2013). Effect of pretreatment temperature on the yield and \nproperties of  bio-oils obtained from the auger pyrolysis of Douglas fir wood. Fuel, 103, 672 -682. \nhttps://doi.org/10.1016/j.fuel.2012.08.016  \nLowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007). Pathogenesis and therapy of psoriasis. Nature , 445(7130), \n866-873. https: //doi.org/10.1038/nature05663  \nLowes, M. A., Su\u00e1rez -Fari\u00f1as, M., & Krueger, J. G. (2014). Immunology of psoriasis. Annual Review of \nImmunology , 32, 227 -255. https://doi.org/10.1146/ann urev-immunol -032713 -120225  \nLv, J., Zhou, D., Wang, Y., Zhao, J., Chen, Z. , Zhang, J., Di, T., Hu, J., Li, B., Li, P., & Huang, F. (2018). \nQuantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta -analysis. \nMolecular Pain , 14, 1744806918762205. https://doi.org/10.1177/1744806918762205  \nMata, R., Fi gueroa, M., Navarrete, A., & Rivero -Cruz, I. (2019). Chemistry and Biology of Selected Mexican \nMedicinal Plants. En A. D. Kinghorn, H. Falk, S. Gibbons, J. Kobayashi, Y. Asakawa, & J. -K. Liu (Eds.), \nProgress in the Chemistry of Organic Natural Products 108  (pp. 1 -142). Springer International \nPublishing. https://doi.org/10.1007/978 -3-030-01099 -7_1 \nMedina, C. (2003). La flora: Riqueza, diversidad y sus relaciones fitogeogr\u00e1ficas. En Las ense\u00f1anzas de San Juan  \n(1a ed., pp. 165 \u2013200). INE -SEMARNAT. \nhttp://www2.i necc.gob.mx/publicaciones2/libros/420/ocho.html  \nMichalek, I. M., Loring, B., & John, S. M. (2017). A systematic review of worldwide epidemiology of psoriasis. \nJournal of the European Academy of Dermatology and Venereology , 31(2), 205 -212. \nhttps://doi.org/1 0.1111/jdv.13854   \n156 Miquel, J., Bernd, A., Sempere, J. M., D\u00edaz -Alperi, J., & Ram\u00edrez, A. (2002). The curcuma antioxidants: \nPharmacological effects and prospects for future clinical use.  A review. Archives of Gerontology and \nGeriatrics , 34(1), 37 -46. \nMohan, D ., Pittman, Charles U., & Steele, P. H. (2006). Pyrolysis of wood/biomass for bio -oil: A critical review. \nEnergy & Fuels , 20(3), 848 -889. https://doi.org/10.1021/ef0502397  \nMontoya Arb el\u00e1ez, J. I., Chejne Janna, F., Castillo Monroy, E. F., Acero Reyes, J. R ., G\u00f3mez Guti\u00e9rrez, C. A., \nSarmiento Chaparro, J. A., Vald\u00e9s Renter\u00eda, C. F., Garz\u00f3n Fuentes, L. L., Osorio Velasco, J., Fernando \nTirado, D., Blanco, L. A., Moreno Safra, N., Marrugo,  G., & Ospina Aguirre, E. Y. (2013). Pir\u00f3lisis \nr\u00e1pida de biomasa  (1.a ed.). Universidad Nacional de Colombia.  \nMoos, S., Mohebiany, A. N., Waisman, A., & Kurschus, F. C. (2019). Imiquimod -induced psoriasis in mice \ndepends on the IL -17 signaling of keratinoc ytes. Journal of Investigative Dermatology , 139(5), 1110 -\n1117. https://do i.org/10.1016/j.jid.2019.01.006  \nMoscaliuc, M. L., Heller, M. M., Lee, E. S., & Koo, J. (2013). Goeckerman therapy: A very effective, yet often \nforgotten treatment for severe generaliz ed psoriasis. Journal of Dermatological Treatment , 24(1), 34 -37. \nhttps:// doi.org/10.3109/09546634.2012.658014  \nMoss, G. P. (2000). Nomenclature of lignans and neolignans (IUPAC recommendations 2000). Pure and Applied \nChemistry , 72(8), 1493 -1523. https://doi.org/10.1351/pac200072081493  \nM\u00fcller, K., Ziereis, K., & Gawlik, I. (1995) . The antipsoriatic Mahonia aquifolium  and its active constituents; II. \nAntiproliferative activity against cell growth of human keratinocytes. Planta Medica , 61(1), 74 -75. \nhttps://doi.org/10.1055/s -2006 -958005  \nMurray, A. R., Kisin, E., Castranova, V., Komm ineni, C., Gunther, M. R., & Shvedova, A. A. (2007). Phenol -\ninduced in vivo  oxidative stress in skin: Evidence for enhanced free radical generation, thiol oxidation, \nand an tioxidant depletion. Chemical Research in Toxicology , 20(12), 1769 -1777. \nhttps://doi .org/10.1021/tx700201z  \nNada, A., Al -Moghazy, M., Soliman, A. A. F., Rashwan, G. M. T., Eldawy, T. H. A., Hassan, A. A. E., & Sayed, \nG. H. (2018). Pyrazole -based compounds i n chitosan liposomal emulsion for antimicrobial cotton fabrics. \nInternational Journa l of Biological Macromolecules , 107(Pt A), 585 -594. \nhttps://doi.org/10.1016/j.ijbiomac.2017.09.031  \nNewby, C. S., Barr, R. M., Greaves, M. W., & Mallet, A. I. (2000). Cytoki ne release and cytotoxicity in human \nkeratinocytes and fibroblasts induced by phenol s and sodium dodecyl sulfate. Journal of Investigative \nDermatology , 115(2), 292 -298. https://doi.org/10.1046/j.1523 -1747.2000.00056.x  \nNjoroge, G. N., & Bussmann, R. W. (200 7). Ethnotherapeautic management of skin diseases among the Kikuyus \nof Central Kenya . Journal of Ethnopharmacology , 111(2), 303 -307. \nhttps://doi.org/10.1016/j.jep.2006.11.025  \nNovaes, E., Kirst, M., Chiang, V., Winter -Sederoff, H., & Sederoff, R. (2010). Li gnin and Biomass: A Negative \nCorrelation for Wood Formation and Lignin Content in Tr ees. Plant Physiology , 154(2), 555 -561. \nhttps://doi.org/10.1104/pp.110.161281  \nN-S Hon, D., & Shiraishi, N. (2000). Wood and cellulosic chemistry . Marcel Dekker Inc. \nhttps://www.nhbs.com/wood -and-cellulosic -chemistry -book  \nOasmaa, A., Fonts, I., Pelaez -Saman iego, M. R., Garcia -Perez, M. E., & Garcia -Perez, M. (2016). Pyrolysis Oil \nMultiphase Behavior and Phase Stability: A Review. Energy & Fuels , 30(8), 6179 -6200. \nhttps ://doi.org/10.1021/acs.energyfuels.6b01287  \nPatwardhan, B. (2005). Ethnopharmacology and dru g discovery. Journal of Ethnopharmacology , 100(1-2), 50 -52. \nhttps://doi.org/10.1016/j.jep.2005.06.006  \nPrashantkumar, P., & Vidyasagar, G. M. (2008). Traditional know ledge on medicinal plants used for the treatment \nof skin diseases in Bidar district, Karnat aka. Indian Journal of Traditional Knowledge , 7(2), 273 -276. \nRapp, S. R., Feldman, S. R., Exum, M. L., Fleischer, A. B., & Reboussin, D. M. (1999). Psoriasis causes as much \ndisability as other major medical diseases. Journal of the American Academy of Derm atology , 41(3), 401 -\n407. https://doi.org/10.1016/S0190 -9622(99)70112 -X \nRoy Chowdhury, R., Fitch, R. W., & Ghosh, S. K. (2013). Efficacy of phytol -derived diterpenoid  immunoadjuvants \nover alum in shaping the murine host\u2019s immune response to Staphylococcus a ureus . Vaccine , 31(8), 1178 -\n1186. https://doi.org/10.1016/j.vaccine.2012.12.069  \nSakkas, L. I., & Bogdanos, D. P. (2017). Are psoriasis and psoriatic arthritis the same disease? The IL -23/IL -17 \naxis data. Autoimmunity Reviews , 16(1), 10 -15. https://doi.org/ 10.1016/j.autrev.2016.09.015   \n157 Scholze, B., & Meier, D. (2001). Characterization of the water -insoluble fraction from pyrol ysis oil (pyrolytic \nlignin). Part I. PY \u2013GC/MS, FTIR, and functional groups. Journal of Analytical and Applied Pyrolysis , \n60(1), 41 -54. https://doi.org/10.1016/S0165 -2370(00)00110 -8 \nSchultz, J. C., Hunter, M. D., & Appel, H. M. (1992). Antimicrobial activit y of polyphenols mediates plant -\nherbivore interactions. En R. W. Hemingway & P. E. Laks (Eds.), Plant Polyphenols: Synthesis, \nPropertie s, Significance  (pp. 621 -637). Springer US. https://doi.org/10.1007/978 -1-4615 -3476 -1_35  \nSekhon, S., Jeon, C., Nakamura, M., Afifi, L., Yan, D., Wu, J. J., Liao, W., & Bhutani, T. (2018). Review of the \nmechanism of action of coal tar in psoriasis. Journal of Dermatological Treatment , 29(3), 230 -232. \nhttps://doi.org/10.1080/09546634.2017.1369494  \nSeki, N., Shimano, K., Kondou,  T., Murase, M., Mitamura, M., Kataoka, H., Sugahara, K., Nakamura, H., & \nYamada, M. (2014). OP0105 Pyrazole -anilide derivatives, a new  class of immunomodulator which \ninhibits IL -17 production, ameliorate CIA and psoriasis -like dermatitis in mice. Annals o f the Rheumatic \nDiseases , 73(Suppl 2), 100 -101. https://doi.org/10.1136/annrheumdis -2014 -eular.3054  \nSharma, J., Gairola, S., Sharma, Y.  P., & Gaur, R. D. (2014). Ethnomedicinal plants used to treat skin diseases by \nTharu community of district Udham Singh N agar, Uttarakhand, India. Journal of Ethnopharmacology , \n158(Part A), 140 -206. https://doi.org/10.1016/j.jep.2014.10.004  \nShen, T., Wang,  X.-N., & Lou, H. -X. (2009). Natural stilbenes: An overview. Natural Product Reports , 26(7), 916 -\n935. https://doi.org/10. 1039/b905960a  \nSteinmann, V. W. (2005). Urticaceae. Flora del Baj\u00edo y de Regiones Adyacentes , 134, 1-74. \nStevanovic, T. (2005). Chimie d u bois . U. Laval.  \nStevanovic, T., Diouf, P. N., & Garcia -Perez, M. E. (2009). Bioactive polyphenols from healthy diets an d forest \nbiomass. Current Nutrition & Food Science , 5(4), 264 -295. \nStevanovic, T., & Perrin, D. (2009). Extractives. En Chimie du bois . EPFL PRESS. \nhttps://www.epflpress.org/produit/448/9782880747992/chimie -du-bois \nStorey, A., McArdle, F., Friedmann, P. S. , Jackson, M. J., & Rhodes, L. E. (2005). Eicosapentaenoic acid and \ndocosahexaenoic acid reduce UVB - and TNF -\u03b1-induced IL -8 secretion in keratinocytes and UVB -induced \nIL-8 in fibroblasts. Journal of Investigative Dermatology , 124(1), 248 -255. \nhttps://doi.o rg/10.1111/j.0022 -202X.2004.23543.x  \nSvendsen, M. T., Jeyabalan, J., Andersen, K. E., Andersen, F., & Johannes sen, H. (2017). Worldwide utilization \nof topical remedies in treatment of psoriasis: A systematic review. The Journal of Dermatological \nTreatment , 28(5), 374 -383. https://doi.org/10.1080/09546634.2016.1254331  \nSykes, R., Yung, M., Novaes, E., Kirst, M., Pet er, G., & Davis, M. (2009). High -throughput screening of plant cell -\nwall composition using pyrolysis molecular beam mass spectroscopy. Methods in M olecular Biology \n(Clifton, N.J.) , 581, 169 -183. https://doi.org/10.1007/978 -1-60761 -214-8_12  \nTalbott, W., & D uffy, N. (2015). Complementary and alternative medicine for psoriasis: What the dermatologist \nneeds to know. American Journal of Clinical Dermatolo gy, 16(3), 147 -165. \nhttps://doi.org/10.1007/s40257 -015-0128 -6 \nTerui, T., Ozawa, M., & Tagami, H. (2000). Role  of neutrophils in induction of acute inflammation in T -cell-\nmediated immune dermatosis, psoriasis: A neutrophil -associated inflammation -boosting l oop. \nExperimental Dermatology , 9(1), 1 -10. https://doi.org/10.1034/j.1600 -0625.2000.009001001.x  \nTurner, J. R.  (2010). New Drug Development \u2014An Introduction to Clinical Trials . \nhttp://www.springer.com/la/book/9781441964175  \nvan de Kerkhof, P. C. M. (2008). Options for the treatment of psoriasis: A multifactorial approach. Clinics in \nDermatology , 26(5), 419 -423. http s://doi.org/10.1016/j.clindermatol.2007.10.029  \nVijayalakshmi, A., Priyanka, M., Priyadharshini, S., Kumar, S. S., & Jayakumari, S. (2019). Antipsor iatic activity \nof Cassia auriculata  L. flowers in Freund\u2019s adjuvant -formaldehyde induced animal model. IJNPR \nVol.10(4) [December 2019] . http://nopr.niscair.res.in/handle/123456789/54201  \nVijayalakshmi, A., Ravichandiran, V., Malarkodi, V., Nirmala, S., & Ja yakumari, S. (2012). Screening of flavonoid \n\u201cquercetin\u201d from the rhizome of Smilax china  Linn. For anti -psori atic activity. Asian Pacific Journal of \nTropical Biomedicine , 2(4), 269 -275. https://doi.org/10.1016/S2221 -1691(12)60021 -5 \nWoolf, R. T., & Smith, C . H. (2010). How genetic variation affects patient response and outcome to therapy for \npsoriasis. Expert Revi ew of Clinical Immunology , 6(6), 957 -966. https://doi.org/10.1586/eci.10.74  \nYau, A. C. Y., L\u00f6nnblom, E., Zhong, J., & Holmdahl, R. (2017). Influenc e of hydrocarbon oil structure on \nadjuvanticity and autoimmunity. Scientific Reports , 7(1), 14998. https://do i.org/10.1038/s41598 -017-\n15096 -z  \n158 Zablocki, J. A., Tarlton, E., Rizzi, J. P., & Mantlo, N. B. (2003). Aryl and heteroaryl substituted fused pyrrole anti -\ninflammatory agents  (United States Patent N.o US6605634B2). \nhttps://patents.google.com/patent/US6605634B 2/en \nZeichner, J. A. (2010). Use of topical coal tar foam for the treatment of psoriasis in difficult -to-treat areas. The \nJournal of Clinical and Aesthetic Dermatology , 3(9), 37 -40. \nZhang, S., Liu, X., Mei, L., Wang, H., & Fang, F. (2016). Epigallocatechin -3-gallate (EGCG) inhibits imiquimod -\ninduced psoriasis -like inflammation of BALB/c mice. BMC Complementary and Alternative Medicine , \n16(1), 334. https://doi.org/10.1186/s12906 -016-1325-4 \nZhang, X., Rakesh, K. P., Shantharam, C. S., Manukumar, H. M., Asiri,  A. M., Marwani, H. M., & Qin, H. -L. \n(2018). Podophyllotoxin derivatives as an excellent anticancer aspirant for future chemotherapy: A key \ncurrent imminent needs. Bioorganic & Medic inal Chemistry , 26(2), 340 -355. \nhttps://doi.org/10.1016/j.bmc.2017.11.026  \nZhu, T. H., Nakamura, M., Farahnik, B., Abrouk, M., Singh, R. K., Lee, K. M., Hulse, S., Koo, J., Bhutani, T., & \nLiao, W. (2016). The patient\u2019s guide to psoriasis treatment. Part 4: Goeckerman therapy. Dermatology \nand Therapy , 6(3), 333 -339. https://doi.or g/10.1007/s13555 -016-0132 -7 \nZiboh, V. A., Miller, C. C., & Cho, Y. (2000). Metabolism of polyunsaturated fatty acids by skin epidermal \nenzymes: Generation of antiinflammatory and ant iproliferative metabolites. The American Journal of \nClinical Nutrition , 71(1), 361s -366s. https://doi.org/10.1093/ajcn/71.1.361s  \n \n \n \n  \n159 XI. ANEXOS  \n \nXI.1.  ANEXO 1  - La psoriasis: de la investigaci\u00f3n b\u00e1sica y cl\u00ednica al \ndesarrollo de nuevos tratamien tos \n \n \nXI.1.1.  PREFACIO  \n \nEste anexo corresponde a un art\u00edculo de revisi\u00f3n titulado \u201c La psoriasis: de la  investigaci\u00f3n \nb\u00e1sica y cl\u00ednica al desarrollo de nuevos tratamientos \u201d. El cual fue publicado en Gaceta M\u00e9dica \nde M\u00e9xico . 154 : 502 -508. Su identificador de objeto digital es: \nhttps://doi.org/10.24875/GMM. 17003182  \n \nEl art\u00edculo consiste en una revisi\u00f3n de la informaci\u00f3n cient\u00edfica para analizar el impacto de la \nmedicina traslacional en el  desarrollo de medicamentos antipsori\u00e1sicos asociados a nuevas \ndianas farmacol\u00f3gicas.  \n \n \n \n \n \n \n \n \n \n  \n160  \nXI.1.2.  ART\u00cdCULO  \n \n \n \n \nXI.1.3.  Resumen  \n \n \n \n \n \n \nXI.1.4.  Abstract  \n \n \n \n \n \n \n \n \n \n \n \n161  \nXI.1.5.  Introducci\u00f3n  \n \n \n \n \nXI.1.6.  Conceptos etiopatog\u00e9nicos actuales de la psoriasis  \n \n \n \n162  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nPatog\u00e9nesis de la psoriasis e implicaci\u00f3n de los nuevos f\u00e1rmacos en desarrollo.  \n \n \n \n \n \n \n \n \n \n163  \nXI.1.7.  De la investigaci\u00f3n b\u00e1sica y cl\u00ednica al desarrollo de  tratamientos \nantipsori\u00e1sicos  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n164  \n \nXI.1.8.  Nuevos f\u00e1rmacos antipsori\u00e1sicos en desarrollo  \n \n \nXI.1.9.  Perspectivas futuras en el desarrollo de nuevos medicamentos \nantipsori\u00e1sicos  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n165  \n \nNuevos medicamentos en desarrollo para el tratamiento de la psoriasis  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nXI.1.10.  Bibliograf\u00eda  \n \n \n \n  \n166  \n", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}